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Abstract: Background: The mechanism underlying non-severe and severe 
asthma remains unclear although it is commonly associated with increased 
airway smooth muscle (ASM) mass. Long non-coding RNAs (lncRNAs) are known 
to be important in regulating healthy primary ASM cells whilst changed 
expression has been observed in CD8 T-cells from patients with severe 
asthma. 
Methods: Primary ASM cells were isolated from healthy individuals (n=9), 
patients classified as having non-severe asthma (n=9) or severe asthma 
(n=9). ASM cells were exposed to dexamethasone and fetal calf serum 
(FCS). mRNA and lncRNA expression was measured by microarray and 
quantitative real-time PCR. Bioinformatic analysis was used to examine 
for relevant biological pathways. Finally, the lncRNA; Plasmacytoma 
Variant Translocation (PVT1) was inhibited by transfection of primary ASM 
cells with siRNAs, and the effect upon ASM cell phenotype was examined. 
Results: The mRNA expression profile was significantly different between 
patient groups following exposure to dexamethasone and FCS and these were 
associated with biological pathways that may be relevant to the 
pathogenesis of asthma including cellular proliferation and pathways 
associated with glucocorticoid activity. We also observed a significant 
change in the expression of lncRNAs, yet only one (PVT1) is decreased in 
expression in the corticosteroid sensitive non-severe asthmatics, and 
increased in expression in the corticosteroid-insensitive severe 
asthmatics. Subsequent targeting studies demonstrated the importance of 
this lncRNA in controlling both proliferation and IL-6 release in ASM 
cells from patients with severe asthma. 
Conclusions: lncRNAs are associated with the aberrant phenotype observed 
in ASM cells from patients with asthma. Targeting of PVT1 may be 




EDITOR'S SPECIFIC COMMENTS: 
 
 
Reviewer #2: MAJOR COMMENTS: 
1) In lines 111-112 the authors describe they focused on PVT1 because "it was differentially 
expressed between non-severe and severe asthmatics"; currently that is the only sentence in 
the methods that attempts to describe why PVT1 was selected. In the results, PVT1 is not 
among the top genes in any of the tables, and it is first mentioned in line 248. The most clear 
explanation of why further study PVT1 is in lines 258-260: PVT1 was the only lncRNA that 
was decreased in non-severe asthmatics and increased in severe asthmatics. So if I understand 
correctly, PVT1 was not at all selected based on the pathway analysis or the prior analytical 
steps? Did the authors further study any of the genes derived from the IPA? 
 
Thank you for this, and we can see how this might need clarifying. 
We have now mentioned in the abstract and the introduction, the fact that PVT1 was the only 
lncRNA, out of those that were measured, to be decreased in expression in the corticosteroid 
sensitive non-severe asthmatics, and increased in expression in the corticosteroid-insensitive 
severe asthmatics. Hence why we further examined the action of this lncRNA in the 
corticosteroid response between these two asthmatic phenotypes. 
 
In regards to the IPA, we confirmed the expression levels of NAV2, NFIB, PTGIS, CHI3L1, 
NOVA1, PTPRD, IL6, PGM5 and NNAT by qRT-PCR (Figure 1D) and have previously 
demonstrated the effect or targeting IL6 in primary ASM cells, both from asthmatics and 
patients with COPD 
(1-3)
. Furthermore this paper is part of a very large study measuring all 
known mRNAs, miRNAs, and lncRNAs in ASM cells isolated from healthy individuals, and 
those with non-severe or severe asthma. We decided to split the very large volume of results 
that we obtained into numerous papers, hence the first paper described mRNA and ncRNA 
expression in healthy ASM 
(4)
, this paper aims to address the role of lncRNAs in non-severe 
and severe asthmatics, and we aim to follow this with a further report discussing the role of 
miRNAs and mRNAs in non-severe and severe asthmatics. It has not proven feasible to 
publish all the research together as previous reviewers/editors etc. have said that it was too 
detailed, and lacked focus. 
 
2) Methods: Some of the methods could be moved to the supplementary material, in 
particular some of the minute protocol details. On the other hand, only two lines on the 
microarray analysis (lines 152-153) seems quite insufficient, since this is the basis for the rest 
of the study. The authors should provide more detail on the microarray analysis (protocol, 
specifications, quality control, etc.) given that this is how they selected the pathways and 
genes on which to focus in latter experiments. 
 
We thank the reviewer for their suggestion. 
We have trimmed down all sections on cell culture, RNA extraction, and transfections in the 
main text, and included the full details in the Supplemental data file. 
Conversely, we have included the full methodology for the Microarray and subsequent 
analysis in the main text. 
 
3) Is there any data evaluating how well cultured ASMC miRNA and lncRNA profiles 
correlate to in vivo (or recently ex vivo) profiling? In other words, there are some studies 
evaluating gene expression between cultured and "fresh" ASMC; but are there studies or data 
Responses to Comments
supporting that miRNA and lncRNA in cultured cells represent what happens in vivo in 
humans (or perhaps in animal models)? 
 
Thank you for this, it is an excellent point that we hope to address soon! 
In regards to the studies of miRNAs in animals models of asthma; we reviewed recent work 
of miRNAs in asthma
(5)
, and reported that the miRNAs miR-1 and miR-145 have been used 
to inhibit lung inflammation in mouse models of asthma. We have recently described a 
similar effect for miR-145 in isolated ASM cells from patients with COPD
(3)
. Furthermore, 
we have previously shown that miR-221 regulates both proliferation and IL-6 release of ASM 
cells from patients with severe asthma
(2)
. Both miRNAs are also present in asthmatic airway 
biopsy samples after inhaled corticosteroid treatment, compared with pre-treatment 
samples
(6)
. As such, we feel confident that miRNAs are commonly expressed at the ex-vivo, 
in-vitro AND in-vivo models of asthma. 
However, information on lncRNAs is somewhat limited. At the time of writing, there are 
only 7 papers in PubMed following a search of “lncRNA asthma” with different lncRNAs 
such as GAS5, being described. PVT1 is frequently expressed in numerous cancers (including 
lung), and this is the first time that the lncRNA has been described in asthma. We next hope 




4) Abstract: Ideally the authors should present some objective results in the abstract; 
currently the results are described in a generic and somewhat superficial way. If needed the 
background section could be shortened to allow more space to describe the results. 
 
Thank you. 
We have now re-written the abstract to make it more “reader friendly”. 
 
5) Abstract: Please avoid using abbreviations without an initial definition (e.g. FCS, PVT1). 
 
Thank you. 
We have now defined these in the text. 
 
6) Lines 94-95: Asthma is characterized by chronic airway inflammation which leads to 
recurrent episodes of at least partially reversible airflow obstruction. "Chronic airflow 
obstruction" could be misinterpreted; while severe asthma with airway remodeling may be 
partially irreversible, fixed airway obstruction tends to be more a characteristic of COPD 
rather than asthma. 
 
Thank you. 
We have removed the word “chronic”. 
 
7) Lines 95-98: Please rephrase this sentence to better reflect a plausible mechanism (e.g. 
"through its hyperplastic and hypertrophic qualities" is vague). Perhaps "Airway smooth 
muscle hyperplasia and hypertrophy leads to increased airway wall thickening and airway 
narrowing, contributing to chronic airway obstruction". 
 
Thank you. 
We have now changed this to the following; 
Asthma is characterized by airflow obstruction and chronic airway inflammation and 
remodeling
(1)
. Airway smooth muscle (ASM) hyperplasia and hypertrophy leads to increased 
airway wall thickening and airway narrowing, contributing to the airway obstruction and 
inflammation. 
 
8) Lines 106-107: Related to major comment above, please insert reference on the healthy 
ASMCs study from 2014. 
 
Thank you. 
This has now been inserted. 
 




Yes, this was Figure 2. 
 
COMMENTS FROM THE EDITORIAL OFFICE: 
 
++Please shorten your key messages,  
Thanks you. These have been shortened. 
 
** In order to emphasize the important clinical or mechanistic points of each Original Article, 
we ask that you provide either a Clinical Implications statement or a bulleted listof Key 
Messages. Clinical Implications statements should be contained to a brief paragraph (no more 
than 30 words) that presents the key concepts and diagnostic,therapeutic or management 
implications of the article and should be placed following the abstract in your manuscript. For 
more mechanistic articles, please include a bulleted listof 2-3 complete sentences that present 
the key findings and/or concepts of the article,perhaps commenting on their implications. 
This list should be labeled "Key Messages"and should appear after the abstract in your 
manuscript.  
 
** On the title page, please provide the full name, academic or technical degree, and 
academic institution for each author. If an author has no degree, please advise the Editorial 
Office. 
Thank you. These have been included. 
 
Your revision must include the following items: (1) point-by-point responses to the Editor 
and reviewer comments, (2) a marked copy of your revision showing the changes made, and 
(3) a clean (unmarked) copy of your revised manuscript. If your manuscript has any figures, 
tables, or Online Repository material in separate files, please be sure these are included in the 
revision as well. For further information regarding formatting of these elements, please 
consult the Guidelines for Submitting a Revision (found on the Elsevier Editorial System 
(EES) homepage in the Guide for Authors). To avoid a delay in a final decision on your 
manuscript, please follow these instructions carefully.  
 
If you have questions or encounter difficulties in submitting your revised manuscript, please 
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Abstract 40 
Background: The mechanism underlying non-severe and severe asthma remains 41 
unclear although it is commonly associated with increased airway smooth muscle 42 
(ASM) mass. Long non-coding RNAs (lncRNAs) are known to be important in 43 
regulating healthy primary ASM cells whilst changed expression has been observed in 44 
CD8 T-cells from patients with severe asthma. 45 
Methods: Primary ASM cells were isolated from healthy individuals (n=9), patients 46 
classified as having non-severe asthma (n=9) or severe asthma (n=9). ASM cells were 47 
exposed to dexamethasone and fetal calf serum (FCS). mRNA and lncRNA expression 48 
was measured by microarray and quantitative real-time PCR. Bioinformatic analysis 49 
was used to examine for relevant biological pathways. Finally, the lncRNA; 50 
Plasmacytoma Variant Translocation (PVT1) was inhibited by transfection of primary 51 
ASM cells with siRNAs, and the effect upon ASM cell phenotype was examined. 52 
Results: The mRNA expression profile was significantly different between patient 53 
groups following exposure to dexamethasone and FCS and these were associated with 54 
biological pathways that may be relevant to the pathogenesis of asthma including 55 
cellular proliferation and pathways associated with glucocorticoid activity. We also 56 
observed a significant change in the expression of lncRNAs, yet only one (PVT1) is 57 
decreased in expression in the corticosteroid sensitive non-severe asthmatics, and 58 
increased in expression in the corticosteroid-insensitive severe asthmatics. Subsequent 59 
targeting studies demonstrated the importance of this lncRNA in controlling both 60 
proliferation and IL-6 release in ASM cells from patients with severe asthma. 61 
Conclusions: lncRNAs are associated with the aberrant phenotype observed in ASM 62 
cells from patients with asthma. Targeting of PVT1 may be effective in reducing 63 
airway remodelling in asthma. 64 
 65 
Capsule Summary 66 
Our data suggest that lncRNA patterns are differentially dysregulated in non-severe 67 
asthmatic patients and severe asthmatic patients, and that targeting the lncRNA; PVT1 68 
may provide a treatment for asthma. 69 
 70 
Key Words: Asthma, Airway Smooth Muscle, Proliferation, IL-6, Transcriptome, 71 
Long noncoding RNA, PVT1 72 
 73 
Abbreviations used: 74 
ASMC: Airway Smooth Muscle Cell 75 
CS: Corticosteroids 76 
lncRNA: Long non-coding RNA 77 
miRNA: microRNA 78 
PVT1: Plasmacytoma Variant Translocation 79 
 80 
Key Messages: 81 
 Severe asthma is a worldwide health issue that is mostly unresponsive to 82 
existing therapy. 83 
 lncRNAs are differentially expressed between ASM cells from patients with 84 
non-severe and severe asthma. 85 
 Targeting of the lncRNA; PVT1, can reduce the increased cellular proliferation 86 
and IL-6 release from ASM cells in severe asthma.  87 
Introduction 88 
Asthma is characterized by airflow obstruction and chronic airway inflammation and 89 
remodeling
(1)
. Airway smooth muscle (ASM) hyperplasia and hypertrophy leads to 90 
increased airway wall thickening and airway narrowing, contributing to the airway 91 
obstruction and inflammation. Epigenetic mechanisms are key regulators of ASM 92 
function
(2)
. We have reported that the aberrant phenotype of ASM cells (ASMCs) from 93 
patients with asthma is under the negative regulation of cyclin inhibitors, p21
WAF1
 & 94 
p27
kip1
, which are controlled by microRNA-221
(3)
. Furthermore, by utilizing a 95 
transcriptiomic-based approach, we identified potential miRNA targets and pathways 96 
in activated human ASMCs and observed changes in expression of lncRNAs, 97 
including natural antisense, pseudogenes, intronic lncRNAs, and intergenic 98 
lncRNAs
(4)
.  99 
 100 
Having reported the results of the healthy, (or ‘non-asthmatic’) ASMCs in 2014(4), we 101 
now report upon the asthmatic ASMCs that were studied at the same time. 102 
Specifically, we report upon the differential expression of mRNAs and lncRNAs in 103 
ASMCs isolated from non-severe and severe asthmatic individuals, and treated with 104 
dexamethasone before subsequent activation with the growth medium, fetal calf serum 105 
(FCS). We have then focused upon the only lncRNA found to be decreased in 106 
expression in the corticosteroid sensitive non-severe asthmatics, and increased in 107 
expression in the corticosteroid-insensitive severe asthmatics; plasmacytoma variant 108 
translocation (PVT)1, and performed targeting studies to examine its role in a 109 
corticosteroid insensitivity model in these cells induced by the combination of TGF- 110 
and FCS. 111 
 112 
Methods 113 
Full methodology is available in the Supplemental data file. 114 
 115 
Subject selection and ASMC culture 116 
Primary ASMCs from healthy individuals, non-severe asthmatics and severe 117 
asthmatics were treated as described previously
(4-7)
. Patient characteristics are in Table 118 
1. 119 
 120 
RNA extraction 121 





Microarray Analysis 125 
LncRNA and mRNA expression was determined using the Agilent SurePrint G3 126 
Human GE microarrays following the manufacturer’s instructions, and as previously 127 
described
(4)
. Total RNA samples (50 ng) used in lncRNA and mRNA microarrays 128 
were initially labelled with Spike-In control A (for Cyanine 3-CTP) or B (for Cyanine 129 
5-CTP). Labelled samples were then used for cDNA synthesis using the cDNA Master 130 
Mix (Agilent) and were incubated for 2 h at 40°C followed by 15 min at 70°C to 131 
inactivate the Affinity-Script enzyme. The synthesized cDNA was then used for cRNA 132 
synthesis and amplification using the Transcription Master Mix with either Cyanine 3 133 
or Cyanine 5 and incubated at 40°C for 2 h. Labelled and amplified RNA was then 134 
purified using the RNeasy Mini Kit (Qiagen) and quantified using the NanoDrop 135 
Spectrophotometer’s Microarray Measurement function. The Cyanine 3 or Cyanine 5 136 
concentrations and the cRNA concentration were used to calculate the yield (μg) and 137 
the specific activity (pmol Cy3 or Cy5 per μg cRNA) of each sample. For each 138 
microarray reaction, 300 ng of Cyanine 3- and 300 ng of Cyanine 5-labelled, linearly 139 
amplified cRNA samples were mixed and incubated together with Fragmentation 140 
buffer for 30 min, followed by the addition of Hybridization buffer. Samples were 141 
loaded onto SurePrint G3 (8 × 60 K) microarray slides (Agilent) and hybridized at 142 
65°C for 17 h at 10 rpm using Agilent’s Hybridization oven and SureHyb chamber. 143 
The microarrays were then disassembled and washed in GE Wash Buffer 1 (Agilent) 144 
for 60 sec at RT, followed by GE Wash Buffer 2 for 60 sec at 37°C, followed by an 145 
acetonitrile wash (10 sec at RT) and the final wash in Stabilization and Drying 146 
solution for 30 sec at RT, to improve microarray results by preventing ozone-mediated 147 
fluorescent signal degradation. The microarrays were scanned with the Agilent 148 
Microarray Scanner G2565BA using the profile for 2-colour microarrays 149 
(AgilentG3_GX_2Color) at 5 μm resolution, dyes channel Red&Green, Scan Area 61 150 
× 21.6 mm. Following normalization against internal controls provided within the 151 
labelling kits, probes which had background expression (signal value of mRNA < 4.5) 152 
were removed. The threshold of background expression was determined using samples 153 
that processed but which contained no RNA. Since initial analysis of mRNA and 154 
lncRNA between baseline and FCS-treated cells or dexamethasone + FCS-treated cells 155 
showed none that gave a FDR < 0.1, differential expression (p value) was determined 156 
by 3-way ANOVA using the Partek Genomics Suite. We report changes in expression 157 
with p < 0.05. 158 
 159 
Pathway Analysis 160 
Differentially expressed mRNAs from each dataset were further analysed using the 161 
bioinformatics software application "Ingenuity Pathway Analysis" application 162 
(www.ingenuity.com). A "Core Functional Analysis" was performed to identify 163 
canonical pathways, predicted upstream regulators and gene networks most 164 
significantly associated with the differentially expressed mRNAs.   165 
The significance of the association of a given canonical pathway with the differentially 166 
expressed mRNAs was measured in two ways. Firstly, by the ratio of the number of 167 
differentially expressed mRNAs in the dataset that mapped to the canonical pathway 168 
divided by the total number of genes that map to the canonical pathway. Secondly, 169 
Fisher's exact test was used to calculate a P-value of the association between the 170 
mRNA and the network/canonical pathway. 171 
 172 
Quantitative PCR measurement of miRNA and mRNA expression 173 
lncRNA and mRNA expression was measured as previously described
(4)
. 174 
  175 
Transfection with siRNAs that target PVT1 176 
ASMCs were transfected as previously described
(3;5;9)
. siRNAs designed to target 177 
PVT1 and IL6 were purchased from Ambion/Applied Biosystems, Ltd. ASMCs were 178 
transfected with PVT1 inhibitor (30, 100, 300 nM), IL6 inhibitor (100 nM), or 179 
Silencer
®
 Negative Control #1 (100 nM) and no siRNA (mock transfection). 180 
 181 
Data and statistical analysis  182 
Data were analysed using GraphPad Prism, version 5.03. Data were not normally 183 
distributed (as assessed by the Kolmogorov- Smirnov test), and therefore groups were 184 
compared using the Dunn nonparametric test. All data are expressed as means ± 185 
SEMs. 186 
  187 
Results 188 
mRNAs are differentially expressed between non-severe and severe asthmatic 189 
ASMCs, and are responsible for different pathway activation 190 
Comparison of mRNA expression healthy ASMCs and non-severe or severe 191 
asthmatics showed differential expression (p<0.05) of different gene sets depending 192 
upon the status of the cells being at a ‘baseline’ state, following stimulation with FCS, 193 
and those pre-treated with dexamethasone, before stimulation with FCS. Full gene lists 194 
are in the Supplemental Data File, Tables 1-9.  195 
To identify the pathways that these mRNAs are involved in, we analyzed each dataset 196 
using the bioinformatics software application "Ingenuity Pathway Analysis" 197 
application. At ‘baseline’, those mRNAs that were increased in expression compared 198 
to healthy ASMCs, in the non-severe asthmatic cohort are proposed to be important in 199 
hydrolase activity. Those decreased in expression are involved in the extracellular 200 
matrix, and the whole profile is important for cellular assembly (Figure 1A). 201 
Interestingly, hydrolase activity is known to be important for calcium signaling in 202 
ASM
(10)
, and the extracellular matrix is involved in asthmatic airway remodeling
(11)
. In 203 
the ASMCs from the patients with severe asthma, these profiles changed to an increase 204 
in genes necessary for arachidonic acid metabolism and a decrease in those required 205 
for multicellular organismal process, and the whole profile is involved in gene 206 
expression and organ morphology. Once again, this follows our current knowledge of 207 
ASM function, and the fact that arachidonic acid induces a calcium influx in human 208 
airway smooth muscle, which has been proposed to contribute to increased influx in 209 
asthma
(12)
, and previous methylation profiling of the bronchial mucosa of asthmatics, 210 
has demonstrated a positive relationship to atopy for the multicellular organismal 211 
process
(13)
. Following stimulation with FCS, those mRNAs increased in expression in 212 
the non-severe ASM are associated with the intracellular organelle lumen, those 213 
decreased are involved in single-organism development, and together the profile is 214 
important in the inflammatory response which is well documented in human ASM
(14)
 215 
(Figure 1B). In the severe asthma ASMCs, those increased are involved in respiratory 216 
tube development, and those decreased in signaling. However, together the mRNAs 217 
are proposed to be important in immunological disease which helps explain how ASM 218 
is important for  immunomodulation in acute exacerbations of airway disease, 219 
including asthma
(15)
. When these same ASM cohorts were pretreated with 220 
dexamethasone, before stimulation with FCS (Figure 1C), those pathways activated in 221 
the non-severe ASMCs were associated with glucocorticoid activity, such as 222 
macrophage activation, the inflammatory response
(16)
, and phospholipase activity
(17)
. 223 
The severe asthmatic ASMCs, however, responded by activating genes associated with 224 
cellular growth and proliferation, a phenotype well documented as being aberrant
(4-7)
. 225 
The levels of NAV2, NFIB, PTGIS, CHI3L1, NOVA1, PTPRD, IL6, PGM5 and NNAT 226 
were selected to be verified by qRT-PCR (Figure 1D). For each of these, FCS caused 227 
a significant increase in expression in both the non-severe and severe ASMCs 228 
(p<0.05). Pre-treatment of the non-severe ASMCs with dexamethasone inhibited this 229 
increase in expression in all mRNAs, apart from NAV2. In the severe ASMCs, 230 
dexamethasone caused a further increase in NAV2 and PTGIS expression (p<0.01) in 231 
all other instances, dexamethasone only slightly inhibited the FCS-induced mRNA 232 
expression, to levels that were not comparable to the non-severe ASMCs. 233 
 234 
lncRNAs are differentially expressed between in non-severe and severe asthmatic 235 
ASMCs 236 
We have previously shown that more than 30 long noncoding RNAs (lncRNAs) are 237 
increased in expression in healthy primary ASMCs following treatment with 238 
dexamethasone and stimulation with FCS
(4)
. Hence, to identify novel lncRNAs in our 239 
asthmatic ASMCs, we used ENSEMBLE (www.ensembl.org/index.html) to determine 240 
the genomic position of those probe sets from the microarray that did not match 241 
known protein coding genes. 242 
At baseline, 21 lncRNAs were differentially expressed in ASMCs from non-severe 243 
asthmatics (15 increased and 6 decreased) when compared to the healthy individuals 244 
(Supplemental Table 10). The severe asthmatic ASMCs differentially expressed 19 245 
lncRNAs (13 increased, and 6 decreased) when compared to the healthy individuals 246 
(Supplemental Table 11)
(4)
. Interestingly, 4 lncRNAs were altered in expression in 247 
both disease phenotypes (RP5-1158E12.3, FKBP1A-SDCBP2, LINC00472, and 248 
PVT1), and PVT1 was also differentially expressed in the healthy ASMCs
(4)
. 249 
Following stimulation with FCS, the non-severe ASMCs expressed a completely 250 
different set of lncRNAs (15 increased and 16 decreased), with the exception of PVT1 251 
and RP11-141M1 (Supplemental Table 12). A similar pattern was observed in the 252 
FCS stimulated severe asthmatic ASMCs; of the 32 lncRNAs changed in expression, 253 
only 2 (LINC00940 & RP11-120D5.1) were the same as seen in the baseline non-254 
severe ASMCs (Supplemental Table 14). Furthermore, when the severe asthmatic 255 
ASMCs were treated with dexamethasone before subsequent stimulation with FCS, 256 
the number of differentially expressed lncRNAs doubled (36 increased and 38 257 
decreased in expression) (Supplementary Table 15). 258 
Of those lncRNAs that were expressed in the asthmatic ASMCs, only PVT1 was found 259 
to be decreased in expression in the corticosteroid sensitive non-severe asthmatics, 260 
and increased in expression in the corticosteroid-insensitive severe asthmatics 261 
(Supplemental Tables 10&11). Therefore we further examined the function of this 262 
lncRNA. 263 
 264 
Effect of FCS and TGF-β on PVT1 lncRNA expression in asthmatic ASMCs 265 
We have previously demonstrated that to induce a differential response in both cellular 266 
proliferation and cytokine release in ASMCs from asthmatic individuals, a combined 267 
stimulation of FCS (2.5%) and TGF-β (1ng/ml) is required(3;5). To determine the 268 
potential role of PVT1 in this proliferative and inflammatory response, we examined 269 
the time course of its expression in the presence of FCS and TGF-β. FCS+TGF-β did 270 
not change the expression of PVT1 up to 24h in the healthy ASMCs (Figure 2A), 271 
while at 24h, there was a significant reduction in the expression of PVT1 in the non-272 
severe ASMCs (p<0.01 vs. unstimulated control). Furthermore, FCS+TGF-β led to ~3-273 
fold increase (p<0.01 vs. unstimulated control) in the expression of PVT1 that reached 274 
a plateau at 3h in the severe ASMCs, and remained elevated at 24h (Figure 2A). 275 
At 24h, dexamethasone had no effect upon PVT1 expression in the healthy ASMCs 276 
(Figure 2B). However, the FCS+TGF-β-induced reduction of PVT1 in non-severe 277 
ASMCs returned to basal levels in the presence of dexamethasone (p<0.01). 278 
Furthermore, dexamethasone alone increased PVT1 expression in the severe ASMCs 279 
(~4-fold; p<0.001), and when these cells were subsequently stimulated with 280 
FCS+TGF-β, an even greater increase in expression was observed (~8-fold; p<0.001) 281 
(Figure 2B). 282 
 283 
Inhibition of PVT1 with siRNAs on ASMC proliferation and IL-6 release 284 
To elucidate the role of PVT1, we examined the action of siRNA-mediated inhibition 285 
of PVT1 on dexamethasone-exposed [FCS+TGF-β] induced BrdU incorporation and 286 
IL-6 release. As previously reported
(3;5)
, a significant increase in BrdU incorporation 287 
and IL-6 release was observed in both healthy and severe asthmatic subjects following 288 
stimulation with FCS+TGF-β (p<0.001 vs. unstimulated control) (Figure 3C-F). 289 
Dexamethasone inhibited BrdU incorporation and IL-6 release in the healthy ASMCs, 290 
but had no effect upon the BrdU incorporation in the severe ASMCs, and a limited 291 
effect upon IL-6 release (Figure 3C-F). These results also demonstrate the relative 292 
corticosteroid insensitivity of the cells from severe asthma compared to healthy 293 
subjects with respect to BrdU incorporation and IL-6 release.  294 
Transfection using Amaxa electroporation with siRNAs designed to target PVT1 295 
(300nM), knocked-down expression of PVT1 in healthy ASMCs both at baseline and 296 
following stimulation with FCS+TGF-β (p<0.01) (Figure 3A). When the same cells 297 
were exposed to dexamethasone before stimulation with FCS+TGF-β, a reduction was 298 
still observed, but not to the same level as without dexamethasone (p<0.05). When 299 
PVT1 was targeted with siRNAs in the severe ASMCs, the FCS+TGF-β and 300 
Dex+[FCS+TGF-β]-induced PVT1 was returned to basal levels (Figure 3B).  301 
Knocking down PVT1 had no effect upon BrdU incorporation induced by FCS+TGF-β 302 
in either cohort of ASMCs (Figure 3C&D). However, PVT1 knock-down increased 303 
BrdU incorporation in the severe ASMCs when they were exposed to dexamethasone 304 
before stimulation with FCS+TGF-β (p<0.01 vs. Dex+[FCS+TGF-β]) (Figure 3D). 305 
Furthermore, siRNA targeted inhibition of PVT1 resulted in both an increase in 306 
FCS+TGF-β-induced IL-6 release (p<0.01 vs. FCS+TGF-β), and reversed the 307 
inhibitory action of dexamethasone in the ASMCs from healthy individuals (p<0.01 vs 308 
Dex+[FCS+TGF-β]) (Figure 3E). This suggests that inhibiting expression of PVT1 309 
increases CS insensitivity in ASMCs, however, there was no effect observed upon IL-310 
6 release in the severe asthma ASMCs when PVT1 was targeted, but this is possibly 311 
due to the IL-6 release already being at maximal levels (Figure 3F). 312 
A non-targeting negative control (30-300nM) demonstrated no effect upon either 313 
BrdU incorporation or IL-6 release in either cohort, as previously shown
(5;7;9)
 (data not 314 
shown). To demonstrate evidence of efficient transfection, concurrent studies were 315 
performed to examine the effect of siRNAs (100nM) targeted to IL6 mRNA. A 316 
reduction in IL-6 release induced by FCS+TGF-β stimulation in ASMCs from healthy 317 
subjects (p<0.001) and those from severe asthma (p<0.01) was observed, as previously 318 
described
(3;9)
 (Supplemental Figure 2A&B). Furthermore, to demonstrate that 319 
electroporation had no adverse effect upon cellular viability, MTT assays were 320 
performed both before stimulation with FCS+TGF-β (Supplemental Figure 2C&D), 321 
and after stimulation (Supplemental Figure 2E&F). In either situation, transfection 322 
using Amaxa electroporation had no effect upon cellular viability. 323 
 324 
Effect of PVT1 inhibition on IL6 mRNA in asthmatic ASMCs 325 
In a similar pattern to that seen in the increasing IL-6 protein release induced by 326 
FCS+TGF-β in these ASMCs(3), IL6 mRNA expression is increased in expression in 327 
the healthy cells (~15-fold), greater still in the non-severe asthmatics (~20-fold) and to 328 
the highest degree in the severe ASMCs (~45-fold), when these cells are stimulated 329 
with FCS+TGF-β (p<0.01 vs. unstimulated control) (Figure 4A). Incubation with 330 
dexamethasone before stimulation with FCS+TGF-β resulted in inhibition of IL6 331 
mRNA expression in the healthy and non-severe ASMCs (p<0.001 and p<0.01, 332 
respectively), with no significant effect in the severe ASMCs (Figure 4A). 333 
The effect of PVT1 targeting by siRNAs upon IL6 mRNA was then examined. In the 334 
healthy ASMCs, the FCS+TGF-β induced expression of IL6 was similar to that 335 
observed in Figure 4A, when the cells were either mock transfected or transfected 336 
with 100nM of negative control siRNA (Figure 4C). When the healthy ASMCs were 337 
transfected with a siRNA designed to target IL6 mRNA, the expression of this mRNA 338 
was almost completely attenuated (p<0.001) (Figure 4C). However, when the basal 339 
expression of PVT1 (as described in Figure 2B), was inhibited in these ASMCs with 340 
300nM of siRNA, a significant increase in IL6 mRNA expression was observed, when 341 
the cells were stimulated with FCS+TGF-β (p<0.05) (Figure 4C). Addition of 342 
dexamethasone prior to FCS+TGF-β, resulted in a decrease in IL6 mRNA levels in the 343 
mock and negative siRNA transfected cells, and IL-6 siRNA transfection resulted in 344 
inhibition of IL6 mRNA expression (Figure 4C). 345 
IL6 mRNA expression was similarly affected by the different transfection variables in 346 
the ASMCs from the severe asthmatics (Figure 4E). Either mock transfection or 347 
transfecting with a negative control siRNA had no effect upon the IL6 mRNA 348 
expression. Transfecting with a siRNA designed to target IL6, inhibited the expression 349 
of IL6 mRNA (Figure 4E). However, inhibiting the expression of PVT1 with siRNAs 350 
reduced the expression of IL6 mRNA expression following stimulation with 351 
FCS+TGF-β, both with and without exposure to dexamethasone (p<0.001) (Figure 352 
4E). 353 
 354 
Effect of PVT1 inhibition on c-MYC mRNA in asthmatic ASMCs 355 
PVT1 is transcriptionally activated by the oncogene c-MYC
(4;18)
 and, we have 356 
previously reported that c-MYC in important in controlling ASMC proliferation, but 357 
not cytokine release
(5)
, we therefore examined the effect of targeting PVT1 with 358 
siRNAs upon c-MYC mRNA expression. Stimulation with FCS+TGF-β induced an 359 
increase in c-MYC mRNA expression in ASMCs from the severe asthmatics (p<0.01), 360 
with no effect seen in the healthy or non-severe ASMCs (Figure 4B). Exposure of the 361 
severe asthmatic ASMCs with dexamethasone, either on its own, or before stimulation 362 
with FCS+TGF-β, resulted in a larger increase in c-MYC mRNA expression (both 363 
p<0.001) (Figure 4B). 364 
Transfecting siRNAs designed to target PVT1 (300nM), knocked-down expression of 365 
c-MYC in healthy ASMCs both at baseline and following stimulation with FCS+TGF-366 
β (p<0.01) (Figure 4D). When PVT1 was targeted with siRNAs in the severe ASMCs, 367 
the FCS+TGF-β and Dex+[FCS+TGF-β]-induced c-MYC expression was returned to 368 
basal levels (Figure 4F). 369 
In summary, these results show that in primary ASMCs from non-asthmatic 370 
individuals, inhibiting the endogenous expression of PVT1, results in a reversal of the 371 
inhibitory action of dexamethasone upon the FCS+TGF-β-induced IL6 mRNA 372 
expression and protein release. Furthermore, in ASMCs from patients with severe 373 
asthma, dexamethasone increases the expression of PVT1, and inhibition of this with 374 
siRNAs, results in an increase in FCS+TGF-β-induced cellular proliferation by 375 
targeting of the transcription factor c-MYC. 376 
 377 
Discussion 378 
Utilizing a transcriptiomic-based approach, we have examined the expression of 379 
RNAs (mRNA, miRNA and lncRNA) in primary ASMCs isolated from non-380 
asthmatic, non-severe asthmatics and severe asthmatics. We published the results of 381 
the non-asthmatics in 2014
(4)
, and now, following some additional functional studies, 382 
report upon the non-severe asthmatics and severe asthmatics. 383 
Of the mRNAs that we examined, we found that the mRNA profile differentially 384 





, the inflammatory response
(14)
, and the activity of 386 
glucocorticoids
(16;17)
. Interestingly, the mRNA profile in ASMCs from severe asthma 387 





and possible immunomodulation in acute exacerbations of airway disease, including 389 
asthma
(15)
. Furthermore, when confirming our array results with RT-PCR, we 390 
described mRNAs that have previously been shown to be increased in response to 391 
dexamethasone (NAV2)
(19)
, to regulate cell viability, cell growth, cellular proliferation 392 
and/or airway remodeling (NFIB, NOVA1, PTPRD, PGM5)
(20-23)
, and those acting as 393 
potential tumor suppressors in lung carcinoma (PTPRD & NNAT)
(24;25)
. Furthermore, 394 
we describe a large increase in CHI3L1, which has not only been reported in a number 395 
of inflammatory diseases and cancer, but has been implicated in asthma, with the 396 
discovery of an allele that doubles the risk
(26)
. However, PTGIS is the only one of 397 
these mRNA targets to have been associated with ASM and can induce both 398 
bronchodilation and reverse ASMC remodeling in a mouse model of asthma
(27)
. 399 
We also measured the expression of lncRNAs in our patient cohorts. A large number 400 
of lncRNAs were differentially expressed, under all situations (baseline, corticosteroid 401 
treatment, and mitogen stimulation). Interestingly, only PVT1 was found to be 402 
decreased in the non-severe ASMCs, and increased in the severe ASMCs, and so we 403 
performed functional studies upon this lncRNA in our model of asthmatic 404 
hyperproliferation and corticosteroid insensitivity
(3;5)
. The action of PVT1 in our 405 
asthmatic ASMCs was complex. As such, we have proposed a figure that shows 406 
potential mechanisms for PVT1 in ASMC proliferation and IL-6 release (Figure 5). In 407 
the non-asthmatic ‘healthy’ ASMC, [TGF-β+FCS] induces IL6 mRNA expression, 408 
which translates into IL-6 protein release. Interestingly, the addition of dexamethasone 409 
results in an increase in expression of PVT1, which, when inhibited by siRNAs 410 
(Figure 5A), induces greater IL6 mRNA expression and more IL-6 protein released. In 411 
the ASMCs from patients with severe asthma, [TGF-β+FCS] not only induces IL6 412 
mRNA expression and protein release, but also the expression of PVT1. The effect of 413 
dexamethasone was the same, and when we inhibited PVT1 in these ASMCs with 414 
siRNAs (Figure 5B), a decrease in IL6 mRNA and IL-6 protein release was observed, 415 
along with a concurrent increase in cellular proliferation. The mechanism of action of 416 
PVT1 in human primary ASM is clearly complex. Very little is known about the role 417 





. Furthermore, targeting of PVT1 in these 419 
pathologies has been shown to have a range of effects including decreasing 420 
proliferation and increasing apoptosis
(29;36)
, decreasing resistance to gemcitabine (a 421 
chemotherapy drug)
(37)
, and regulation of genes and proteins involved in ECM 422 
deposition
(33)
. We have demonstrated, for the first time, the novel way in which 423 
targeting PVT1 in human primary ASMCs can affect phenotype. 424 
The variable mechanism of action of PVT1 could simply be a consequence of different 425 
cells, tissues and pathologies examined; however, it may also be due to the action, and 426 
configuration of PVT1 itself. PVT1 is a downstream target of c-MYC that targets and 427 
binds PVT1 driving its transcription
(18)
. We show that in our severe asthmatic ASMC 428 
cohorts; dexamethasone increases the expression of PVT1, and inhibition of this 429 
results in an increase in FCS+TGF-β-induced cellular proliferation, possibly by 430 
targeting of c-MYC.  431 
Finally, PVT1 is unlikely to be the only ncRNA acting in our ASMC model. We have 432 
previously reported upon the role of miRNAs in these cells following stimulation with 433 
[TGF-β+FCS](3), and now it is known that PVT1 can express a cluster of 6 miRNAs 434 
such as miR-1207-5p (of which we discussed previously
(4)
). Although these ncRNAs 435 





In conclusion, we have demonstrated a large difference in ncRNA expression profiles 439 
(including miRNAs, and lncRNAs), in primary human ASMCs from patients with 440 
non-severe and severe asthma and the differential effects of adding corticosteroids and 441 
mitogen. Furthermore we have found that PVT1 regulates both IL-6 release and 442 
proliferation in ASMCs from individuals with severe asthma.  443 
Tables 444 






n  9 9  9  
Age (yrs.) 36.4 ± 12.7 42.4 ± 16.2  48.9 ± 11  
Sex (♂ / ♀) 7 / 2 6 / 4 3 / 6  
Duration of asthma (yrs.) N/A 22.2 ± 16.8  25.6 ± 13.2 
Inhaled corticosteroid dose  
(μg BDP equivalent) 
N/A 
580 ± 576.9  1688.9 ± 176.4  
Atopy (n)* 0 8 8  
Receiving oral 
corticosteroids (n)  
0 
0  7  
FEV
1
 (L) 4.02 ± 0.48 2.81 ± 0.71  2.7 ± 0.82  
FEV
1
 (% Predicted) 104.23 ± 7.28 84.68 ± 12.31  80.48 ± 12.34  
FEV
1
/FVC (%)  78.79 ± 5.98 69.87 ± 9.27  63.98 ± 9.68  
β-agonist reversibility (%)
# 
 N/A 12.3 ± 11.9  19.54 ± 14.56  
PC
20  
(mg/ml)  > 16 0.69 ± 0.64  0.2 ± 0.39  
BDP, beclomethasone dipropionate; FEV1, forced expiratory volume in 1s; FVC, 446 
forced vital capacity; PC20, provocative concentration of methacholine causing a 20% 447 
fall in FEV1; N/A: not available. * Defined as positive skin prick tests to one or more 448 
common aeroallergens. # measured as percent increase in FEV1 after 400 μg 449 
salbutamol. Data shown as mean ± SEM. 450 
 451 
Figure Legends 452 
Figure 1: Venn diagrams showing pathway analysis of differentially expressed 453 
mRNAs in asthmatic ASM 454 
Pathway analysis showing inter-group comparisons at baseline [A], following 455 
stimulation with FCS (2.5%) [B] and FCS (2.5 %) + TGF-β (1 ng/ml) [C]. Data 456 
represents n = 9 for each patient type. To validate the array data, the expression of 9 457 
mRNAs were confirmed by TaqMan RT-PCR [D]. Bars represent mean ± SEM from 9 458 
primary ASM cell donors. * p < 0.05; ** p < 0.01; *** p < 0.001. 459 
 460 
Figure 2: Effect of dexamethasone and [FCS+TGF-β] on PVT1 lncRNA 461 
expression in asthmatic ASM cells. [FCS+TGF-β] induced PVT1 lncRNA expression 462 
was measured by qRT-PCR, over 1, 3, 6 and 24 h [A]. Dexamethasone and 463 
[FCS+TGF-β] induced PVT1 expression was measured by qRT-PCR at 24 h [B] 464 
Points/bars represent mean ± SEM of 9 ASM cell donors. ** p < 0.01; *** p < 0.001. 465 
 466 
Figure 3: Effect of targeting PVT1 with siRNAs upon IL-6 release and BrdU 467 
incorporation in ASM cells from healthy subjects and those with severe asthma. 468 
PVT1 lncRNA expression was measured by RT-PCR after healthy and severe asthma 469 
ASM were transfected with siRNA (300 nM), designed to target PVT1 (A&B). BrdU 470 
incorporation (C&D) and IL-6 release (E&F) were measured by BrdU ELISA and 471 
DuoSet ELISA Assay, respectively, at 8 days. Bars/points represent the means ± SEM 472 
of 9 ASM cell donors. */# p < 0.05; ##/++ p < 0.01; ***/### p < 0.001. 473 
 474 
Figure 4: Effect of targeting PVT1 with siRNAs upon IL6 and c-MYC mRNA in 475 
ASM cells from healthy subjects and those with severe asthma. IL6 and c-MYC 476 
mRNA expression was measured by RT-PCR after exposure to dexamethasone (10
-7
 477 
M) and stimulation with FCS (2.5 %) + TGF-β (1 ng/ml) for 24 h (A&B). Healthy and 478 
severe asthmatic ASM cells were transfected with siRNAs designed to target PVT1, 479 
and the expression of IL6 (C&E) and c-MYC (D&F) mRNA was measured by RT-480 
PCR. Bars represent the means ± SEM of 9 ASM cell donors. # p < 0.05; **/##/++
 
p < 481 
0.01; ***
/###/+++ p < 0.001. 482 
 483 
Figure 5: Potential mechanisms for PVT1 contribution to ASM cells proliferation 484 
and IL-6 release in asthma. 485 
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Abstract 40 
Background: The mechanism underlying non-severe and severe asthma remains 41 
unclear although it is commonly associated with increased airway smooth muscle 42 
(ASM) mass. Long non-coding RNAs (lncRNAs) are known to be important in 43 
regulating healthy primary ASM cells whilst changed expression has been observed in 44 
CD8 T-cells from patients with severe asthma. 45 
Methods: Primary ASM cells were isolated from healthy individuals (n=9), patients 46 
classified as having non-severe asthma (n=9) or severe asthma (n=9). ASM cells were 47 
exposed to dexamethasone and fetal calf serum (FCS). mRNA and lncRNA expression 48 
was measured by microarray and quantitative real-time PCR. Bioinformatic analysis 49 
was used to examine for relevant biological pathways. Finally, the lncRNA; 50 
Plasmacytoma Variant Translocation (PVT1) was inhibited by transfection of primary 51 
ASM cells with siRNAs, and the effect upon ASM cell phenotype was examined. 52 
Results: The mRNA expression profile was significantly different between patient 53 
groups following exposure to dexamethasone and FCS and these were associated with 54 
biological pathways that may be relevant to the pathogenesis of asthma including 55 
cellular proliferation and pathways associated with glucocorticoid activity. We also 56 
observed a significant change in the expression of lncRNAs, yet only one (PVT1) is 57 
decreased in expression in the corticosteroid sensitive non-severe asthmatics, and 58 
increased in expression in the corticosteroid-insensitive severe asthmatics. Subsequent 59 
targeting studies demonstrated the importance of this lncRNA in controlling both 60 
proliferation and IL-6 release in ASM cells from patients with severe asthma. 61 
Conclusions: lncRNAs are associated with the aberrant phenotype observed in ASM 62 
cells from patients with asthma. Targeting of PVT1 may be effective in reducing 63 
airway remodelling in asthma. 64 
 65 
Capsule Summary 66 
Our data suggest that lncRNA patterns are differentially dysregulated in non-severe 67 
asthmatic patients and severe asthmatic patients, and that targeting the lncRNA; PVT1 68 
may provide a treatment for asthma. 69 
 70 
Key Words: Asthma, Airway Smooth Muscle, Proliferation, IL-6, Transcriptome, 71 
Long noncoding RNA, PVT1 72 
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ASMC: Airway Smooth Muscle Cell 75 
CS: Corticosteroids 76 
lncRNA: Long non-coding RNA 77 
miRNA: microRNA 78 
PVT1: Plasmacytoma Variant Translocation 79 
 80 
Key Messages: 81 
 Severe asthma is a worldwide health issue that is mostly unresponsive to 82 
existing therapy. 83 
 lncRNAs are differentially expressed between ASM cells from patients with 84 
non-severe and severe asthma. 85 
 Targeting of the lncRNA; PVT1, can reduce the increased cellular proliferation 86 
and IL-6 release from ASM cells in severe asthma.  87 
Introduction 88 
Asthma is characterized by airflow obstruction and chronic airway inflammation and 89 
remodeling
(1)
. Airway smooth muscle (ASM) hyperplasia and hypertrophy leads to 90 
increased airway wall thickening and airway narrowing, contributing to the airway 91 
obstruction and inflammation. Epigenetic mechanisms are key regulators of ASM 92 
function
(2)
. We have reported that the aberrant phenotype of ASM cells (ASMCs) from 93 
patients with asthma is under the negative regulation of cyclin inhibitors, p21
WAF1
 & 94 
p27
kip1
, which are controlled by microRNA-221
(3)
. Furthermore, by utilizing a 95 
transcriptiomic-based approach, we identified potential miRNA targets and pathways 96 
in activated human ASMCs and observed changes in expression of lncRNAs, 97 
including natural antisense, pseudogenes, intronic lncRNAs, and intergenic 98 
lncRNAs
(4)
.  99 
 100 
Having reported the results of the healthy, (or ‘non-asthmatic’) ASMCs in 2014(4), we 101 
now report upon the asthmatic ASMCs that were studied at the same time. 102 
Specifically, we report upon the differential expression of mRNAs and lncRNAs in 103 
ASMCs isolated from non-severe and severe asthmatic individuals, and treated with 104 
dexamethasone before subsequent activation with the growth medium, fetal calf serum 105 
(FCS). We have then focused upon the only lncRNA found to be decreased in 106 
expression in the corticosteroid sensitive non-severe asthmatics, and increased in 107 
expression in the corticosteroid-insensitive severe asthmatics; plasmacytoma variant 108 
translocation (PVT)1, and performed targeting studies to examine its role in a 109 
corticosteroid insensitivity model in these cells induced by the combination of TGF- 110 
and FCS. 111 
 112 
Methods 113 
Full methodology is available in the Supplemental data file. 114 
 115 
Subject selection and ASMC culture 116 
Primary ASMCs from healthy individuals, non-severe asthmatics and severe 117 
asthmatics were treated as described previously
(4-7)
. Patient characteristics are in Table 118 
1. 119 
 120 
RNA extraction 121 





Microarray Analysis 125 
LncRNA and mRNA expression was determined using the Agilent SurePrint G3 126 
Human GE microarrays following the manufacturer’s instructions, and as previously 127 
described
(4)
. Total RNA samples (50 ng) used in lncRNA and mRNA microarrays 128 
were initially labelled with Spike-In control A (for Cyanine 3-CTP) or B (for Cyanine 129 
5-CTP). Labelled samples were then used for cDNA synthesis using the cDNA Master 130 
Mix (Agilent) and were incubated for 2 h at 40°C followed by 15 min at 70°C to 131 
inactivate the Affinity-Script enzyme. The synthesized cDNA was then used for cRNA 132 
synthesis and amplification using the Transcription Master Mix with either Cyanine 3 133 
or Cyanine 5 and incubated at 40°C for 2 h. Labelled and amplified RNA was then 134 
purified using the RNeasy Mini Kit (Qiagen) and quantified using the NanoDrop 135 
Spectrophotometer’s Microarray Measurement function. The Cyanine 3 or Cyanine 5 136 
concentrations and the cRNA concentration were used to calculate the yield (μg) and 137 
the specific activity (pmol Cy3 or Cy5 per μg cRNA) of each sample. For each 138 
microarray reaction, 300 ng of Cyanine 3- and 300 ng of Cyanine 5-labelled, linearly 139 
amplified cRNA samples were mixed and incubated together with Fragmentation 140 
buffer for 30 min, followed by the addition of Hybridization buffer. Samples were 141 
loaded onto SurePrint G3 (8 × 60 K) microarray slides (Agilent) and hybridized at 142 
65°C for 17 h at 10 rpm using Agilent’s Hybridization oven and SureHyb chamber. 143 
The microarrays were then disassembled and washed in GE Wash Buffer 1 (Agilent) 144 
for 60 sec at RT, followed by GE Wash Buffer 2 for 60 sec at 37°C, followed by an 145 
acetonitrile wash (10 sec at RT) and the final wash in Stabilization and Drying 146 
solution for 30 sec at RT, to improve microarray results by preventing ozone-mediated 147 
fluorescent signal degradation. The microarrays were scanned with the Agilent 148 
Microarray Scanner G2565BA using the profile for 2-colour microarrays 149 
(AgilentG3_GX_2Color) at 5 μm resolution, dyes channel Red&Green, Scan Area 61 150 
× 21.6 mm. Following normalization against internal controls provided within the 151 
labelling kits, probes which had background expression (signal value of mRNA < 4.5) 152 
were removed. The threshold of background expression was determined using samples 153 
that processed but which contained no RNA. Since initial analysis of mRNA and 154 
lncRNA between baseline and FCS-treated cells or dexamethasone + FCS-treated cells 155 
showed none that gave a FDR < 0.1, differential expression (p value) was determined 156 
by 3-way ANOVA using the Partek Genomics Suite. We report changes in expression 157 
with p < 0.05. 158 
 159 
Pathway Analysis 160 
Differentially expressed mRNAs from each dataset were further analysed using the 161 
bioinformatics software application "Ingenuity Pathway Analysis" application 162 
(www.ingenuity.com). A "Core Functional Analysis" was performed to identify 163 
canonical pathways, predicted upstream regulators and gene networks most 164 
significantly associated with the differentially expressed mRNAs.   165 
The significance of the association of a given canonical pathway with the differentially 166 
expressed mRNAs was measured in two ways. Firstly, by the ratio of the number of 167 
differentially expressed mRNAs in the dataset that mapped to the canonical pathway 168 
divided by the total number of genes that map to the canonical pathway. Secondly, 169 
Fisher's exact test was used to calculate a P-value of the association between the 170 
mRNA and the network/canonical pathway. 171 
 172 
Quantitative PCR measurement of miRNA and mRNA expression 173 
lncRNA and mRNA expression was measured as previously described
(4)
. 174 
  175 
Transfection with siRNAs that target PVT1 176 
ASMCs were transfected as previously described
(3;5;9)
. siRNAs designed to target 177 
PVT1 and IL6 were purchased from Ambion/Applied Biosystems, Ltd. ASMCs were 178 
transfected with PVT1 inhibitor (30, 100, 300 nM), IL6 inhibitor (100 nM), or 179 
Silencer
®
 Negative Control #1 (100 nM) and no siRNA (mock transfection). 180 
 181 
Data and statistical analysis  182 
Data were analysed using GraphPad Prism, version 5.03. Data were not normally 183 
distributed (as assessed by the Kolmogorov- Smirnov test), and therefore groups were 184 
compared using the Dunn nonparametric test. All data are expressed as means ± 185 
SEMs. 186 
  187 
Results 188 
mRNAs are differentially expressed between non-severe and severe asthmatic 189 
ASMCs, and are responsible for different pathway activation 190 
Comparison of mRNA expression healthy ASMCs and non-severe or severe 191 
asthmatics showed differential expression (p<0.05) of different gene sets depending 192 
upon the status of the cells being at a ‘baseline’ state, following stimulation with FCS, 193 
and those pre-treated with dexamethasone, before stimulation with FCS. Full gene lists 194 
are in the Supplemental Data File, Tables 1-9.  195 
To identify the pathways that these mRNAs are involved in, we analyzed each dataset 196 
using the bioinformatics software application "Ingenuity Pathway Analysis" 197 
application. At ‘baseline’, those mRNAs that were increased in expression compared 198 
to healthy ASMCs, in the non-severe asthmatic cohort are proposed to be important in 199 
hydrolase activity. Those decreased in expression are involved in the extracellular 200 
matrix, and the whole profile is important for cellular assembly (Figure 1A). 201 
Interestingly, hydrolase activity is known to be important for calcium signaling in 202 
ASM
(10)
, and the extracellular matrix is involved in asthmatic airway remodeling
(11)
. In 203 
the ASMCs from the patients with severe asthma, these profiles changed to an increase 204 
in genes necessary for arachidonic acid metabolism and a decrease in those required 205 
for multicellular organismal process, and the whole profile is involved in gene 206 
expression and organ morphology. Once again, this follows our current knowledge of 207 
ASM function, and the fact that arachidonic acid induces a calcium influx in human 208 
airway smooth muscle, which has been proposed to contribute to increased influx in 209 
asthma
(12)
, and previous methylation profiling of the bronchial mucosa of asthmatics, 210 
has demonstrated a positive relationship to atopy for the multicellular organismal 211 
process
(13)
. Following stimulation with FCS, those mRNAs increased in expression in 212 
the non-severe ASM are associated with the intracellular organelle lumen, those 213 
decreased are involved in single-organism development, and together the profile is 214 
important in the inflammatory response which is well documented in human ASM
(14)
 215 
(Figure 1B). In the severe asthma ASMCs, those increased are involved in respiratory 216 
tube development, and those decreased in signaling. However, together the mRNAs 217 
are proposed to be important in immunological disease which helps explain how ASM 218 
is important for  immunomodulation in acute exacerbations of airway disease, 219 
including asthma
(15)
. When these same ASM cohorts were pretreated with 220 
dexamethasone, before stimulation with FCS (Figure 1C), those pathways activated in 221 
the non-severe ASMCs were associated with glucocorticoid activity, such as 222 
macrophage activation, the inflammatory response
(16)
, and phospholipase activity
(17)
. 223 
The severe asthmatic ASMCs, however, responded by activating genes associated with 224 
cellular growth and proliferation, a phenotype well documented as being aberrant
(4-7)
. 225 
The levels of NAV2, NFIB, PTGIS, CHI3L1, NOVA1, PTPRD, IL6, PGM5 and NNAT 226 
were selected to be verified by qRT-PCR (Figure 1D). For each of these, FCS caused 227 
a significant increase in expression in both the non-severe and severe ASMCs 228 
(p<0.05). Pre-treatment of the non-severe ASMCs with dexamethasone inhibited this 229 
increase in expression in all mRNAs, apart from NAV2. In the severe ASMCs, 230 
dexamethasone caused a further increase in NAV2 and PTGIS expression (p<0.01) in 231 
all other instances, dexamethasone only slightly inhibited the FCS-induced mRNA 232 
expression, to levels that were not comparable to the non-severe ASMCs. 233 
 234 
lncRNAs are differentially expressed between in non-severe and severe asthmatic 235 
ASMCs 236 
We have previously shown that more than 30 long noncoding RNAs (lncRNAs) are 237 
increased in expression in healthy primary ASMCs following treatment with 238 
dexamethasone and stimulation with FCS
(4)
. Hence, to identify novel lncRNAs in our 239 
asthmatic ASMCs, we used ENSEMBLE (www.ensembl.org/index.html) to determine 240 
the genomic position of those probe sets from the microarray that did not match 241 
known protein coding genes. 242 
At baseline, 21 lncRNAs were differentially expressed in ASMCs from non-severe 243 
asthmatics (15 increased and 6 decreased) when compared to the healthy individuals 244 
(Supplemental Table 10). The severe asthmatic ASMCs differentially expressed 19 245 
lncRNAs (13 increased, and 6 decreased) when compared to the healthy individuals 246 
(Supplemental Table 11)
(4)
. Interestingly, 4 lncRNAs were altered in expression in 247 
both disease phenotypes (RP5-1158E12.3, FKBP1A-SDCBP2, LINC00472, and 248 
PVT1), and PVT1 was also differentially expressed in the healthy ASMCs
(4)
. 249 
Following stimulation with FCS, the non-severe ASMCs expressed a completely 250 
different set of lncRNAs (15 increased and 16 decreased), with the exception of PVT1 251 
and RP11-141M1 (Supplemental Table 12). A similar pattern was observed in the 252 
FCS stimulated severe asthmatic ASMCs; of the 32 lncRNAs changed in expression, 253 
only 2 (LINC00940 & RP11-120D5.1) were the same as seen in the baseline non-254 
severe ASMCs (Supplemental Table 14). Furthermore, when the severe asthmatic 255 
ASMCs were treated with dexamethasone before subsequent stimulation with FCS, 256 
the number of differentially expressed lncRNAs doubled (36 increased and 38 257 
decreased in expression) (Supplementary Table 15). 258 
Of those lncRNAs that were expressed in the asthmatic ASMCs, only PVT1 was found 259 
to be decreased in expression in the corticosteroid sensitive non-severe asthmatics, 260 
and increased in expression in the corticosteroid-insensitive severe asthmatics 261 
(Supplemental Tables 10&11). Therefore we further examined the function of this 262 
lncRNA. 263 
 264 
Effect of FCS and TGF-β on PVT1 lncRNA expression in asthmatic ASMCs 265 
We have previously demonstrated that to induce a differential response in both cellular 266 
proliferation and cytokine release in ASMCs from asthmatic individuals, a combined 267 
stimulation of FCS (2.5%) and TGF-β (1ng/ml) is required(3;5). To determine the 268 
potential role of PVT1 in this proliferative and inflammatory response, we examined 269 
the time course of its expression in the presence of FCS and TGF-β. FCS+TGF-β did 270 
not change the expression of PVT1 up to 24h in the healthy ASMCs (Figure 2A), 271 
while at 24h, there was a significant reduction in the expression of PVT1 in the non-272 
severe ASMCs (p<0.01 vs. unstimulated control). Furthermore, FCS+TGF-β led to ~3-273 
fold increase (p<0.01 vs. unstimulated control) in the expression of PVT1 that reached 274 
a plateau at 3h in the severe ASMCs, and remained elevated at 24h (Figure 2A). 275 
At 24h, dexamethasone had no effect upon PVT1 expression in the healthy ASMCs 276 
(Figure 2B). However, the FCS+TGF-β-induced reduction of PVT1 in non-severe 277 
ASMCs returned to basal levels in the presence of dexamethasone (p<0.01). 278 
Furthermore, dexamethasone alone increased PVT1 expression in the severe ASMCs 279 
(~4-fold; p<0.001), and when these cells were subsequently stimulated with 280 
FCS+TGF-β, an even greater increase in expression was observed (~8-fold; p<0.001) 281 
(Figure 2B). 282 
 283 
Inhibition of PVT1 with siRNAs on ASMC proliferation and IL-6 release 284 
To elucidate the role of PVT1, we examined the action of siRNA-mediated inhibition 285 
of PVT1 on dexamethasone-exposed [FCS+TGF-β] induced BrdU incorporation and 286 
IL-6 release. As previously reported
(3;5)
, a significant increase in BrdU incorporation 287 
and IL-6 release was observed in both healthy and severe asthmatic subjects following 288 
stimulation with FCS+TGF-β (p<0.001 vs. unstimulated control) (Figure 3C-F). 289 
Dexamethasone inhibited BrdU incorporation and IL-6 release in the healthy ASMCs, 290 
but had no effect upon the BrdU incorporation in the severe ASMCs, and a limited 291 
effect upon IL-6 release (Figure 3C-F). These results also demonstrate the relative 292 
corticosteroid insensitivity of the cells from severe asthma compared to healthy 293 
subjects with respect to BrdU incorporation and IL-6 release.  294 
Transfection using Amaxa electroporation with siRNAs designed to target PVT1 295 
(300nM), knocked-down expression of PVT1 in healthy ASMCs both at baseline and 296 
following stimulation with FCS+TGF-β (p<0.01) (Figure 3A). When the same cells 297 
were exposed to dexamethasone before stimulation with FCS+TGF-β, a reduction was 298 
still observed, but not to the same level as without dexamethasone (p<0.05). When 299 
PVT1 was targeted with siRNAs in the severe ASMCs, the FCS+TGF-β and 300 
Dex+[FCS+TGF-β]-induced PVT1 was returned to basal levels (Figure 3B).  301 
Knocking down PVT1 had no effect upon BrdU incorporation induced by FCS+TGF-β 302 
in either cohort of ASMCs (Figure 3C&D). However, PVT1 knock-down increased 303 
BrdU incorporation in the severe ASMCs when they were exposed to dexamethasone 304 
before stimulation with FCS+TGF-β (p<0.01 vs. Dex+[FCS+TGF-β]) (Figure 3D). 305 
Furthermore, siRNA targeted inhibition of PVT1 resulted in both an increase in 306 
FCS+TGF-β-induced IL-6 release (p<0.01 vs. FCS+TGF-β), and reversed the 307 
inhibitory action of dexamethasone in the ASMCs from healthy individuals (p<0.01 vs 308 
Dex+[FCS+TGF-β]) (Figure 3E). This suggests that inhibiting expression of PVT1 309 
increases CS insensitivity in ASMCs, however, there was no effect observed upon IL-310 
6 release in the severe asthma ASMCs when PVT1 was targeted, but this is possibly 311 
due to the IL-6 release already being at maximal levels (Figure 3F). 312 
A non-targeting negative control (30-300nM) demonstrated no effect upon either 313 
BrdU incorporation or IL-6 release in either cohort, as previously shown
(5;7;9)
 (data not 314 
shown). To demonstrate evidence of efficient transfection, concurrent studies were 315 
performed to examine the effect of siRNAs (100nM) targeted to IL6 mRNA. A 316 
reduction in IL-6 release induced by FCS+TGF-β stimulation in ASMCs from healthy 317 
subjects (p<0.001) and those from severe asthma (p<0.01) was observed, as previously 318 
described
(3;9)
 (Supplemental Figure 2A&B). Furthermore, to demonstrate that 319 
electroporation had no adverse effect upon cellular viability, MTT assays were 320 
performed both before stimulation with FCS+TGF-β (Supplemental Figure 2C&D), 321 
and after stimulation (Supplemental Figure 2E&F). In either situation, transfection 322 
using Amaxa electroporation had no effect upon cellular viability. 323 
 324 
Effect of PVT1 inhibition on IL6 mRNA in asthmatic ASMCs 325 
In a similar pattern to that seen in the increasing IL-6 protein release induced by 326 
FCS+TGF-β in these ASMCs(3), IL6 mRNA expression is increased in expression in 327 
the healthy cells (~15-fold), greater still in the non-severe asthmatics (~20-fold) and to 328 
the highest degree in the severe ASMCs (~45-fold), when these cells are stimulated 329 
with FCS+TGF-β (p<0.01 vs. unstimulated control) (Figure 4A). Incubation with 330 
dexamethasone before stimulation with FCS+TGF-β resulted in inhibition of IL6 331 
mRNA expression in the healthy and non-severe ASMCs (p<0.001 and p<0.01, 332 
respectively), with no significant effect in the severe ASMCs (Figure 4A). 333 
The effect of PVT1 targeting by siRNAs upon IL6 mRNA was then examined. In the 334 
healthy ASMCs, the FCS+TGF-β induced expression of IL6 was similar to that 335 
observed in Figure 4A, when the cells were either mock transfected or transfected 336 
with 100nM of negative control siRNA (Figure 4C). When the healthy ASMCs were 337 
transfected with a siRNA designed to target IL6 mRNA, the expression of this mRNA 338 
was almost completely attenuated (p<0.001) (Figure 4C). However, when the basal 339 
expression of PVT1 (as described in Figure 2B), was inhibited in these ASMCs with 340 
300nM of siRNA, a significant increase in IL6 mRNA expression was observed, when 341 
the cells were stimulated with FCS+TGF-β (p<0.05) (Figure 4C). Addition of 342 
dexamethasone prior to FCS+TGF-β, resulted in a decrease in IL6 mRNA levels in the 343 
mock and negative siRNA transfected cells, and IL-6 siRNA transfection resulted in 344 
inhibition of IL6 mRNA expression (Figure 4C). 345 
IL6 mRNA expression was similarly affected by the different transfection variables in 346 
the ASMCs from the severe asthmatics (Figure 4E). Either mock transfection or 347 
transfecting with a negative control siRNA had no effect upon the IL6 mRNA 348 
expression. Transfecting with a siRNA designed to target IL6, inhibited the expression 349 
of IL6 mRNA (Figure 4E). However, inhibiting the expression of PVT1 with siRNAs 350 
reduced the expression of IL6 mRNA expression following stimulation with 351 
FCS+TGF-β, both with and without exposure to dexamethasone (p<0.001) (Figure 352 
4E). 353 
 354 
Effect of PVT1 inhibition on c-MYC mRNA in asthmatic ASMCs 355 
PVT1 is transcriptionally activated by the oncogene c-MYC
(4;18)
 and, we have 356 
previously reported that c-MYC in important in controlling ASMC proliferation, but 357 
not cytokine release
(5)
, we therefore examined the effect of targeting PVT1 with 358 
siRNAs upon c-MYC mRNA expression. Stimulation with FCS+TGF-β induced an 359 
increase in c-MYC mRNA expression in ASMCs from the severe asthmatics (p<0.01), 360 
with no effect seen in the healthy or non-severe ASMCs (Figure 4B). Exposure of the 361 
severe asthmatic ASMCs with dexamethasone, either on its own, or before stimulation 362 
with FCS+TGF-β, resulted in a larger increase in c-MYC mRNA expression (both 363 
p<0.001) (Figure 4B). 364 
Transfecting siRNAs designed to target PVT1 (300nM), knocked-down expression of 365 
c-MYC in healthy ASMCs both at baseline and following stimulation with FCS+TGF-366 
β (p<0.01) (Figure 4D). When PVT1 was targeted with siRNAs in the severe ASMCs, 367 
the FCS+TGF-β and Dex+[FCS+TGF-β]-induced c-MYC expression was returned to 368 
basal levels (Figure 4F). 369 
In summary, these results show that in primary ASMCs from non-asthmatic 370 
individuals, inhibiting the endogenous expression of PVT1, results in a reversal of the 371 
inhibitory action of dexamethasone upon the FCS+TGF-β-induced IL6 mRNA 372 
expression and protein release. Furthermore, in ASMCs from patients with severe 373 
asthma, dexamethasone increases the expression of PVT1, and inhibition of this with 374 
siRNAs, results in an increase in FCS+TGF-β-induced cellular proliferation by 375 
targeting of the transcription factor c-MYC. 376 
 377 
Discussion 378 
Utilizing a transcriptiomic-based approach, we have examined the expression of 379 
RNAs (mRNA, miRNA and lncRNA) in primary ASMCs isolated from non-380 
asthmatic, non-severe asthmatics and severe asthmatics. We published the results of 381 
the non-asthmatics in 2014
(4)
, and now, following some additional functional studies, 382 
report upon the non-severe asthmatics and severe asthmatics. 383 
Of the mRNAs that we examined, we found that the mRNA profile differentially 384 





, the inflammatory response
(14)
, and the activity of 386 
glucocorticoids
(16;17)
. Interestingly, the mRNA profile in ASMCs from severe asthma 387 





and possible immunomodulation in acute exacerbations of airway disease, including 389 
asthma
(15)
. Furthermore, when confirming our array results with RT-PCR, we 390 
described mRNAs that have previously been shown to be increased in response to 391 
dexamethasone (NAV2)
(19)
, to regulate cell viability, cell growth, cellular proliferation 392 
and/or airway remodeling (NFIB, NOVA1, PTPRD, PGM5)
(20-23)
, and those acting as 393 
potential tumor suppressors in lung carcinoma (PTPRD & NNAT)
(24;25)
. Furthermore, 394 
we describe a large increase in CHI3L1, which has not only been reported in a number 395 
of inflammatory diseases and cancer, but has been implicated in asthma, with the 396 
discovery of an allele that doubles the risk
(26)
. However, PTGIS is the only one of 397 
these mRNA targets to have been associated with ASM and can induce both 398 
bronchodilation and reverse ASMC remodeling in a mouse model of asthma
(27)
. 399 
We also measured the expression of lncRNAs in our patient cohorts. A large number 400 
of lncRNAs were differentially expressed, under all situations (baseline, corticosteroid 401 
treatment, and mitogen stimulation). Interestingly, only PVT1 was found to be 402 
decreased in the non-severe ASMCs, and increased in the severe ASMCs, and so we 403 
performed functional studies upon this lncRNA in our model of asthmatic 404 
hyperproliferation and corticosteroid insensitivity
(3;5)
. The action of PVT1 in our 405 
asthmatic ASMCs was complex. As such, we have proposed a figure that shows 406 
potential mechanisms for PVT1 in ASMC proliferation and IL-6 release (Figure 5). In 407 
the non-asthmatic ‘healthy’ ASMC, [TGF-β+FCS] induces IL6 mRNA expression, 408 
which translates into IL-6 protein release. Interestingly, the addition of dexamethasone 409 
results in an increase in expression of PVT1, which, when inhibited by siRNAs 410 
(Figure 5A), induces greater IL6 mRNA expression and more IL-6 protein released. In 411 
the ASMCs from patients with severe asthma, [TGF-β+FCS] not only induces IL6 412 
mRNA expression and protein release, but also the expression of PVT1. The effect of 413 
dexamethasone was the same, and when we inhibited PVT1 in these ASMCs with 414 
siRNAs (Figure 5B), a decrease in IL6 mRNA and IL-6 protein release was observed, 415 
along with a concurrent increase in cellular proliferation. The mechanism of action of 416 
PVT1 in human primary ASM is clearly complex. Very little is known about the role 417 





. Furthermore, targeting of PVT1 in these 419 
pathologies has been shown to have a range of effects including decreasing 420 
proliferation and increasing apoptosis
(29;36)
, decreasing resistance to gemcitabine (a 421 
chemotherapy drug)
(37)
, and regulation of genes and proteins involved in ECM 422 
deposition
(33)
. We have demonstrated, for the first time, the novel way in which 423 
targeting PVT1 in human primary ASMCs can affect phenotype. 424 
The variable mechanism of action of PVT1 could simply be a consequence of different 425 
cells, tissues and pathologies examined; however, it may also be due to the action, and 426 
configuration of PVT1 itself. PVT1 is a downstream target of c-MYC that targets and 427 
binds PVT1 driving its transcription
(18)
. We show that in our severe asthmatic ASMC 428 
cohorts; dexamethasone increases the expression of PVT1, and inhibition of this 429 
results in an increase in FCS+TGF-β-induced cellular proliferation, possibly by 430 
targeting of c-MYC.  431 
Finally, PVT1 is unlikely to be the only ncRNA acting in our ASMC model. We have 432 
previously reported upon the role of miRNAs in these cells following stimulation with 433 
[TGF-β+FCS](3), and now it is known that PVT1 can express a cluster of 6 miRNAs 434 
such as miR-1207-5p (of which we discussed previously
(4)
). Although these ncRNAs 435 





In conclusion, we have demonstrated a large difference in ncRNA expression profiles 439 
(including miRNAs, and lncRNAs), in primary human ASMCs from patients with 440 
non-severe and severe asthma and the differential effects of adding corticosteroids and 441 
mitogen. Furthermore we have found that PVT1 regulates both IL-6 release and 442 
proliferation in ASMCs from individuals with severe asthma.  443 
Tables 444 






n  9 9  9  
Age (yrs.) 36.4 ± 12.7 42.4 ± 16.2  48.9 ± 11  
Sex (♂ / ♀) 7 / 2 6 / 4 3 / 6  
Duration of asthma (yrs.) N/A 22.2 ± 16.8  25.6 ± 13.2 
Inhaled corticosteroid dose  
(μg BDP equivalent) 
N/A 
580 ± 576.9  1688.9 ± 176.4  
Atopy (n)* 0 8 8  
Receiving oral 
corticosteroids (n)  
0 
0  7  
FEV
1
 (L) 4.02 ± 0.48 2.81 ± 0.71  2.7 ± 0.82  
FEV
1
 (% Predicted) 104.23 ± 7.28 84.68 ± 12.31  80.48 ± 12.34  
FEV
1
/FVC (%)  78.79 ± 5.98 69.87 ± 9.27  63.98 ± 9.68  
β-agonist reversibility (%)
# 
 N/A 12.3 ± 11.9  19.54 ± 14.56  
PC
20  
(mg/ml)  > 16 0.69 ± 0.64  0.2 ± 0.39  
BDP, beclomethasone dipropionate; FEV1, forced expiratory volume in 1s; FVC, 446 
forced vital capacity; PC20, provocative concentration of methacholine causing a 20% 447 
fall in FEV1; N/A: not available. * Defined as positive skin prick tests to one or more 448 
common aeroallergens. # measured as percent increase in FEV1 after 400 μg 449 
salbutamol. Data shown as mean ± SEM. 450 
 451 
Figure Legends 452 
Figure 1: Venn diagrams showing pathway analysis of differentially expressed 453 
mRNAs in asthmatic ASM 454 
Pathway analysis showing inter-group comparisons at baseline [A], following 455 
stimulation with FCS (2.5%) [B] and FCS (2.5 %) + TGF-β (1 ng/ml) [C]. Data 456 
represents n = 9 for each patient type. To validate the array data, the expression of 9 457 
mRNAs were confirmed by TaqMan RT-PCR [D]. Bars represent mean ± SEM from 9 458 
primary ASM cell donors. * p < 0.05; ** p < 0.01; *** p < 0.001. 459 
 460 
Figure 2: Effect of dexamethasone and [FCS+TGF-β] on PVT1 lncRNA 461 
expression in asthmatic ASM cells. [FCS+TGF-β] induced PVT1 lncRNA expression 462 
was measured by qRT-PCR, over 1, 3, 6 and 24 h [A]. Dexamethasone and 463 
[FCS+TGF-β] induced PVT1 expression was measured by qRT-PCR at 24 h [B] 464 
Points/bars represent mean ± SEM of 9 ASM cell donors. ** p < 0.01; *** p < 0.001. 465 
 466 
Figure 3: Effect of targeting PVT1 with siRNAs upon IL-6 release and BrdU 467 
incorporation in ASM cells from healthy subjects and those with severe asthma. 468 
PVT1 lncRNA expression was measured by RT-PCR after healthy and severe asthma 469 
ASM were transfected with siRNA (300 nM), designed to target PVT1 (A&B). BrdU 470 
incorporation (C&D) and IL-6 release (E&F) were measured by BrdU ELISA and 471 
DuoSet ELISA Assay, respectively, at 8 days. Bars/points represent the means ± SEM 472 
of 9 ASM cell donors. */# p < 0.05; ##/++ p < 0.01; ***/### p < 0.001. 473 
 474 
Figure 4: Effect of targeting PVT1 with siRNAs upon IL6 and c-MYC mRNA in 475 
ASM cells from healthy subjects and those with severe asthma. IL6 and c-MYC 476 
mRNA expression was measured by RT-PCR after exposure to dexamethasone (10
-7
 477 
M) and stimulation with FCS (2.5 %) + TGF-β (1 ng/ml) for 24 h (A&B). Healthy and 478 
severe asthmatic ASM cells were transfected with siRNAs designed to target PVT1, 479 
and the expression of IL6 (C&E) and c-MYC (D&F) mRNA was measured by RT-480 
PCR. Bars represent the means ± SEM of 9 ASM cell donors. # p < 0.05; **/##/++
 
p < 481 
0.01; ***
/###/+++ p < 0.001. 482 
 483 
Figure 5: Potential mechanisms for PVT1 contribution to ASM cells proliferation 484 
and IL-6 release in asthma. 485 
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Subject selection 10 
Patients with non-severe and severe asthma as defined by European Respiratory 11 
Society/American Thoracic Society Workshop on Severe Asthma
(1)
 were recruited. Current 12 
smokers and former smokers with greater than 5 pack-year history were excluded. Non-13 
asthmatic normal subjects with no previous history of asthma and a PC20 >16 mg/ml were also 14 
recruited. The subject characteristics are shown in Table 1. Each subject underwent a 15 
fiberoptic bronchoscopic study under sedation with midazolam and topical anaesthesia to the 16 
airways with lidocaine. Airway biopsies were taken from segmental and sub-segmental 17 
airways of the right lower lobe. This study was approved by the Ethics Committee and all 18 
subjects gave written informed consent. 19 
 20 
ASM cell culture and stimulation 21 
ASM cells were cultured as previously described
(2-6)
. Confluent cells were growth-arrested by 22 
FCS deprivation for 24 h in Dulbecco’s Modified Eagle’s Medium supplemented with sodium 23 
pyruvate (1 mM), L-glutamine (2 mM), non-essential amino acids (1:100), penicillin (100 24 
U/ml)/streptomycin (100 mg/ml), amphotericin B (1.5 mg/ml), and BSA (0.1 %). Human 25 
Repository - Marked Text
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airway smooth muscle cells at passages 3–4 from nine different donors were used. Cells were 26 
pre-treated with dexamethasone (10
-7
 M) for 1 h, before being stimulated with 2.5 % FCS for 27 
24 h. The supernatants were removed and IL-6 levels were determined by DuoSet ELISA 28 
(R&D Systems, Abingdon, UK) as a measure of ASM cell activation (Supplementary Data 29 
File 1). Cell proliferation was measured by the Cell Proliferation ELISA BrdU kit (Roche 30 
Applied Science), an assay comparable to cell counting as confirmed by flow cytometry
(2-5)
. 31 
Cellular viability was assessed by MTT assay
(7)
. Each patient sample was replicated over 3 32 
wells. 33 
 34 
RNA extraction 35 
Total RNA was extracted using the mirVana™miRNA isolation kit (Ambion Europe). RNA 36 
was eluted in 50 μl RNase-free water (Promega UK, Southampton, UK) and stored at -70 °C. 37 
RNA content and purity was measured using a BioTek PowerWave XS (SSi Robotics, Tustin, 38 
CA, U.S.A.) spectrophotometer (yield (± SD): 1.1 ± 0.3 mg/ml; purity (A260/A280): 2.0 ± 0.1). 39 
 40 
Microarray Analysis 41 
LncRNA and mRNA expression was determined using the Agilent SurePrint G3 Human GE 42 




Pathway Analysis 45 
Differentially expressed mRNAs from each dataset were further analysed using the 46 
bioinformatics software application "Ingenuity Pathway Analysis" application 47 
(www.ingenuity.com). A "Core Functional Analysis" was performed to identify canonical 48 
pathways, predicted upstream regulators and gene networks most significantly associated 49 
with the differentially expressed mRNAs.   50 
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The significance of the association of a given canonical pathway with the differentially 51 
expressed mRNAs was measured in two ways. Firstly, by the ratio of the number of 52 
differentially expressed mRNAs in the dataset that mapped to the canonical pathway divided 53 
by the total number of genes that map to the canonical pathway. Secondly, Fisher's exact test 54 
was used to calculate a P-value of the association between the mRNA and the 55 
network/canonical pathway. 56 
 57 
Quantitative PCR measurement of miRNA and mRNA expression 58 
miRNA expression was undertaken with the 2-step Applied Biosystems TaqMan RT-PCR 59 
protocol (Applied Biosystems) and normalized to 18S, as previously described
(2;3;8)
. mRNA 60 
expression was determined using TaqMan RT-PCR with Assays on Demand (Applied 61 
Biosystems). The separate-well 2
-(ΔΔCt)
 method was used to determine relative quantitative 62 
levels of individual miRNAs and mRNAs. 63 
  64 
Transfection with siRNAs that target PVT1 65 
ASMCs were transfected as previously described
(2;9;10)
. siRNAs designed to target PVT1 and 66 
IL6 were purchased from Ambion/Applied Biosystems, Ltd. ASMCs were transfected with 67 
PVT1 inhibitor (30, 100, 300 nM), IL6 inhibitor (100 nM), or Silencer
®
 Negative Control #1 68 
(100 nM) and no siRNA (mock transfection). 69 
 70 
Data and statistical analysis  71 
Data were analysed using GraphPad Prism, version 5.03. Data were not normally distributed 72 
(as assessed by the Kolmogorov- Smirnov test), and therefore groups were compared using 73 




Supplemental Table 1: Baseline mRNA expression in non-severe ASM compared to healthy ASM cells 76 
 77 
Gene P value FC Gene P value FC 
ERCC8 0.00256679 8.12903 GAL 0.0394773 2.1095 
SLC16A6 0.0166426 4.65081 AKR1B10 0.0449671 2.07792 
HMSD 0.00663085 4.3893 FITM2 0.0183232 2.07506 
HSD17B2 0.0443303 3.89864 SYTL2 0.0198481 2.06856 
IGDCC4 0.0465114 3.6928 FLYWCH2 0.0121742 2.06587 
MMP1 0.0259227 3.35243 EVI2A 0.0277221 2.06063 
MMP3 0.0304801 3.22102 SLC7A14 0.0383132 2.03911 
TRPA1 0.01778 3.13945 GNASAS 0.0482069 2.03829 
SALL1 0.0052357 2.99666 RAB30 0.0289699 2.03204 
RGS2 0.00555875 2.95017 KIAA1217 0.0265248 2.01769 
FLI1 0.00364385 2.8631 PTH1R 0.0329649 1.97698 
HRK 0.0429068 2.83682 C4orf36 0.0290853 1.96317 
UCP2 0.00851212 2.79613 EID2B 0.00613632 1.96143 
RARRES2 0.020582 2.77563 ARRDC4 0.0328818 1.95579 
CLEC2B 0.00642905 2.77082 PAX4 0.0409322 1.95439 
CARD17 0.00592314 2.70494 KCNN2 0.0242211 1.95348 
TSHZ2 0.0134582 2.6941 SNORA53 0.0220681 1.94978 
RNMT 0.00515799 2.63754 ARHGAP18 0.0106662 1.93914 
C20orf196 0.0479645 2.62389 TBPL1 0.00781103 1.93791 
CARD16 0.00841454 2.61194 TMEM97 0.00858623 1.93744 
C9orf110 0.043834 2.55355 LRP8 0.0443823 1.93136 
C17orf60 0.0267141 2.5307 SIPA1L3 0.00637892 1.91352 
ICAM4 0.0437101 2.40862 NR_024569 0.0186056 1.90429 
HMGCS1 0.0424883 2.39058 SAR1P3 0.00898055 1.89096 
CCDC68 0.0233077 2.37967 C17orf86 0.00453316 1.88747 
COL10A1 0.0250919 2.35495 CKS2 0.0142289 1.87502 
EPHX4 0.00462827 2.34974 CDK17 0.020251 1.872 
CST2 0.0389638 2.34496 C8orf41 0.00323954 1.856 
CDYL2 0.00955754 2.34042 SEMA3A 0.0369473 1.85269 
LCE2A 0.0266531 2.32617 COQ3 0.0370812 1.84123 
TNFSF4 0.0253868 2.31612 GLRX 0.0111158 1.82913 
IL7R 0.0408885 2.2781 GIT1 0.00646277 1.81225 
NES 0.00362585 2.27808 C13orf1 0.0333645 1.80632 
SC4MOL 0.0481442 2.26589 STMN3 0.0166473 1.80345 
CCDC102B 0.0140359 2.21734 SPRY1 0.032023 1.79181 
LOC100130938 0.00548399 2.20849 FANCA 0.00139521 1.78639 
ADAMTS9 0.0199445 2.20162 PPP1R2P3 0.030498 1.78449 
TTC12 0.00392433 2.18397 LOC728353 0.0144362 1.76044 
LYN 0.0191528 2.17462 FAIM3 0.0129136 1.75518 
LPPR3 0.0220692 2.17076 COPG2 0.00572741 1.75405 
C13orf15 0.0234561 2.13801 KIR3DL3 0.035418 1.74011 
SATB2 0.012104 2.13354 ATG9B 0.0388154 1.73542 
SNORA74B 0.041715 2.12524 LOC100128340 0.0329169 1.73146 
MRPS23 0.0117045 2.12179 RIPK3 0.0234775 1.73035 
ATP2A2 0.0172857 2.11786 TMC4 0.00187281 1.72712 
PTGES 0.0464004 1.72193 LPO 0.0312946 1.51464 
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SGIP1 0.0427581 1.71441 C1orf97 0.0127892 1.51182 
C11orf85 0.022358 1.70651 TCERG1 0.0210095 1.50193 
LY6G5B 0.0323101 1.70556 C11orf94 0.03963 1.50051 
PDCD1LG2 0.0460351 1.69217 C12orf34 0.0134796 -1.50109 
MOGAT2 0.0454009 1.6802 OLFML2B 0.00965737 -1.50279 
ITIH1 0.0179354 1.67862 GAA 0.027051 -1.5045 
DGCR11 0.0295952 1.67359 SLC13A3 0.0227501 -1.51245 
LOC374443 0.0248206 1.6646 IQCE 0.031671 -1.51583 
DUSP18 0.0406348 1.65337 SLIT3 0.0098095 -1.51648 
ETV4 0.0257434 1.64981 COL16A1 0.0296194 -1.51924 
CD99 0.0252357 1.64791 METRNL 0.0290532 -1.51963 
R3HDML 0.0197006 1.64091 CLDN15 0.0472718 -1.53115 
APIP 0.0293658 1.62597 MUC4 0.0243439 -1.5319 
ICAM5 0.0162558 1.62544 LAMB2 0.027407 -1.53783 
KLHL7 0.0397881 1.62432 KCND3 0.017771 -1.5382 
FBXO3 0.0496671 1.61443 PBX3 0.00198743 -1.53883 
TGDS 0.00616609 1.61348 RN18S1 0.0385365 -1.54727 
C20orf135 0.0285209 1.61253 SH3BP5 0.00623863 -1.56086 
IL1RAPL1 0.00713879 1.61077 CAND2 0.0156141 -1.5663 
AX748082 0.0126975 1.60578 SYNE2 0.0382512 -1.59534 
CEPT1 0.040725 1.60157 P2RY11 0.0449651 -1.60603 
LRP11 0.0436053 1.59635 CCDC19 0.0123329 -1.6178 
WNT6 0.0235748 1.59304 TGFB3 0.0278389 -1.62348 
NAAA 0.0289171 1.58906 ZNF230 0.0114767 -1.63745 
ASB8 0.027996 1.58609 NPIPL3 0.0361165 -1.63849 
ZNF222 0.0223744 1.58609 KCNG1 0.031928 -1.64202 
S100P 0.0345147 1.58354 FAT4 0.0394372 -1.65585 
HTR7 0.0486079 1.58315 GMDS 0.010624 -1.65937 
FAM176A 0.0455432 1.58124 PIP5KL1 0.0423751 -1.6623 
ATL1 0.0229584 1.56837 AQP3 0.0283477 -1.6645 
ARSG 0.0105803 1.5673 FBXO32 0.0433856 -1.6664 
ADAM9 0.0375495 1.55888 DIRAS1 0.038796 -1.66986 
LOC442572 0.0258556 1.5564 GYPA 0.0230486 -1.68431 
ZNF789 0.0282785 1.5487 GLIS2 0.0127594 -1.68923 
LIPT1 0.0292182 1.54776 PBX1 0.00848981 -1.69002 
ASL 0.0349748 1.5466 ATP1B1 0.045649 -1.69544 
GALNT4 0.00944573 1.54382 DMD 0.0497104 -1.69705 
MGC16703 0.0079992 1.54334 NEK10 0.0329041 -1.6991 
VWA2 0.00431907 1.54086 TLX2 0.00613515 -1.70613 
TATDN1 0.0400969 1.53946 CCDC80 0.0452328 -1.71459 
CNR2 0.0366879 1.53872 NPR1 0.00816906 -1.71749 
CASS4 0.0270782 1.52985 NNAT 0.0314012 -1.72845 
OSGIN1 0.0088119 1.52734 GHR 0.0306231 -1.73155 
ZNF195 0.00969063 1.52537 NAV2 0.0113647 -1.73644 
OSTF1 0.0349153 1.52403 CACNB2 0.0467284 -1.74416 
ZNF417 0.0383173 1.52402 ZNF503 0.00907856 -1.74658 
RAD51 0.0388823 1.52261 C9orf96 0.0105939 -1.74742 
S100A3 0.0113228 1.51853 DACT1 0.023388 -1.75241 
ZNF107 0.0215264 -1.76592 ACCN1 0.0331635 -2.10818 
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GKAP1 0.0490861 -1.76878 C5orf39 0.0450539 -2.11464 
SNAR-G1 0.0383436 -1.77303 PRKCH 0.00336745 -2.13392 
SHANK2 0.048114 -1.783 TMEM151B 0.0380533 -2.13457 
DOK5 0.0136432 -1.78756 CRL2 0.00269115 -2.16473 
SEMA3F 0.0276809 -1.79524 ANGPTL1 0.0236193 -2.18693 
PGM5 0.00393577 -1.80463 CMYA5 0.000900832 -2.19022 
PEG10 0.0233929 -1.81285 PPL 0.0122776 -2.19369 
OR2A9P 0.0494225 -1.81684 KIAA1644 0.0292289 -2.21229 
LOC388242 0.00329465 -1.81988 NOVA1 0.0146329 -2.21791 
REP15 0.00864225 -1.8237 STAC 0.0195427 -2.23498 
PDE8B 0.035244 -1.82845 KCNJ8 0.00643319 -2.28672 
HTRA1 0.0112554 -1.83021 PDLIM4 0.0041358 -2.29975 
CCDC151 0.00528945 -1.832 NR3C2 0.0201973 -2.30728 
HLX 0.0257786 -1.8349 KLHDC7B 0.00447221 -2.31489 
SPTLC3 0.0129416 -1.83967 C10orf11 0.0397767 -2.32799 
BEST4 0.0010698 -1.84151 SLC39A5 0.01412 -2.3978 
NFIA 0.0218309 -1.87978 CYP2J2 0.0314292 -2.4092 
SLC6A9 0.0234398 -1.8842 GALNT12 0.00283954 -2.445 
FNBP1L 0.0286074 -1.88962 GDF10 0.0227301 -2.45552 
MFAP4 0.0489281 -1.9139 EPHA5 0.00717682 -2.54064 
L2HGDH 0.00913428 -1.9146 TNNT2 0.0353226 -2.54526 
CLU 0.00740704 -1.92507 CGNL1 0.023339 -2.56621 
NLGN1 0.0099885 -1.92683 C10orf10 0.0327907 -2.57199 
TMEM59L 0.00108387 -1.93338 IGF1 0.0103895 -2.58664 
DIRC3 0.0470113 -1.93538 NRCAM 0.00254471 -2.60154 
MATN2 0.0142377 -1.93694 DPT 0.00643853 -2.60339 
ABCC9 0.0358009 -1.94478 MFAP5 0.044958 -2.61452 
ZFPM2 0.0194637 -1.94683 SULF1 0.00534576 -2.66216 
TMOD4 0.00319358 -1.95017 COL14A1 0.000357204 -2.66577 
ABLIM1 0.00177999 -1.96815 KIAA1324L 0.0359039 -2.67384 
FUCA1 0.0405767 -1.97474 DHRS3 0.00774106 -2.75273 
SLIT3 0.0398184 -1.98453 FGF18 0.000896677 -2.80081 
VWCE 0.0312087 -1.98542 JAM2 0.00305768 -2.80562 
FGF13 0.0138649 -1.99866 GPER 0.000233449 -2.84791 
LAMA3 0.0341782 -2.00515 COL6A6 0.0472692 -2.92356 
OR10G3 0.00739 -2.01027 EPHB6 0.0216317 -2.92423 
TACSTD2 0.0488225 -2.01974 CHRDL1 0.012315 -2.92678 
SCN2A 0.00858522 -2.02318 GPR68 0.0122055 -3.02474 
C8orf46 0.00669657 -2.03351 FLJ41603 0.00358055 -3.02479 
ITIH3 0.0435118 -2.03558 PTGIS 0.0300997 -3.05012 
ADAMTS3 0.00983634 -2.03924 GNAZ 0.031785 -3.07734 
HTRA3 0.0243531 -2.04246 C7orf69 0.0411363 -3.09401 
SERPINA3 0.0225425 -2.05235 NEFM 0.00778604 -3.13218 
LIF 0.00101274 -2.06048 FNDC1 0.0119883 -3.2049 
SLC4A4 0.0246772 -2.08013 OGN 0.00233206 -3.27812 
FOXC1 0.015423 -2.08185 SCN4B 0.0159437 -3.38216 
COBLL1 0.0270806 -2.10497 C13orf33 0.0265376 -3.4087 
AKAP12 0.0137054 -2.10649 TMEM30B 0.00673075 -3.61571 
CRLF1 0.00736869 -3.6385 PTPRD 0.00132004 -4.4638 
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AGT 0.020381 -3.64996 TMEFF2 8.25E-06 -4.54125 
CCDC3 0.0117285 -3.7839 PI16 0.0304839 -4.90266 
CXCR7 0.0178151 -3.94469 NFIB 0.0111192 -4.94463 
MGP 0.000631693 -3.97238 SCN2B 0.000479454 -7.85751 
CCKAR 0.00487403 -4.32258    
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Supplemental Table 2: Baseline mRNA expression in severe ASM compared to healthy ASM cells 79 
 80 
Gene P value FC Gene P value FC 
CHI3L1 0.00322219 6.61982 SYTL2 0.0328305 1.96693 
TRIM63 0.0231446 4.09239 ENTPD7 0.0257107 1.96311 
APBA2 0.0445882 3.82477 LPPR3 0.0489578 1.9601 
IL34 0.0191848 3.69834 COQ3 0.026979 1.95358 
CDC73 0.0269521 3.68601 CES1 0.0362807 1.89267 
HRK 0.0211963 3.44723 EFNB1 0.0338861 1.87755 
KIAA1199 0.0148091 3.38659 INA 0.019085 1.81494 
LRRC15 0.0295012 3.24591 FLJ31715 0.0352514 1.81384 
WISP2 0.0258918 3.08252 GGT5 0.0384159 1.79639 
HLA-DRB3 0.0241551 3.0408 UPF0621 0.0193493 1.79492 
PLA2G5 0.0270857 3.02936 LOC390251 0.0129469 1.76937 
FCRL1 0.0229921 2.81958 B3GALTL 0.0357022 1.76502 
BOC 0.0496743 2.69953 PLA2G16 0.0429882 1.76186 
RANBP2 0.0213297 2.67464 ST3GAL5 0.0351087 1.7441 
KCND2 0.0474138 2.63907 ZNF91 0.0336617 1.73603 
SERPINB9 0.0267262 2.36852 CDK17 0.0436539 1.73378 
AQP11 0.00276018 2.32601 PIGZ 0.0496192 1.72694 
ASB2 0.0247058 2.25971 SERPINE2 0.0453189 1.72255 
CCL28 0.0294344 2.18907 MT1G 0.0347974 1.71768 
P2RX7 0.0176809 2.18229 POLR2F 0.0103218 1.69222 
LOC649941 0.00266206 2.13469 C4orf22 0.0364316 1.69198 
PLXDC2 0.0285438 2.07502 TRIM78P 0.0377634 1.68077 
SCUBE3 0.00809742 2.06145 GNPTAB 0.00505003 1.67564 
SLC30A3 0.0191482 2.05979 ELOVL4 0.0384621 1.67198 
LOC645431 0.00327623 2.04048 MID2 0.0272579 1.66531 
PLXNC1 0.03469 2.00889 MYO1E 0.00629935 1.64458 
TSKS 0.0404227 2.00233 DA992326 0.0232459 1.63417 
ARRDC4 0.0322396 1.99718 FAM179A 0.016525 1.62278 
SBSN 0.0333072 1.98322 ARL4C 0.0299183 1.61076 
GPRC5C 0.00819651 1.97791 RGNEF 0.0401281 1.60602 
FZD8 0.0445338 1.97657 AIMP1 0.0260581 1.59682 
OR6N1 0.0459387 1.97118 ZNF850P 0.0490557 1.59094 
GPC3 0.0416173 1.5907 TMOD4 0.0126156 -1.75445 
CU678159 0.0435196 1.58094 FHL3 0.00232316 -1.76187 
MAF 0.0488807 1.5683 KCNMB4 0.044772 -1.76424 
PCOTH 0.0189505 1.56159 NLGN1 0.0257432 -1.76981 
FAM107B 0.0134004 1.5443 LOC100128340 0.0273873 -1.79563 
RASGRP4 0.0091248 1.53014 TMSB15A 0.0472232 -1.80402 
ZC3H12C 0.0366664 1.52823 G6PD 0.0143391 -1.80527 
ALX3 0.01248 1.52661 PGA3 0.029713 -1.82591 
EPB42 0.0404321 1.52063 GSTM2 0.00624907 -1.83722 
SOAT1 0.0465077 1.51478 RTF1 0.0342033 -1.83891 
ZNF417 0.0468942 1.51189 MIR155HG 0.0463894 -1.84051 
SUSD2 0.0267075 1.50014 EDIL3 0.00907355 -1.846 
EID1 0.0372519 1.5 FOXC1 0.0436204 -1.84634 
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RXRB 0.0192761 -1.51577 BC013171 0.0176268 -1.85591 
COL9A3 0.0275545 -1.52281 LEMD2 0.0283376 -1.87251 
THC2551759 0.025643 -1.5293 TEKT4 0.0253215 -1.87611 
LIF 0.0360369 -1.54658 MATN2 0.0206684 -1.88823 
DNAJC4 0.0231423 -1.55047 GLIS1 0.0160045 -1.90408 
LOC100129721 0.0389218 -1.55148 UCN2 0.00691849 -1.93071 
PARVB 0.0485998 -1.56027 NOVA1 0.041179 -1.95198 
KIAA1683 0.030854 -1.57456 HBA2 0.00836222 -1.9605 
OLFML3 0.0229235 -1.58161 EDNRA 0.00849789 -1.98684 
LOC606724 0.0305021 -1.58414 HCLS1 0.0126303 -2.01169 
CMYA5 0.0382822 -1.58529 CCDC36 0.0361258 -2.03234 
AF495723 0.0197298 -1.5889 COL7A1 0.00806561 -2.03399 
PIWIL4 0.00386534 -1.59655 C8orf46 0.00705425 -2.06141 
FES 0.013501 -1.59932 DPT 0.0325449 -2.10323 
AK124041 0.0098982 -1.6135 TMEM151B 0.0410405 -2.15069 
HSD11B2 0.0361224 -1.61447 PEG10 0.00432019 -2.2238 
LOC100130557 0.0223642 -1.63702 EPHA5 0.0167505 -2.30662 
BHLHE23 0.0374452 -1.642 CCDC85A 0.0364354 -2.32329 
DCHS1 0.0245409 -1.6444 ZNF462 0.0207553 -2.35787 
SH3GL1P3 0.00380501 -1.64995 WBSCR27 0.0236313 -2.39805 
COL14A1 0.0445964 -1.65881 KIAA0430 0.037571 -2.52596 
CYBA 0.0107948 -1.65884 FLRT3 0.0499926 -2.55809 
BAT2 0.0467807 -1.67443 KIAA1324L 0.0370802 -2.72654 
PIK3C2B 0.0268458 -1.71271 FGF13 0.000851033 -2.79977 
LGI4 0.027596 -1.71907 POMC 0.0269916 -2.89054 
PRR16 0.0161184 -1.73578 PSKH1 0.0218528 -2.97571 
LOC100130713 0.0158694 -1.73869 BCHE 0.0043359 -3.02392 
RAX2 0.0264997 -1.74198 TWF2 0.0336147 -3.03413 
PTPRD 0.0128931 -3.08855 ACBD6 0.0498267 -3.4529 
TMEFF2 0.000287566 -3.16613 DCTN3 0.0201069 -3.82185 
RNF216L 0.0428454 -3.20267 CCKAR 0.00317157 -4.91171 
NUDT22 0.0286962 -3.40754 CADM1 0.00090556 -5.16425 
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Supplemental Table 3: Common baseline mRNA expression changes in ASM cells from patients with non-82 
severe or severe asthma vs. healthy 83 
 84 
  Non-Severe Asthma Severe Asthma 
Gene Symbol Gene Name Microarray (FC) Microarray (FC) 
ARRDC4 Arrestin domain containing 4 2.0 (p < 0.01) 2.0 (p < 0.01) 
C8orf46 Chromosome 8 open reading frame 46 -2.0 (p < 0.01) -2.1 (p < 0.01) 
CCKAR Cholecystokinin A receptor -4.3 (p < 0.01) -4.9 (p < 0.01) 
CDK17 Cyclin-dependent kinase 17 1.9 (p < 0.01) 1.7 (p < 0.01) 
CMYA5 Cardiomyopathy associated 5 -2.2 (p < 0.01) -1.6 (p < 0.01) 
COL14A1 Collagen, type XIV, alpha 1 -2.7 (p < 0.01) -1.7 (p < 0.01) 
COPG2 Coatomer protein complex, subunit γ-2 1.8 (p < 0.01) 1.5 (p < 0.01) 
COQ3 Coenzyme Q3 homolog 1.8 (p < 0.01) 2.0 (p < 0.01) 
DPT Dermatopontin -2.6 (p < 0.01) -2.1 (p < 0.01) 
EPHA5 EPH receptor A5 -2.5 (p < 0.01) -2.3 (p < 0.01) 
FGF13 Fibroblast growth factor 13 -2.0 (p < 0.01) -2.8 (p < 0.01) 
FOXC1 Forkhead box C1 -2.1 (p < 0.01) -1.8 (p < 0.01) 
HRK Harakiri, BCL2 interacting protein 2.8 (p < 0.01) 3.4 (p < 0.01) 
KIAA1324L Estrogen-induced gene 121-like protein -2.7 (p < 0.01) -2.7 (p < 0.01) 
LIF Leukemia inhibitory factor -2.1 (p < 0.01) -1.5 (p < 0.01) 
LPPR3 Lipid phosphate protein type 3 2.2 (p < 0.01) 2.0 (p < 0.01) 
MATN2 Matrilin 2 -1.9 (p < 0.01) -1.9 (p < 0.01) 
NLGN1 Neuroligin 1 -1.9 (p < 0.01) -1.8 (p < 0.01) 
NOVA1 Neuro-oncological ventral antigen 1 -2.2 (p < 0.01) -2.0 (p < 0.01) 
PBX3 Pre-B-cell leukemia homeobox 3 -1.5 (p < 0.01) -1.4 (p < 0.01) 
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PEG10 Paternally expressed 10 -1.8 (p < 0.01) -2.2 (p < 0.01) 
PTPRD Protein tyrosine phosphatase, receptor type, D -4.5 (p < 0.01) -3.1 (p < 0.01) 
SYTL2 Synaptotagmin-like 2 2.1 (p < 0.01) 2.0 (p < 0.01) 
TMEFF2 Transmembrane protein with EGF-like and two 
follistatin-like domains 2 
-4.5 (p < 0.01) -3.2 (p < 0.01) 
TMEM151B Transmembrane protein 151B -2.1 (p < 0.01) -2.2 (p < 0.01) 
TMOD4 Tropomodulin 4 (muscle) -2.0 (p < 0.01) -1.8 (p < 0.01) 
ZNF417 Zinc finger protein 417 1.5 (p < 0.01) 1.5 (p < 0.01) 
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Supplemental Table 4: mRNAs in non-severe ASM changed in expression following stimulation with FCS 86 
(2.5 %) 87 
 88 
Gene P value FC Gene P value FC 
HIST1H2AL 0.042169 15.2972 LOC644662 0.0433908 3.00074 
AFP 0.045175 13.6111 RNFT2 0.0460387 2.99992 
KIF2C 0.0179581 12.5638 GAPDHP32 0.0409119 2.98881 
TACC3 0.00420819 10.3329 LHFPL4 0.0125018 2.96321 
HIST1H2BE 0.0237102 9.36812 C14orf145 0.0256065 2.95993 
UBE2C 0.0492036 8.21674 CLN6 0.00278737 2.95722 
KRTAP1-5 0.0103114 8.12693 ASF1B 0.0246229 2.92533 
CENPL 0.0417908 7.93986 MTHFD2 0.0292476 2.92091 
ACTG2 0.0226104 7.84917 CECR3 0.00506878 2.88227 
FAM64A 0.0385425 6.96685 PPIL5 0.0235481 2.83299 
CENPF 0.0256589 6.85437 GINS4 0.0189066 2.78582 
GINS1 0.0236215 6.52347 PPP1R12B 0.0369438 2.76528 
CENPM 0.046922 5.98313 MS4A18 0.0105 2.71174 
DGCR14 0.0340715 5.74079 DONSON 0.00280379 2.62237 
DTL 0.0424873 5.71324 PPIH 0.0486878 2.54108 
PKMYT1 0.0467408 5.32092 NEK10 0.0372871 2.53094 
PSG5 0.0411558 5.0389 TRMT11 0.0143645 2.52293 
NRP1 0.0207293 4.99781 DARS2 0.0384515 2.52127 
PSG3 0.0430847 4.96387 PPPDE2 0.0226035 2.5107 
SLC7A5 0.0168647 4.91765 CLEC4A 0.0271478 2.50964 
RP11-717D12 0.0125387 4.74994 UHRF1 0.0114807 2.5059 
SNORA62 0.0480651 4.53985 FAM183A 0.0115952 2.50458 
BLM 0.0359356 4.47101 OSGEPL1 0.0055552 2.50087 
DHFR 0.0362396 4.38697 MCM8 0.0046727 2.48865 
TPX2 0.0236064 4.36345 ZNF761 0.0124803 2.48471 
RP11-631M21.2 0.0391902 4.32804 CD99 0.0476624 2.48135 
PSAT1 0.00586812 4.21463 PSMD9 0.0224133 2.44675 
C6orf173 0.0116616 4.19215 SFRS7 0.0198257 2.44667 
C12orf48 0.0150602 4.152 C2orf63 0.00306824 2.4222 
COMP 0.0417089 4.04159 C22orf23 0.00530128 2.41289 
FGD2 0.00851702 4.00545 MCOLN2 0.0355785 2.39538 
HIST1H3G 0.0346906 3.91419 IFI44L 0.00670638 2.39198 
E2F2 0.0170241 3.75432 MAGOHB 0.0143099 2.36689 
C7orf69 0.0423192 3.69353 SLC25A19 0.0401612 2.32236 
DNMT3B 0.0019108 3.60621 CALML4 0.020143 2.31044 
HPVC1 0.00500671 3.57815 C1orf135 0.000107269 2.30686 
POLQ 0.00972538 3.53489 AK310642 0.0129591 2.29593 
SLC4A4 0.0457484 3.46774 SFRS1 0.00309224 2.2717 
MPP2 0.0203948 3.46566 THC2698732 0.014244 2.26837 
SLC12A8 0.0148354 3.41566 MCCC2 0.0239829 2.25976 
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CR979835 0.0119406 3.35836 C3orf26 0.000136262 2.24602 
PSRC1 0.0319164 3.26343 M27336 0.00519858 2.23891 
SEMA3C 0.0277254 3.23105 Uncharacterized 0.0413966 2.23347 
LOC100127904 0.0108389 3.19899 KIAA0467 0.0471104 2.19476 
HIST1H3E 0.00995016 3.14865 HN1L 0.0115622 2.19265 
ZNF286A 0.0106128 3.09122 C1orf88 0.00356268 2.19033 
EID3 0.0158955 3.07464 FITM2 0.0276101 2.14598 
AX747988 0.0100492 3.02907 TRIM61 0.0214664 2.1356 
TLR3 0.0109683 2.13293 TRPC4 0.000482049 1.71844 
FBF1 0.00359897 2.13183 FAM163B 0.0238488 1.71416 
KPNA2 0.0287595 2.11384 HIF1A 0.0175851 1.71293 
TOMM34 0.047636 2.10906 LOC401357 0.0271595 1.70815 
PTPLA 0.0216557 2.10699 RXFP3 0.0308157 1.701 
SLC7A1 0.00855046 2.10298 FLJ43315 0.00189219 1.6953 
ZNF846 0.0485604 2.10036 ANKRD23 0.0327944 1.68543 
RNF170 0.0324877 2.09984 RG9MTD2 0.0420216 1.68441 
RAD51 0.010671 2.05954 EME1 0.0208152 1.68283 
IPMK 0.0462493 2.05872 ZNF773 0.0178852 1.67989 
DAZAP1 0.00609129 2.04506 PPT1 0.0113626 1.67657 
AC009065.1 0.0220591 2.0435 MTDH 0.0378097 1.67045 
DHODH 0.0229538 2.02404 TARS 0.0489756 1.66668 
MRPL52 0.0174852 2.00324 LZIC 0.0228597 1.66613 
CLDN15 0.00391595 2.00082 ILKAP 0.0466723 1.65865 
CBS 0.0320916 1.98625 HUWE1 0.0393995 1.65522 
DAD1L 0.0467537 1.98429 DHX32 0.0290673 1.65436 
TNC 0.043421 1.978 PSMD1 0.0448396 1.65114 
C17orf75 0.0345164 1.96439 C8orf12 0.046566 1.65041 
TSR1 0.016276 1.94851 C14orf106 0.0374258 1.64948 
TIPIN 0.0119014 1.93712 LOC497257 0.0126151 1.64176 
IGHV4 0.0498597 1.9338 CASD1 0.0389019 1.63331 
RRP15 0.010714 1.93131 HIST2H4B 0.0278259 1.62088 
EIF4E 0.0256744 1.93005 ADAMTS2 0.0346808 1.62082 
LRRC23 0.0336998 1.92391 PGAM5 0.00983565 1.61832 
ANKFY1 0.00990802 1.9159 AB305862 0.00236905 1.61206 
NSFP1 0.0200841 1.90634 RACGAP1P 0.00628056 1.60766 
ZNF232 0.0331495 1.89857 DHX34 0.0489499 1.60645 
MARS 0.0195536 1.89063 KBTBD2 0.035033 1.60309 
LOC388796 0.0490232 1.8668 PIGA 0.0329098 1.59928 
GSTCD 0.0129876 1.86522 ZNF259P1 0.0285483 1.59487 
DDIT4L 0.0224462 1.86291 CCDC75 0.0261684 1.58904 
ATP10A 0.00458931 1.85362 XPO1 0.0481318 1.58287 
USP49 0.00316534 1.85184 RAGE 0.00904688 1.57975 
PMPCA 0.0361554 1.84998 REP15 0.036773 1.57611 
TUBB 0.00098612 1.83791 MGC14436 0.0452944 1.57506 
CACYBP 0.0116392 1.83219 FUS 0.022933 1.56518 
EPS15 0.0139386 1.81679 ALKBH8 0.0186885 1.56504 
DPP3 0.0152883 1.81394 IFRD2 0.0338035 1.55328 
LOC100132774 0.0251185 1.80329 PHTF1 0.0213646 1.55108 
MKNK2 0.00159673 1.78837 FH 0.0428265 1.55003 
DLD 0.00708761 1.78761 SMN2 0.00451399 1.54349 
KIAA1310 0.0309488 1.78021 SIL1 0.0137999 1.54321 
AIFM2 0.0486621 1.77614 SLC19A3 0.0429533 1.53829 
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PLA2G16 0.0145217 1.77477 SFRS3 0.0114201 1.53351 
ATP6V1C2 0.0241497 1.76747 RNF8 0.044035 1.53324 
FASTKD2 0.0189688 1.76226 CDC10L 0.0161337 1.53244 
FLVCR1 0.0244468 1.7581 SDS 0.0497296 1.52589 
KLHL26 0.0095282 1.75207 GLRX2 0.0337985 1.52024 
BLZF1 0.0139667 1.74802 C2orf86 0.030794 1.50989 
OGFOD1 0.0492616 1.74646 LRP11 0.0327101 1.50692 
TGM2 0.00809875 1.72013 TTC39B 0.0304907 1.50559 
PAN3 0.0261818 1.50394 LOC283335 0.0407034 -1.93147 
LOC100130093 0.00400245 -1.50118 TMEM158 0.0307114 -1.94396 
SLC35B4 0.0420702 -1.50184 FLJ10357 0.0264898 -1.95443 
SPINK7 0.00238846 -1.50987 TCF7L1 0.0408114 -1.95539 
NFKBIE 0.00217181 -1.51769 SLC37A2 0.0245677 -1.97465 
SIX4 0.0455931 -1.52335 PDZD2 0.036989 -1.98523 
BTNL8 0.0479463 -1.52593 BC038245 0.00630883 -1.99291 
APBA2 0.00966014 -1.53101 CDKN2B 0.0371591 -2.00957 
TMTC4 0.0431429 -1.53995 IGKV2D 0.00469022 -2.01651 
PIP5K1C 0.0483843 -1.54103 BAI1 0.0245881 -2.05008 
COL8A1 0.0391784 -1.5436 TLR2 0.0304678 -2.05671 
KLF3 0.0337641 -1.54606 MAF 0.0182159 -2.05987 
AK097103 0.0211365 -1.55156 IGDCC4 0.0250946 -2.10885 
C1QL1 0.0124643 -1.55905 CCL8 0.0410618 -2.11255 
USP7 8.85E-05 -1.56233 C3orf17 0.00177469 -2.16793 
B3GNT8 0.0184764 -1.57443 SEZ6L2 0.00263898 -2.20901 
GAL3ST4 0.0323236 -1.58089 TMEM100 0.023037 -2.22181 
LOC100131831 0.018233 -1.5968 UACA 0.0244656 -2.24136 
EGR1 0.0459262 -1.6054 CCDC102B 0.0363297 -2.28346 
C21orf7 0.0280334 -1.60858 EMILIN2 0.0240823 -2.32076 
EVC2 0.0240317 -1.61969 C14orf138 0.0412158 -2.33047 
GLUL 0.010041 -1.62454 ISYNA1 0.0384217 -2.33646 
GPC2 0.0302108 -1.62894 ARHGAP26 0.0437545 -2.34708 
CYBRD1 0.0271256 -1.63724 CCDC68 0.0399964 -2.34718 
TCTE1 0.0489872 -1.64832 APCDD1L 0.0160971 -2.41235 
UCN 0.0037761 -1.64946 DCHS1 0.00752015 -2.43273 
TMEM86A 0.00964896 -1.64994 KRT3 0.041891 -2.44482 
SART3 0.0154546 -1.65959 ADH1C 0.0260881 -2.45803 
GOLGA2P2 0.0142093 -1.67088 DLK2 0.040191 -2.47085 
TRNP1 0.0439195 -1.67769 GSN 0.0477098 -2.47101 
HEPH 0.0381521 -1.68225 FLJ46875 0.0201755 -2.47952 
MARVELD2 0.0381364 -1.68234 HMGCS1 0.0499847 -2.575 
PLAC9 0.0377636 -1.68649 TRIB2 0.0380756 -2.64709 
SH3KBP1 0.0451682 -1.69882 LAG3 0.0398748 -2.68553 
HPCAL1 0.0189406 -1.69957 THBS4 0.0256252 -2.7205 
SCT 0.0418042 -1.71813 HSD17B2 0.0330886 -2.75754 
PRKG1 0.0184531 -1.72592 ABTB1 0.0369234 -2.85716 
RADIL 0.00662583 -1.75871 FAM78A 0.038982 -3.11112 
C20orf135 0.0309732 -1.76323 FLJ30698 0.0426586 -3.13743 
TMEM37 0.0334918 -1.79774 RABL2B 0.00800631 -3.16736 
AGER 0.0496659 -1.8104 ETV4 0.0365959 -3.26767 
SHROOM3 0.0489757 -1.82287 LOC339192 0.0342404 -3.38369 
SMO 0.0380795 -1.823 C13orf16 0.0248009 -3.45668 
PLCL2 0.0359885 -1.826 LOC642335 0.0265109 -3.65619 
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LRRC16B 0.0159671 -1.84618 STMN3 0.0318109 -3.69304 
COL14A1 0.0286924 -1.84778 TMEM176B 0.0221529 -3.79105 
OGN 0.0368907 -1.85259 C13orf33 0.037319 -4.30016 
BFSP1 0.0214947 -1.85693 TRPA1 0.0494467 -4.73558 
METTL12 0.003944 -1.86401 HBA2 0.00661282 -5.8041 
SMAD1 0.0403424 -1.89878 SIPA1L2 0.0337634 -6.76115 
LPIN3 0.0474008 -1.91035 ICOSLG 0.0154353 -6.86364 
ARRB1 0.014972 -1.91722 MMP10 0.0472607 -9.51461 
TLE2 0.0321331 -9.55024 CYP7B1 0.0270015 -10.1216 
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Supplemental Table 5: mRNAs in severe ASM changed in expression following stimulation with FCS (2.5 90 
%) 91 
 92 
Gene P value FC Gene P value FC 
SAE1 0.0315319 28.776 DDN 0.0128671 2.29176 
NUDT22 0.0383927 23.1666 EDN1 0.0104384 2.2315 
TRIP12 0.0374441 20.7629 TAGLN 0.0487656 2.22898 
C6orf108 0.0247918 19.7578 TMEM88B 0.0323484 2.22675 
ACBD6 0.0429061 18.8501 LOC389842 0.0454044 2.21946 
RNF216L 0.0361313 17.2554 E2F2 0.0165037 2.19929 
FAM50A 0.0396457 14.9825 LSR 0.0235457 2.19467 
PSKH1 0.0486055 14.7079 ZIC4 0.0429361 2.18695 
SDSL 0.0225439 14.5717 DA567289 0.00549359 2.15372 
ATAD3A 0.030444 13.8475 NDUFS8 0.00381808 2.14945 
SNRNP27 0.0327279 11.8091 ID4 0.0137383 2.1279 
ASNSD1 0.0354113 11.2429 PLCB2 0.0184724 2.12514 
TULP3 0.0370215 9.8634 FAM54A 0.00265674 2.11959 
OXSM 0.0301995 9.78723 AFP 0.0470928 2.11115 
RAB21 0.0491913 9.77369 HIST1H1B 0.0116681 2.10204 
ARHGEF17 0.0388136 9.28091 ARHGDIB 0.0162116 2.09234 
C7orf50 0.0253458 9.19125 SGOL2 0.00482879 2.0429 
RPL10AP6 0.0442215 6.49763 MMP3 0.00927657 2.03684 
CAPNS2 0.040892 6.1604 ENST00000404580 0.0151055 2.03313 
PIGX 0.0335979 5.642 ACTBL2 0.0165729 2.02833 
LOC283761 0.0362225 4.92652 APOBEC3G 0.00703699 2.01329 
RELL2 0.0303205 4.52845 LIG3 0.00210713 2.01078 
HIST2H3A 0.0116836 4.43854 DKK1 0.00945856 2.00856 
NAA50 0.0304966 4.18773 C18orf50 0.0152191 2.00559 
ACTG2 0.0118337 4.01062 FMO2 0.0204379 1.98753 
COMP 0.0274281 3.84419 LIPN 0.00158453 1.97156 
C7orf69 0.000417546 3.39355 WDR85 0.0288708 1.96528 
ID1 0.00487957 3.37276 CDCA4 0.0140678 1.95348 
ID3 0.000162498 3.15246 BLM 0.00836898 1.95115 
SERP2 0.0458915 2.86087 C19orf36 0.0414973 1.93632 
ASTN2 0.000738895 2.83591 EIF4EBP1 0.0105519 1.93568 
DHRS3 0.000668734 2.7709 CNN1 0.0193895 1.90859 
SYT3 0.0318851 2.71504 ACTL9 0.0408739 1.90733 
GIYD1 0.0363437 2.70562 TMEM110 0.00729636 1.90372 
PHF7 0.024339 2.67045 ULBP1 0.00337033 1.9001 
LOC100129324 0.00911405 2.6471 ALDH1B1 0.00183288 1.89709 
NPW 0.00445001 2.59169 AC120194.1 0.0421492 1.89433 
SNORA74B 0.00355454 2.59106 DONSON 0.00667162 1.89237 
CDC45L 0.0219393 2.4589 ELMO3 0.0194432 1.88445 
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FAM83D 0.0106239 2.45033 PXDN 0.00678331 1.87335 
FAM183A 0.034768 2.42204 DGKG 0.0111504 1.87098 
PI16 0.0174762 2.39663 CDCA8 0.0434952 1.87042 
MMP24 0.00989577 2.37446 KLF7 0.00991614 1.86591 
HJURP 0.0491266 2.35793 PSG8 0.0466474 1.85618 
SLC7A5 0.0181817 2.332 C14orf138 0.0225217 1.85215 
SLC17A9 0.0280329 2.30034 SNAR-A3 0.0274161 1.85096 
FAM132A 0.00176382 1.84438 ALPK2 0.021769 1.63973 
LOC100128429 0.0289081 1.84399 WARS 0.012276 1.63779 
PDLIM7 0.0110294 1.84335 HR 0.010702 1.63613 
ACTA2 0.00446266 1.84298 AIFM2 0.0412398 1.63467 
NPAS1 0.000454168 1.82921 TCIRG1 0.0178322 1.62906 
HMMR 0.0202382 1.82606 TNC 0.00521396 1.62092 
CSRP2 0.0249357 1.8154 APOL5 0.042588 1.61928 
OIP5 0.0242851 1.81163 PRPS1L1 0.0330893 1.61876 
ENPP4 0.000291782 1.80634 HEG1 0.0292205 1.61529 
ALDH1A1 0.0155456 1.79998 POTEF 0.0125938 1.6145 
NDNL2 0.0407615 1.79555 ODC1 0.0404126 1.61089 
ABCC3 0.00528059 1.79542 TGFBI 0.0232463 1.60382 
TACC3 0.0146334 1.78537 LOC90246 0.0417054 1.60312 
CDK12 0.0403507 1.77716 CDH6 0.0273261 1.60102 
CXorf36 0.0399867 1.77386 DKFZp779M0652 0.0369208 1.5986 
PPAPDC1A 0.00459146 1.77208 LOC391334 0.0187152 1.59564 
KRTAP19-8 0.0111527 1.768 SHCBP1 0.0125923 1.5899 
CCNE2 0.040152 1.76776 SRPK3 0.0395365 1.58695 
CDH15 0.00514977 1.76617 TUBB2A 0.036036 1.58243 
CDRT8 0.0476002 1.76148 KRT18 0.0289952 1.57967 
EARS2 0.026841 1.75945 IL6 0.0286464 1.57711 
TPM1 0.00128356 1.75561 ZWINT 0.0272534 1.57286 
NUAK2 0.0408128 1.75403 ATF6 0.0116662 1.56936 
IGKV2D-26 0.0381266 1.73547 TUBGCP4 0.0306173 1.56756 
EXO1 0.00344069 1.73461 CHMP5 0.0456459 1.56092 
SH2D4A 0.0188817 1.73319 PFN1 0.00875389 1.55958 
GPR173 0.0293878 1.73188 ANO7 0.0434326 1.55938 
CRYAB 0.000394639 1.72738 ARRDC4 0.042354 1.55865 
SQLE 0.0291135 1.72525 PDSS1 0.0327617 1.54896 
MCM6 0.00443025 1.72247 PGAM5 0.0237636 1.54858 
UCHL3 0.00591859 1.72062 BE897625 0.0450089 1.54428 
MTP18 0.0387551 1.71943 IL17REL 0.0244906 1.54247 
PKMYT1 0.0442163 1.70402 NOP16 0.0355891 1.53584 
FGF1 0.0341872 1.70077 EYA2 0.0304183 1.53301 
SDHB 0.0175247 1.6982 URB2 0.00172548 1.53158 
MGC31957 0.0441615 1.6915 OR8B8 0.0210497 1.52967 
CENPM 0.0455267 1.68005 LOC644686 0.0121129 1.52698 
GATA6 0.000328035 1.67938 IL23A 0.0306401 1.5269 
C17orf55 0.0317488 1.67516 SNAPC2 0.0493027 1.52311 
SLC7A1 0.0277587 1.67209 DLEU1 0.0397625 1.52274 
EPHX4 0.0457424 1.66998 CCDC134 0.012816 1.52022 
NP511207 0.0470343 1.66315 DHODH 0.0341323 1.5189 
BATF3 0.0474352 1.66035 KIF23 0.0385091 1.51864 
UXT 0.0200589 1.65571 TUBA1B 0.0485987 1.51811 
LOC100133478 0.0162422 1.65485 FABP5 0.0111229 1.51057 
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MPI 0.013293 1.65459 ANO9 0.0480375 1.50866 
PRKCI 0.0103238 1.65242 TNFRSF12A 0.0253343 1.50694 
FBXW8 0.00214241 1.65007 ASB2 0.00227959 1.5052 
HHEX 0.00717586 1.64445 AIMP2 0.0183562 1.50163 
NCL 0.0212408 1.64283 IGJ 0.0277505 1.50158 
ZBTB8OSP1 0.00288391 1.64143 CD83 0.0282823 -1.50228 
TMEM138 0.00161397 1.64023 SPTBN4 0.0282382 -1.50281 
KCNH2 0.0469862 -1.50303 DPT 0.0164097 -1.6272 
SPRY1 0.025703 -1.50499 TBC1D22B 0.0116999 -1.6273 
NFKBIA 0.0164733 -1.50535 OPN1SW 0.0380872 -1.63001 
HEXIM2 0.0265515 -1.50677 ARVCF 0.0097111 -1.63635 
KIAA0495 0.0424653 -1.50793 RASA4 0.0404237 -1.63808 
PABPC3 0.00939298 -1.50982 ETV1 0.0172944 -1.64143 
GFRA1 0.0271806 -1.51225 LOC100132197 0.0017269 -1.64502 
KIAA0895L 0.0408107 -1.51644 PLCL2 0.0227026 -1.64503 
METTL7A 0.0308474 -1.51819 ZNF29P 0.00222593 -1.64536 
BTG1 0.0412704 -1.51955 ADAM8 0.0220746 -1.64573 
TRERF1 0.0192006 -1.52049 SCN2A 0.0160161 -1.64932 
ZBTB46 0.0406111 -1.52212 OXER1 0.0155099 -1.65046 
RAP2B 0.0235145 -1.53124 MXRA5 0.00549818 -1.65166 
PDZRN3 0.00504218 -1.53388 ADRBK2 0.036771 -1.65168 
EPHB3 0.0281024 -1.53478 PPL 0.0354628 -1.65483 
NDRG3 0.0411172 -1.53567 FAM59A 0.0131217 -1.65541 
KLRG1 0.00484315 -1.53642 PTPRU 0.000647812 -1.65573 
ZMIZ2 0.00599439 -1.5395 PANX3 0.0435711 -1.65639 
TMEM120B 0.00832699 -1.54006 CCL27 0.023936 -1.66092 
MYOF 0.0140487 -1.54498 CLN8 0.0067489 -1.66444 
ANKRD36 0.0342401 -1.54625 NNAT 0.0193647 -1.67641 
GAS1 0.0342949 -1.5472 AGER 1.80E-05 -1.6812 
UBTF 0.0463208 -1.54893 ARRB1 0.0053879 -1.6816 
SNHG7 0.0276343 -1.55065 ARHGAP6 0.0293974 -1.68299 
BACH2 0.0422622 -1.55106 PHEX 0.0352096 -1.68449 
EHD3 0.017498 -1.55421 IRAK2 0.0133486 -1.68593 
MRPS6 0.0102987 -1.55456 SCXA 0.0441773 -1.70553 
ZNF596 0.0323015 -1.55726 SGIP1 0.0077103 -1.70833 
SNCAIP 0.00703485 -1.55821 NTN1 0.00603033 -1.71195 
GRIN3B 0.00278114 -1.56203 CRMP1 0.0402138 -1.71328 
DCHS1 0.0493557 -1.56359 C19orf67 0.0442978 -1.71828 
LOC91450 0.0149978 -1.56424 SYNE2 0.0164992 -1.73058 
C14orf139 0.0111174 -1.56482 CCL15 0.0481097 -1.73132 
MAPK10 0.0468834 -1.56652 BC030764 0.0106245 -1.73984 
NPR1 0.00656877 -1.5676 USP21 0.000202573 -1.74008 
GGTLC1 0.022507 -1.57194 KBTBD3 0.0351395 -1.75224 
C3orf65 0.00511018 -1.57454 PHLDA1 0.0157209 -1.75268 
PLGLB1 0.0230776 -1.57603 LOC92973 0.0467445 -1.75423 
OTUD4 0.00801676 -1.58681 SEMA3D 0.0390407 -1.75514 
FAM179A 0.0284816 -1.58839 FRMD4A 0.024925 -1.75934 
MEG8 0.00128523 -1.59095 CD19 0.0104817 -1.76635 
PIK3CA 0.00813475 -1.59644 SH2B2 0.00634026 -1.76713 
RNF122 0.0131832 -1.6004 MTVR2 0.0278556 -1.76758 
IFIT1 0.0334282 -1.60155 C6orf225 0.0160706 -1.77255 
JAK2 0.0363478 -1.60258 KRTAP10-5 0.0170766 -1.77611 
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C3orf25 0.00786974 -1.60261 AGBL2 0.0258052 -1.80999 
DLGAP3 0.0034738 -1.60553 SPTLC3 0.00397278 -1.81215 
NKX3-2 0.00942769 -1.60586 AX747836 0.00124121 -1.8345 
ZNF263 0.0440153 -1.60785 PDE4D 0.0227853 -1.8369 
HBM 0.0225791 -1.6087 NFIA 0.0319257 -1.83882 
DYTN 0.021317 -1.61031 PLA2R1 0.0385392 -1.83937 
TTLL8 0.00711562 -1.6134 COL4A6 0.0234852 -1.84027 
OR4A15 0.0102407 -1.84033 C3orf58 0.0234418 -2.15172 
C12orf70 0.0427254 -1.84058 SCN7A 0.00669843 -2.2424 
PPP1R1B 0.0456885 -1.84318 FLJ41484 0.0423813 -2.24948 
OR52K2 0.0251642 -1.86224 SIPA1L2 0.0388468 -2.25607 
LEF1 0.0189959 -1.87785 SYT7 0.00680712 -2.27284 
RELB 0.00251178 -1.87954 ZSWIM1 0.0193076 -2.28022 
ABCA1 0.0478522 -1.88101 ZNF165 0.0322561 -2.29244 
PAX8 0.00654786 -1.88673 CHRDL1 0.00714013 -2.33939 
PLA2G4F 0.00644873 -1.89378 OLFML2A 0.0368902 -2.36171 
C7orf53 0.0175538 -1.8955 AL832161 0.0147706 -2.3768 
CRTC1 0.00214418 -1.89906 LRRC66 0.023585 -2.3824 
PCDHB9 0.0122211 -1.90041 OR2Y1 0.0424392 -2.38439 
KILLIN 0.0391846 -1.91338 AX747124 0.0432925 -2.41574 
SLC5A3 0.015224 -1.91469 COL13A1 0.00735126 -2.4369 
LOC646936 0.0176281 -1.91957 POLR2F 0.0286454 -2.45184 
SP5 0.0380915 -1.92488 HOXA10 0.0173438 -2.46894 
GPR115 0.0381257 -1.92707 ZNF606 0.0102262 -2.47866 
FLJ38717 0.0172665 -1.92854 KISS1 0.0368085 -2.4838 
ENST00000380859 0.0172847 -1.93667 FLJ13197 0.0284087 -2.50724 
STON1-GTF2A1L 0.0194851 -1.94012 USP9X 0.0205324 -2.54888 
CNIH3 0.00835817 -1.94043 PLAT 0.0247061 -2.56001 
ASPRV1 0.00875346 -1.94749 CENPM 0.0453517 -2.605 
NXPH3 0.0435522 -1.949 SDCBP2 0.00585325 -2.66208 
GRAMD1A 0.00926919 -1.97029 KIAA2026 0.0432449 -2.74054 
TUB 0.0369388 -1.98155 OR1K1 0.00985021 -2.84986 
C12orf53 0.0234272 -1.9904 CILP 0.00252968 -2.94239 
LOC100129888 0.0435407 -1.99092 OR10G9 0.0212547 -3.1438 
COL4A5 0.0448822 -1.99106 KRTAP13-2 0.0168551 -3.30306 
HBA2 0.0324804 -2.00028 CCL11 0.00678786 -4.09672 
SCGBL 0.0444717 -2.00533 OR6N1 0.0249156 -5.33171 
MATN2 0.0215137 -2.02372 CHST8 0.0475643 -5.62812 
PCDHB5 0.0288846 -2.10017 CD274 0.020515 -5.80621 
PRRT2 0.0313314 -2.11684 HLA-DRB3 0.0452149 -11.3561 
PPARGC1A 0.0307013 -2.13856    
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Supplemental Table 6: Common mRNA expression changes in ASM cells from patients with non-severe or 94 






Gene Symbol Gene Name Microarray (FC) Microarray (FC) 
AFP Alpha-fetoprotein 13.6 (p < 0.01) 2.2 (p < 0.01) 
TACC3 
Transforming, acidic coiled-coil containing 
protein 3 
10.3 (p < 0.01) 1.8 (p < 0.01) 
ACTG2 Actin, gamma 2, smooth muscle, enteric 7.9 (p < 0.01) 4 (p < 0.01) 




Solute carrier family 7 (amino acid 
transporter light chain, L system), member 
5 
4.9 (p < 0.01) 2.3 (p < 0.01) 
BLM Bloom syndrome, RecQ helicase-like 4.5 (p < 0.01) 2 (p < 0.01) 
COMP Cartilage oligomeric matrix protein 4.0 (p < 0.01) 3.8 (p < 0.01) 
E2F2 E2F transcription factor 2 3.8 (p < 0.01) 2.2 (p < 0.01) 
C7orf69 Chromosome 7 open reading frame 69 3.7 (p < 0.01) 3.4 (p < 0.01) 
DONSON Downstream neighbour of SON 2.7 (p < 0.01) 1.9 (p < 0.01) 
FAM183A 
Family with sequence similarity 183, 
member A 
2.5 (p < 0.01) 2.4 (p < 0.01) 
SLC7A1 
Solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
2.1 (p < 0.01) 1.7 (p < 0.01) 




1.8 (p < 0.01) 1.6 (p < 0.01) 
AGER 
Advanced glycosylation end product-
specific receptor 
-1.8 (p < 0.01) -1.7 (p < 0.01) 
ARRB1 Arrestin, beta 1 -1.9 (p < 0.01) -1.7 (p < 0.01) 
IGKV2D-26 Immunoglobulin kappa variable 2D-26 -2.0 (p < 0.01) 1.7 (p < 0.01) 
C14orf138 Methyltransferase like 21D -2.3 (p < 0.01) 1.9 (p < 0.01) 
DCHS1 Dachsous 1 -2.4 (p < 0.01) -1.6 (p < 0.01) 
HBA2 Hemoglobin, alpha 2 -5.8 (p < 0.01) -2.0 (p < 0.01) 
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Supplemental Table 7: mRNAs in non-severe ASM changed in expression following treatment with 98 
dexamethasone (10
-7
 M), before stimulation with FCS (2.5 %) 99 
 100 
Gene P value FC Gene P value FC 
EGFL6 0.0224845 9.85829 CR591103 0.0186415 3.12462 
SCN2B 0.0284043 9.27174 BC047615 0.00346642 3.08526 
ICAM2 0.0145181 8.29318 CPVL 0.0368554 3.05313 
CPXM2 0.0152785 8.15319 GLYATL1 0.00971849 3.04558 
C3 0.0319192 7.59113 RSPH6A 0.0132347 3.0372 
FOS 0.0326376 6.21901 SLC7A2 0.023903 2.97487 
CYP7B1 0.00219021 5.83924 PDGFRL 0.0306045 2.96067 
MTTP 4.54E-05 5.79869 UNQ6228 0.0132763 2.93464 
CYTL1 0.00570101 5.57193 PAPLN 0.00211136 2.92105 
AQP1 0.00918987 5.30482 LOC100128343 0.00424291 2.8933 
SHC2 0.0229531 5.13233 LOC145783 0.0100316 2.88 
C21orf90 0.0235437 4.95966 BEGAIN 0.017262 2.87315 
ITM2A 0.0174152 4.79411 MFSD4 0.00521417 2.8624 
NEFH 0.0027194 4.44272 OR8S1 0.0127905 2.8326 
AF072164 0.0188097 4.34572 LOC100130218 0.0434096 2.83212 
FOSB 0.0225566 4.26843 LOC389831 0.0332219 2.80806 
EFHB 0.0107258 4.22377 PACSIN1 0.00266411 2.80071 
RNF212 0.0147874 3.82536 LOC100130276 0.0300703 2.79567 
SLC17A9 0.0150972 3.80832 MGC20647 0.0488981 2.76145 
TIAM1 0.0238606 3.67755 DPRX 0.0382461 2.75117 
TMEM211 0.00572655 3.66668 IRAK3 0.0407267 2.74829 
UNQ3028 0.0173281 3.59575 GRIA3 0.022389 2.74313 
DA759359 0.0115304 3.34984 PCDHGB3 0.0286299 2.73755 
MYO15A 0.0312493 3.34296 LOC651900 0.0238231 2.72276 
LOC440173 3.07E-05 3.28153 E00167 0.00848514 2.69841 
FAM184B 1.01E-05 3.23284 COL4A4 0.049413 2.69739 
LOC392335 0.00466136 3.22476 LOC253039 0.0100862 2.69359 
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LOC100293193 0.0125121 3.17947 DC378344 0.0345073 2.68776 
C7orf29 0.0252444 3.17744 CACNG7 0.00858398 2.67851 
LOC100132368 0.00272669 3.15585 MORN5 0.0141567 2.67189 
GLB1L 0.0341164 3.1296 C9orf96 0.00116525 2.66608 
ATP13A1 0.0127753 2.6656 CLDN20 0.0246253 2.31225 
CD511677 0.0261348 2.65122 RABGAP1 0.0229787 2.30133 
RTP1 0.0420071 2.63694 STK31 0.0399854 2.29911 
ARID3C 0.041896 2.62656 LOC100130454 0.0115812 2.29336 
C1orf187 0.0354729 2.61687 SOX8 0.0171318 2.27971 
LOC100133227 0.0143937 2.60259 SLC35D3 0.00676386 2.27606 
FAM110B 0.0152177 2.59557 BX104605 0.0389744 2.27346 
LOC730020 0.0204273 2.57775 TRAV7 0.0240724 2.26266 
C5ORF56 0.0370495 2.5736 LOC100131744 0.0321835 2.22234 
LOC728347 0.0206348 2.56986 SLCO2A1 0.0294004 2.21862 
LOC100128019 0.0100883 2.5681 FAM27E1 0.0201259 2.21555 
FAM177B 0.00951209 2.56634 PUS7L 0.0101342 2.214 
DLX6AS 0.0412825 2.55491 LOC652554 0.0366983 2.21147 
FLJ39061 0.00800903 2.54887 BEST3 0.00473454 2.20322 
FAM43B 0.0118631 2.53446 RAB17 0.00510537 2.19712 
KIAA0485 0.00176249 2.53122 TCN1 0.0107946 2.18241 
LOC100132428 0.00528968 2.52949 C4orf47 0.0237212 2.18075 
LOC100129292 0.00622093 2.52809 BM930849 0.00261303 2.17787 
GJA8 0.0331591 2.52799 ASPHD1 0.0165594 2.17764 
ZSWIM5 0.00888449 2.52752 FLJ42220 0.0271359 2.17659 
KLKB1 0.0147225 2.50704 LOC100129280 0.0191425 2.17518 
KIF26A 0.0390661 2.50692 BCORL2 0.0385956 2.1724 
UNQ6494 0.0209033 2.49631 PRKCE 0.00770568 2.16966 
C6orf15 0.0465234 2.48525 LOC100129048 0.0468273 2.16744 
FLJ42351 0.0305779 2.48101 DLEC1 0.00271548 2.16663 
NFE2 0.0161531 2.48053 LMO3 0.000173794 2.16137 
RFPL1S 0.0338504 2.47875 DUSP9 0.0414663 2.16082 
C12orf50 0.0395112 2.47662 SNAR-E 0.0250995 2.15839 
BAIAP2L2 0.00879244 2.46611 FOXE3 0.0292607 2.15296 
RGPD1 0.018853 2.46436 BLID 0.0348142 2.15038 
ZFR2 0.0407983 2.43805 CCDC110 0.0106732 2.14595 
ASTN1 0.000239932 2.43532 D21S2088E 0.0204949 2.14226 
PHF7 0.0494961 2.42975 TRIM50 0.0066816 2.13884 
ADRA1D 0.0061145 2.4213 RPS15AP10 0.0120046 2.13503 
LOC100289418 0.0364615 2.42035 GGT8P 0.0301629 2.13128 
SMTNL2 0.00837463 2.41454 HOPX 0.0196611 2.12091 
LOC100129380 0.0234232 2.40886 LOC100128562 0.0349627 2.11421 
TSPY16P 0.0442626 2.38998 X51791 0.0440148 2.11385 
LOC729041 0.0452279 2.38739 CPAMD8 0.024003 2.11303 
LOC727844 0.00878575 2.38436 RHPN1 0.0111075 2.10808 
STAG3 0.0342446 2.38192 SLC17A1 0.0223298 2.10807 
TDRD6 0.0285918 2.3769 CU691765 0.00847318 2.10361 
LOC100131608 0.00697544 2.37241 ZNF334 0.017776 2.0923 
HEPACAM 0.0243969 2.36755 KCNA6 0.00750647 2.08436 
PAQR5 0.0217854 2.35641 TTTY7 0.0363452 2.07877 
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LOC100131657 0.0294199 2.35553 CHDH 0.0363727 2.07317 
IGHV1-58 0.028446 2.35106 PLEC 0.0471604 2.06796 
C6orf103 0.0106071 2.3392 TCL1B 0.000474969 2.06752 
TSSK2 0.0305164 2.32101 PCDHB6 0.0410447 2.06634 
LOC401561 0.0419644 2.05753 PIP5K1A 0.00247996 1.79475 
UTP23 0.0470728 2.04735 EFR3B 0.0449516 1.78646 
LOC439950 0.0105374 2.04028 LOC645146 0.0343767 1.78442 
PAIP2B 0.00970691 2.03869 RAB6B 0.00298074 1.77689 
C2orf83 0.0229905 2.03791 LOC283911 0.0487751 1.77496 
QSOX2 0.0364102 2.03504 TREM2 0.0157232 1.77476 
MYL7 0.0495107 2.03266 PROL1 0.0126878 1.76938 
IL1B 0.00337457 2.01875 LOC100506302 0.0348837 1.76898 
CEACAM7 0.00425023 2.01502 C21orf58 0.0105458 1.75753 
CTSL 0.0164967 2.01376 LOC100288412 0.0218689 1.74799 
C9orf152 0.0159139 2.00518 SERPINB12 0.0229203 1.74729 
GPR123 0.0133016 1.98501 KRTAP10-12 0.0272806 1.74726 
FHL1 0.0258499 1.97289 KRT17 0.0331374 1.74684 
CACNA1I 0.0177944 1.971 tAKR 0.0171625 1.73752 
NET1 0.0022538 1.9696 GBX1 0.0416199 1.73375 
CEACAM18 0.0115634 1.96952 KU-MEL-3 0.0443896 1.72162 
LOC644075 0.044254 1.96929 NECAB1 0.0262466 1.72067 
OLFML1 0.00653956 1.96783 PATE2 0.0012714 1.71786 
VMO1 0.0138649 1.96773 LOC100131825 0.00739712 1.71753 
MAGEA13P 0.0177464 1.96604 LOC283174 0.0368537 1.71613 
C8orf67 0.017583 1.96038 SBNO2 0.0185852 1.71416 
INHBC 0.0293898 1.95938 FBXO47 0.0303511 1.71365 
ARHGAP26 0.0199751 1.9388 ARHGAP27 0.0453791 1.70604 
LOC154860 0.0168305 1.93675 RICH2 0.0455539 1.70033 
CU691877 0.00895458 1.93611 CLEC4G 0.00484712 1.69154 
IQCH 0.0168583 1.9353 SLCO2B1 0.0350121 1.68995 
CD244 0.0146865 1.92737 LOC100130354 0.0499476 1.68954 
OLFML2B 0.0121324 1.92565 YIPF3 0.0303159 1.68865 
LOC731312 0.0306703 1.92023 TSPAN8 0.0252275 1.68416 
TMEM174 0.00551208 1.91576 FAM9A 0.0325952 1.67987 
ADAM11 0.0208085 1.91515 MAML1 0.0347817 1.67804 
KRTAP23-1 0.031784 1.9062 ZNF445 0.0271602 1.67569 
CALML4 0.0287723 1.90351 GPR32 0.0350271 1.67274 
SLIT2 0.0498067 1.89512 DA666023 0.0430406 1.67235 
LOC339568 0.0215577 1.89024 C6orf195 0.0242215 1.66734 
OR6K3 0.036102 1.88625 IFNA2 0.00802891 1.6637 
LOC100133089 0.0258844 1.87293 LOC100268168 0.025986 1.65787 
PM20D1 0.023256 1.86964 NDRG2 0.0442569 1.65369 
ND6 0.0371702 1.86015 LOC389033 0.0217474 1.65276 
TPH1 0.0307384 1.85883 LOC100130710 0.0299083 1.65148 
RIBC2 0.0029066 1.85262 RAB33B 0.00183748 1.6505 
LOC651845 0.0149557 1.85036 KLC2 0.021582 1.64417 
TBX10 0.0337038 1.83411 PRODH 0.034482 1.63989 
DKFZP586B0319 0.000230914 1.82648 DPYSL5 0.00493524 1.63763 
LOC100128747 0.0396306 1.82634 PLD3 0.0463304 1.6364 
Perry 19 
 
KCNH6 0.00580284 1.81941 AJAP1 0.0302189 1.63436 
LOC729479 7.09E-09 1.81097 FAM81A 0.0439556 1.63142 
C10orf67 0.0481221 1.79864 POR 0.0430517 1.62831 
C1QL4 0.0146332 1.79761 DKFZP434I0714 5.22E-05 1.62454 
LOC340017 0.000930056 1.61948 UBE4B 0.000178117 1.49723 
HEPH 0.0291872 1.61907 FLJ39051 0.0207371 1.48876 
LOC286058 0.0182636 1.61866 ZNF787 0.0249678 1.47737 
CHRNA9 0.0052177 1.61802 STK38L 0.0337557 1.47362 
LOC729494 0.0430389 1.61712 ELOVL7 0.0355321 1.47254 
C22orf32 0.000799759 1.6171 C20orf70 0.0380086 1.47186 
KIR3DL2 0.0476025 1.61614 BCL9L 0.0437571 1.46794 
FAM159A 0.0271374 1.61373 ANKRD34B 0.0392712 1.46612 
SKCG-1 0.0470318 1.61284 IL11RA 0.0240191 1.46109 
ZNF423 0.0359766 1.60837 TRIM29 0.0422691 1.4454 
MAF 0.0387875 1.60742 TAF10 0.00373934 1.4429 
C9ORF147 0.0275508 1.60594 LOC400756 0.0254187 1.43656 
KCNV1 7.01E-06 1.60464 ZNF804B 0.0434655 1.43543 
LOC100130456 0.0302841 1.60259 LOC284373 0.0469246 1.42999 
FREM2 0.0030197 1.59876 AB305825 0.0266727 1.42943 
CRISPLD1 0.011944 1.5938 SLC4A11 0.042295 1.42717 
KHK 0.0121562 1.58493 GABRA1 0.0420077 1.42689 
NYNRIN 0.0421409 1.58189 COL23A1 0.0474148 1.40249 
GOLGA6L2 0.0354207 1.5813 COL11A2 0.0323107 1.39073 
PNMA5 0.0164874 1.57732 INSL5 0.00294359 1.38953 
C21orf94 0.0351323 1.57598 GALR3 0.0198297 1.37979 
SYNGR4 0.030568 1.56816 ETFDH 0.0221111 1.37676 
DB335107 0.0215759 1.56787 LOC728875 0.0405595 1.37306 
FAIM3 0.0296525 1.56452 PR47 0.0320595 1.36965 
TPH2 0.0209772 1.56404 UBASH3A 0.0313047 1.36855 
CNFN 0.00969497 1.56004 TOR2A 0.0472085 1.36779 
RUSC2 0.0337211 1.55193 ATP8B3 0.00121018 1.36592 
SHPK 0.0323088 1.55079 BPIL3 0.000446043 1.36341 
LOC100130288 0.000151666 1.54996 LOC100128893 0.0465814 1.35989 
LOC440419 0.0122559 1.54553 LST-3TM12 0.0271738 1.35959 
PAQR6 0.0409996 1.54483 IL1R2 0.0493842 1.35455 
UNQ3104 0.0308211 1.54306 BC038732 0.031831 1.3537 
KCNG3 0.0411575 1.54151 TYROBP 0.0460439 1.35297 
STAP1 0.0350517 1.53383 ATP1A1 0.0346405 1.35051 
LOC388564 0.00360479 1.5331 RAD9B 0.00672859 1.34225 
CCNYL3 0.000321594 1.53128 ESYT3 0.0193972 1.33735 
LOC283516 0.0138627 1.53019 TLE1 0.0289195 1.33728 
HSD17B13 0.0106886 1.53015 MYH16 0.00728031 1.33569 
SULT4A1 0.0308749 1.52772 MFSD2A 0.0369064 1.33288 
LOC407835 0.0293713 1.52761 RTP3 0.0224333 1.33233 
FOXS1 0.0486199 1.52565 LOC100133959 0.00243993 1.32764 
RFX2 0.0349621 1.52095 C8orf23 0.000126475 1.3212 
LRCH4 0.0418985 1.52027 SARS2 0.0177337 1.32111 
ACTR3C 0.0155141 1.51954 LOC100129036 0.0258009 1.31652 
ZNF768 0.0263864 1.51948 GPR64 0.0227623 1.30967 
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HLA-DRB1 0.0496063 1.51891 AP1S2 0.0304579 1.30014 
ASB5 0.0321277 1.51685 LOC100129449 0.00127755 1.29849 
MAST3 0.0400648 1.51681 CV572371 0.0161569 1.29073 
KRT81 0.0261695 1.51343 CRISP3 0.0271476 1.27679 
RPE65 0.025819 1.27407 TMPRSS11F 0.0456055 -1.09864 
PGLYRP4 0.036499 1.26499 LOC100128889 0.0461903 -1.10646 
TMEM44 0.0371009 1.26306 ADH6 0.0281598 -1.12724 
MUC21 0.0109483 1.26161 ZSCAN23 0.0368113 -1.12983 
TAOK2 0.0325985 1.26161 TIFA 0.033797 -1.13958 
MED12L 0.00227837 1.25117 RPP21 0.0496079 -1.18122 
POLD4 0.045117 1.25011 TTTY12 0.0350541 -1.19127 
MRPL55 0.0181834 1.24403 PLA2G4D 0.0346843 -1.20836 
HRNR 0.0397009 1.24037 LOC339751 0.0406197 -1.21402 
LOC100132972 0.00405942 1.23661 LOC100128477 0.0146921 -1.22535 
UNC5CL 0.02062 1.23546 IGLV1-44 0.0283777 -1.22657 
PARD6B 0.004883 1.23262 ARFGEF1 0.0349307 -1.23045 
LOC339260 0.0326179 1.22263 ILF2 0.048405 -1.23527 
LRRC70 0.00738901 1.19213 ZC3HC1 0.0166388 -1.23692 
WDR55 0.0472904 1.18886 FLJ45721 0.0153009 -1.25978 
OR5M1 0.00471608 1.18431 TEX264 0.0234891 -1.27281 
FABP9 0.0169342 1.18204 RANGRF 0.0377242 -1.27903 
PLD5 0.0443132 1.1777 DTX1 0.0257816 -1.28439 
LOC728147 0.0428683 1.17184 ARAP1 0.0164053 -1.29282 
MYH4 0.0093955 1.16987 PCDH8 0.0449058 -1.29606 
MAPK4 0.000413154 1.16784 RPL14 0.0416995 -1.29855 
HCG27 0.0431368 1.15153 EIF3K 0.0327072 -1.30717 
ANKRD19 0.0121885 1.14466 COPS6 0.0321624 -1.31843 
EXOC6B 0.0481348 1.14053 BF733045 0.00167963 -1.32042 
CTCFL 0.0174172 1.12855 NDUFA9 0.0469431 -1.32602 
FIGLA 0.0305764 1.12619 PKHD1L1 0.0494912 -1.33834 
LOC729409 0.0274765 1.10431 MOBP 0.0170939 -1.34063 
CYP27C1 0.0249948 1.09287 ANKRD5 0.0147312 -1.36002 
RP11-218C14.6 0.0135067 1.07401 CT45A5 0.0367247 -1.36032 
ECHDC1 0.0154592 -1.04898 NEUROD6 0.0261876 -1.36043 
LOC401445 0.0146153 -1.05782 C6orf70 0.038348 -1.36457 
ELF5 0.00800403 -1.06654 TST 0.0247942 -1.365 
TAAR3 0.0233372 -1.06767 BIRC8 0.0113783 -1.3714 
SPDYE1 0.0464789 -1.06918 CORO1B 0.0295777 -1.37383 
LOC100129717 0.00881801 -1.07103 BAI3 0.0260008 -1.37729 
PTCHD1 0.0340978 -1.07122 NSFL1C 0.0241619 -1.37979 
IRX1 0.00867645 -1.07144 C11orf48 0.0327563 -1.38163 
WDR72 0.0261069 -1.07253 PLG 0.0325968 -1.38824 
TMC5 0.011084 -1.07276 MRPL16 0.00522512 -1.39013 
TTR 0.0334625 -1.08564 CLNS1A 0.0215771 -1.39112 
LOC285965 0.0447548 -1.08603 FLJ45872 0.0380872 -1.39117 
PRR23A 0.0488675 -1.08614 LOC100134139 0.0292488 -1.39632 
C1orf105 0.0067356 -1.09049 POU3F2 0.0238103 -1.40624 
CLEC4GP1 0.0400279 -1.09058 OBFC1 0.0350366 -1.4104 
SMEK3P 0.0365378 -1.09113 SLC15A1 0.0245224 -1.43041 
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OR51B4 0.0416735 -1.09296 C6orf164 0.0463458 -1.43086 
MS4A8B 0.0287862 -1.09366 MRPL3 0.028822 -1.43289 
PDILT 0.0352373 -1.09781 MRPL12 0.0189764 -1.43367 
TNFAIP8L2 0.0415126 -1.09822 CTAGE4 0.0318006 -1.43402 
C2orf27B 0.0127679 -1.45544 GPX6 0.0300355 -1.6865 
COX5A 0.0203388 -1.45682 SDC2 0.0167533 -1.68738 
FUBP1 0.0431114 -1.4631 PCIF1 0.0215369 -1.6876 
MYRIP 0.0112902 -1.47356 UBA6 0.0366945 -1.69066 
ESD 0.0275872 -1.47665 CDA 0.0424501 -1.69099 
TP53TG5 0.0219031 -1.47881 SFTPA1 0.0258629 -1.69425 
RSBN1L 0.0265224 -1.48784 ZBTB16 0.0187443 -1.69934 
NAA38 0.0380492 -1.48932 FASTKD2 0.0284946 -1.69956 
TFAM 0.0067683 -1.49219 BEND6 0.0327597 -1.70459 
DUOXA2 0.0347074 -1.49359 IGKV1D-16 0.00625904 -1.71148 
MGC15705 0.0364406 -1.49375 PPHLN1 0.0244872 -1.71436 
TCFL5 0.0375455 -1.51012 ANKRD34A 0.039789 -1.71619 
OTOS 0.016899 -1.52633 MRPL48 0.0392436 -1.72211 
DCHS2 0.0253431 -1.53272 SFTA2 0.00982478 -1.7225 
SDSL 0.0347529 -1.54678 ABCB7 0.0249674 -1.72458 
FAM171A2 0.01809 -1.54799 FLJ37798 0.0473696 -1.72555 
USP4 0.00211787 -1.54909 AP1M2 0.0366944 -1.7276 
SRRD 0.0168979 -1.55799 TYW3 0.0408083 -1.74336 
LOC221710 0.000955977 -1.56203 CAPNS2 0.030342 -1.74481 
ABCC6P1 0.0251204 -1.56227 UTP6 0.0309216 -1.75103 
SLC12A5 0.0273618 -1.56248 LPO 0.0241068 -1.75458 
APOM 0.000720936 -1.56283 STIM2 0.0251011 -1.75954 
ARMCX6 0.0399629 -1.56553 ZNF420 0.00769476 -1.76578 
LOC100132874 0.0348226 -1.57066 KIF18A 0.0449543 -1.77577 
TMEM223 0.0349219 -1.57095 AFMID 0.0381957 -1.77832 
NMNAT1 0.01655 -1.57297 GLS2 0.0147042 -1.78134 
RAB4B 0.00832978 -1.57885 LOC286299 0.0295837 -1.78713 
STYXL1 0.0157409 -1.58396 CYP46A1 0.00876744 -1.79645 
RP11-403I13.9 0.0445731 -1.58819 C9orf140 0.008924 -1.79783 
CCNH 0.0419571 -1.59265 STAT4 0.0388631 -1.79812 
ZNF187 0.0347383 -1.5933 NDUFS3 0.0193552 -1.80603 
SIX3 0.0414476 -1.60428 PFKFB1 0.0298504 -1.81156 
EAPP 0.0376325 -1.60634 SDHB 0.0100156 -1.81744 
TPRKB 0.0366331 -1.6117 SFRS3 0.0402468 -1.81989 
FLJ34208 0.0476374 -1.62624 C6orf108 0.0133844 -1.83204 
NCRNA00160 0.0401118 -1.63183 C16orf74 0.00862393 -1.83255 
B3GALT1 0.0303402 -1.63266 NKD2 0.0348643 -1.83698 
C1QTNF3 0.0230505 -1.63381 GUCY1A3 0.0460035 -1.847 
PCDH12 0.0248739 -1.63423 LECT2 0.0185627 -1.852 
ZNF778 0.0497829 -1.63921 MALT1 0.0234089 -1.854 
OSBP2 0.0242293 -1.64528 NLRP10 0.0270145 -1.86595 
TRIP12 0.0240859 -1.66324 VAV1 0.0308983 -1.87005 
LOC391767 0.04405 -1.66609 VLDLR 0.0487244 -1.87175 
FLJ16171 0.0478968 -1.66854 GPR20 0.0442183 -1.87301 
ZNF607 0.032604 -1.672 HEBP2 0.0494134 -1.87345 
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DNAH2 0.044721 -1.67467 LOC100131542 0.00693669 -1.87349 
RNASEH2B 0.0370652 -1.67546 LOC150568 0.0468719 -1.87393 
TIMM44 0.00107801 -1.67683 TMEM60 0.044222 -1.87516 
LOC100133224 0.0132813 -1.6781 NOS1AP 0.0143965 -1.87874 
PCDHAC1 0.0263291 -1.89643 RASAL2 0.00892127 -2.18315 
CDCA3 0.048928 -1.89865 VN1R1 0.0115255 -2.2053 
CR607463 0.0242893 -1.90138 FLJ45950 0.011803 -2.20917 
CAB39L 0.0375589 -1.90893 ZNF77 0.0490546 -2.21015 
PPM1L 0.0465441 -1.90908 DONSON 0.0208259 -2.22181 
SAE1 0.00682671 -1.91643 TADA1 0.0134694 -2.22358 
RTF1 0.0359386 -1.91712 LOC100335030 0.0401339 -2.23138 
EXOC5 0.0436936 -1.91726 PRINS 0.0294081 -2.25029 
OR6A2 0.0373859 -1.92839 DCAF15 0.0335145 -2.25425 
C6orf150 0.0255693 -1.93105 DEFB128 0.0332666 -2.28786 
STOX1 0.04999 -1.93657 CD36 0.0499506 -2.29363 
FCRLB 0.0442974 -1.95086 CHN2 0.0129252 -2.29944 
MAP6D1 0.0193414 -1.96376 ECEL1 0.00335713 -2.3002 
INPP5B 0.00978147 -1.96507 KCNRG 0.00372492 -2.31241 
LOC201477 0.0199036 -1.96661 VILL 0.00186831 -2.3235 
KCNU1 0.0186844 -1.97358 LPCAT2 0.00257542 -2.32538 
ZNF583 0.0306699 -1.97481 INTS8 0.0396496 -2.33448 
DCTN3 0.0218782 -1.97551 LOH12CR1 0.0101759 -2.34799 
SUV420H1 0.00836247 -1.98208 AVL9 0.00787749 -2.35523 
SCAPER 0.0124862 -1.99993 ILKAP 0.0490355 -2.35916 
FASTKD3 0.0240289 -2.00515 ACPP 0.0487522 -2.37048 
CENPT 0.0388359 -2.00572 NKX6-1 0.0241127 -2.37093 
LCE3B 0.0310833 -2.00984 SHC4 0.035591 -2.39069 
ZNF266 0.0156899 -2.01565 CR612090 0.0170573 -2.39411 
ANGPT4 0.0425998 -2.02442 KCTD14 0.0232979 -2.40181 
SLC27A4 0.0225529 -2.02761 LOC374443 0.0418283 -2.41002 
STAMBPL1 0.0425329 -2.02813 DSCC1 0.0445259 -2.41409 
OPTC 0.031607 -2.03657 DHDDS 0.00260125 -2.44501 
LOC144742 0.0334827 -2.0412 OR4K14 0.0404942 -2.49172 
LOC440518 0.0242885 -2.04559 FMN2 0.0380029 -2.52012 
TACR3 0.00414029 -2.04981 SHMT1 0.0250764 -2.53136 
LOC285740 0.0281476 -2.06003 FLJ33360 0.0307568 -2.55112 
LOC727900 0.005461 -2.07472 FAM26E 0.0158991 -2.56312 
TDO2 0.0217135 -2.07555 INPP4A 0.0300925 -2.57306 
ADCY2 0.014242 -2.0777 GAB1 0.0326721 -2.60154 
LOC402377 0.027925 -2.08423 ZNF142 0.0167231 -2.61827 
ASNSD1 0.0363381 -2.09126 BTBD19 0.0167944 -2.63699 
SNORA59B 0.0178836 -2.1052 CEP97 0.00114581 -2.64601 
ASCL1 0.0481069 -2.10654 DBF4 0.023114 -2.67845 
C7orf65 0.0471925 -2.11276 CCDC89 0.0461908 -2.69102 
GPR183 0.0426155 -2.12437 ZNF208 0.0176612 -2.69905 
SLC17A3 0.0139654 -2.12506 FAM83D 0.0444039 -2.74292 
ZNF430 0.0478224 -2.12801 POLE2 0.0477631 -2.85062 
C9orf125 0.012377 -2.13302 PITPNM2 0.00883297 -2.85263 
GYG2 0.040705 -2.13839 LOC100290819 0.0115081 -2.857 
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PRX 0.0117804 -2.13843 TRMT13 0.0397206 -2.86425 
ZNF823 0.0235157 -2.14283 LOC552889 0.041421 -2.88387 
CASD1 0.0458806 -2.15138 LOC100132658 0.0040329 -2.91454 
PECAM1 0.0389329 -2.18241 COPG2 0.0175791 -2.93662 
SLC32A1 0.0118395 -2.93921 ZNF700 0.0127506 -3.53078 
CB962925 0.0406413 -2.94258 ZNF660 0.0185591 -3.55258 
MIR17HG 0.00503779 -2.96279 KCTD16 0.026767 -3.62981 
FGD4 0.00460589 -2.97469 KCNK18 0.0288435 -3.67756 
KIAA1383 0.0349422 -2.99342 PLEK2 0.031753 -3.67869 
SLA 0.0124339 -2.99922 DEPDC1 0.040848 -3.71229 
ACSL6 0.00167299 -3.03124 RGAG1 0.00415394 -3.84478 
LOC100130176 0.0285593 -3.0509 CXORF67 0.0146076 -3.87188 
CXORF28 0.0288017 -3.05342 C18orf54 0.00363234 -3.87393 
SPP1 0.0396132 -3.06286 AMBP 0.0107961 -3.92483 
OR11H6 0.00187437 -3.09524 ZNF536 0.0430415 -3.94608 
MMP16 0.000340787 -3.10346 USF1 0.0150606 -4.00724 
ACTR5 0.00655942 -3.10794 HSF2BP 0.0443773 -4.02576 
ABHD3 0.013552 -3.11161 OR10AD1 0.0159812 -4.1007 
LOC729983 0.0484273 -3.1273 IGLV3-22 0.00322099 -4.15799 
ZNF280A 0.00132765 -3.1666 SOX6 0.0124537 -4.36315 
LOC646993 0.0471719 -3.20639 SALL1 0.0120465 -5.30655 
EPHX4 0.0273351 -3.23078 SYT1 0.00941826 -5.56205 
FLVCR1 0.00126143 -3.33992 MLC1 0.0306403 -6.24952 
NCOA2 0.027666 -3.3441 LOC100240735 0.00225577 -6.34631 
DKK2 0.0139107 -3.43965 UCP2 0.00701355 -6.60541 
GPR37 0.011303 -3.46342 LOC100144602 0.0192818 -7.04829 
C14orf50 0.00235508 -3.47589 MND1 0.0128997 -7.28275 
SNRNP27 0.00145885 -3.50165    
 101 
Supplemental Table 8: mRNAs in severe ASM changed in expression following treatment with 102 
dexamethasone (10
-7
 M), before stimulation with FCS (2.5 %) 103 
 104 
Gene P value FC Gene P value FC 
SAE1 0.0293833 30.8509 COL4A4 0.00861455 5.08209 
FKBP5 1.75E-06 25.891 GPM6B 0.0108153 4.98446 
NUDT22 0.0357378 24.8109 TIMP4 0.00176917 4.81366 
TRIP12 0.0336078 22.9363 WFDC1 0.00892648 4.76096 
GGT5 0.000192039 18.7544 ENST00000379816 0.000181883 4.72378 
RNF216L 0.0330866 18.6092 SORT1 6.23E-05 4.67066 
DCTN3 0.0457529 18.0032 MAP2 0.00126428 4.65171 
C6orf108 0.027999 17.8552 KCNK6 0.0139623 4.64616 
FAM50A 0.0351623 16.5548 FAM83D 0.00107002 4.60643 
ZBTB16 0.00307208 16.2454 RNF144B 0.0151476 4.57625 
IGFBP2 0.00274071 15.7287 CDIPT 0.0426481 4.56102 
PSKH1 0.0467332 15.2121 PTX3 0.000904222 4.49363 
FAM107A 0.00653331 14.7382 INHBB 0.0266491 4.43562 
ATAD3A 0.0297641 14.0888 SAMHD1 0.000396778 4.24656 
ARHGEF17 0.0272866 11.8389 COL8A1 0.000775198 4.22817 
RASL11B 0.00210506 11.7764 ERRFI1 8.50E-06 4.21409 
ITGA10 0.0019372 11.7542 MT1X 0.000333054 4.20059 
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CORIN 0.00111639 11.3277 COMP 0.0219541 4.19289 
SNRNP27 0.0348066 11.294 MOBKL2B 0.0457821 4.15896 
ASNSD1 0.0364774 11.0048 MT1M 0.000145813 4.13462 
TULP3 0.036178 10.0216 RELL2 0.0377615 4.11776 
OXSM 0.0312126 9.57611 FOXO1 0.00100229 4.10549 
SPARCL1 0.000351684 8.71945 IFI44L 0.00160796 4.10517 
SDSL 0.0469366 8.65442 FBN2 0.00045236 4.09649 
MAOA 4.71E-05 8.65072 ID3 6.30E-05 4.04241 
ID1 0.000380069 8.50726 GABBR2 0.00244403 4.04052 
MESDC1 0.0343102 8.06953 MT1H 0.000234725 4.02909 
LOC100128054 0.000177149 8.04811 GALNTL2 0.00651786 4.02419 
CACNB2 5.95E-05 7.71055 CTGF 0.00172937 4.01877 
C7orf50 0.0370643 7.28522 LEMD2 0.0426577 3.97875 
C13orf15 0.00154918 6.93071 TSC22D3 1.14E-05 3.93961 
ADRA1B 0.00508932 6.89065 DUSP1 0.000455907 3.93387 
ACTG2 0.00301672 6.88999 NP274062 0.00209432 3.92619 
PIGX 0.0233662 6.82221 FAM196A 0.0393619 3.89455 
CAPNS2 0.0353172 6.69009 C10orf10 0.0167328 3.89057 
ENST00000399893 0.0441167 6.50664 GADD45B 0.000273981 3.84901 
RP3-402G11.5 0.0460247 6.50258 SCRG1 0.0429723 3.83316 
GPX3 0.000199301 6.36918 NAA50 0.0379298 3.82847 
B3GALT2 0.0181628 6.27837 RASAL2 0.0290488 3.81753 
SPINT2 0.0154338 6.07396 PER1 0.000613973 3.75164 
GLUL 8.88E-06 6.04048 SUSD2 0.000676035 3.70154 
OMD 0.00035564 5.82124 MT1A 0.000541503 3.66803 
FLJ37798 0.0408714 5.56809 MT1L 0.000574419 3.62364 
RASL11A 0.0003236 5.34133 HSPA2 0.0140091 3.58406 
FMO2 0.000465789 5.27339 MT1B 0.000402572 3.55976 
HSD11B1 0.000577978 5.14342 TAGLN 0.00998786 3.48216 
CCK 0.0357132 3.47118 SNORA74B 0.00309697 2.67189 
NEXN 0.000673327 3.45126 MYADM 0.00209306 2.64763 
MT1E 0.0001665 3.44808 LOC100129104 0.0379053 2.64592 
CDH4 0.0278858 3.44373 YIF1B 0.00912271 2.64548 
ADAMTS1 0.00316131 3.38848 STMN2 0.0429079 2.63713 
USP53 0.00533808 3.37808 GCNT1 0.000525352 2.6321 
ALCAM 0.000415557 3.37174 LOC643650 0.0230739 2.61701 
TRNP1 0.000101656 3.36238 CTSC 0.0125391 2.59394 
C2orf81 0.0471609 3.36115 SRGN 0.0113194 2.5707 
ARHGDIB 0.00210903 3.34564 CRISPLD2 0.0144604 2.56427 
FMO3 0.0200423 3.33518 OR1N1 0.0213216 2.55823 
PRUNE2 0.00292861 3.33047 C13orf1 0.0216735 2.54744 
IMPA2 0.00106513 3.32463 CYR61 0.0149191 2.52572 
NEDD9 0.00515643 3.31 EDN1 0.00588036 2.5197 
FIBIN 0.000939865 3.28638 TMPPE 0.0427563 2.51672 
ASTN2 0.000400936 3.28043 RPS6KA2 0.00023674 2.51198 
MMD 0.00132298 3.24091 LOC100130433 0.0277066 2.50269 
GIYD1 0.020399 3.23461 ACTBL2 0.00608095 2.485 
ID4 0.00231071 3.18559 ENDOD1 0.0212248 2.48295 
ITIH3 0.0022738 3.15811 TCEAL4 0.000119079 2.47177 
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ITGA1 3.24E-05 3.07376 C5orf62 0.00726222 2.46289 
OXTR 0.0354296 3.0722 NPW 0.00563788 2.46064 
GPC4 0.00987549 3.05569 DNAJB4 0.000156835 2.45446 
FBXL16 0.0343697 3.05342 CALCOCO2 8.49E-05 2.43369 
DHRS3 0.000445054 3.04017 DUSP5 0.0116667 2.42986 
AOX1 0.00432776 3.03646 PTPLB 0.00205711 2.42043 
FSTL3 0.00037622 2.93921 C19orf36 0.0149041 2.41685 
FAM105A 0.000683306 2.93841 DNAJB13 0.0278071 2.41509 
CRYAB 1.55E-05 2.90751 CCDC68 0.00352976 2.39002 
ACTN4 0.0071471 2.89902 ANPEP 0.0140188 2.37735 
ADARB1 0.0169215 2.89265 ENST00000402541 0.0293413 2.37316 
PRODH 0.00432797 2.88292 AB072904 0.0134451 2.37294 
SYNPO2 0.00245813 2.86211 C6orf145 0.00378103 2.36902 
DNAJC6 0.0174459 2.84397 NNMT 0.00245006 2.36272 
ANGPTL1 0.000998193 2.84395 ALDH1A1 0.00328273 2.36271 
LOC285300 0.00217058 2.83903 LOC100133047 0.00604439 2.34181 
LOC729314 0.0169639 2.83454 ABCC3 0.00102183 2.33761 
ACTA2 0.000410772 2.82078 KCNS3 0.00568082 2.332 
PLA2G2D 0.0402534 2.81014 APOD 0.00605547 2.33058 
MCOLN2 0.0285976 2.77763 COL7A1 0.0112029 2.32901 
AX747335 0.0368348 2.77485 CDC45L 0.0276114 2.32437 
KLF9 2.05E-05 2.74138 ALDH1B1 0.000519545 2.32301 
DDAH1 0.0117291 2.74024 MORF4L2 0.000383087 2.31079 
DMD 0.0234342 2.73938 DKFZp686L14188 0.0417111 2.30624 
THC2512536 0.0194684 2.73473 MYL9 0.0106104 2.29158 
F3 0.0171058 2.72834 CST5 0.015985 2.28543 
CLIC3 8.50E-05 2.70758 TEX2 0.00158427 2.27641 
VGF 0.00536216 2.70377 SYTL4 0.00441957 2.27422 
CDC42EP3 0.0062412 2.70142 ADM 0.00242228 2.27403 
TXNRD1 0.0387953 2.26557 RABL2B 0.0304508 2.09569 
SLC26A6 0.0030031 2.2592 ENST00000391684 0.0256501 2.09526 
PDLIM5 0.00641439 2.2577 COL4A1 0.000461987 2.09426 
AKAP2 0.0179959 2.25682 TMEM204 0.0051942 2.09185 
CPPED1 4.89E-05 2.2549 HIGD1A 0.00200655 2.09133 
SPON1 0.00945096 2.24465 PHF17 0.000722498 2.08993 
ENST00000390431 0.0157644 2.23779 NDUFS8 0.00451451 2.0872 
ACTN3 0.0342007 2.23762 PDLIM7 0.00526287 2.08165 
TMEM88B 0.0321441 2.23007 CORO6 0.00796894 2.07296 
MT1G 0.000196228 2.2281 BCAT2 2.85E-05 2.0727 
EPSTI1 0.0136577 2.22378 TMEM47 0.00940008 2.07108 
ATP10A 0.00434919 2.2225 CITED2 0.00632978 2.07009 
ENST00000432803 0.0312689 2.22134 MTP18 0.0135319 2.06869 
GDNF 0.00269501 2.21216 HPD 0.00988168 2.06862 
ELMO3 0.0081153 2.21138 ZDHHC23 0.00079984 2.06565 
SERPINE1 0.00445858 2.20768 ST8SIA3 0.029852 2.0624 
ARMC8 3.76E-05 2.20455 TCEAL1 0.000157088 2.05244 
NUAK2 0.0120228 2.20189 ZCCHC6 0.00543392 2.05179 
ITGA5 0.00848922 2.19775 CFL1 0.00803712 2.05126 
DIO3OS 0.042181 2.19679 FGD4 0.000368076 2.05079 
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SLC17A9 0.034645 2.18829 PFN1 0.00109584 2.05005 
DAAM2 0.000143499 2.18418 LDHA 0.00034808 2.04853 
MYL2 0.0120666 2.18221 PCDH7 0.0217007 2.04643 
METTL7A 0.00263576 2.17311 TXNRD2 0.0432052 2.04268 
KIAA0408 0.0299493 2.1718 TBX10 0.00410111 2.04007 
MYC 0.00142509 2.16842 KLF7 0.00575005 2.03958 
BATF3 0.0105979 2.16133 THBS1 0.021792 2.03869 
TLN1 0.00532275 2.15891 BAIAP2L2 0.0460722 2.03592 
ASPN 0.0186281 2.15457 MCAM 0.0218424 2.03524 
THC2499666 0.0167206 2.14283 PHC2 0.000105738 2.03368 
PAWR 0.00517323 2.14082 MGP 0.00528811 2.02627 
MT2A 0.0311945 2.13848 PRKAG2 0.00351825 2.02516 
PTPRJ 0.000263112 2.13055 CD513837 0.00266014 2.02135 
PIK3R1 0.00136677 2.12926 THC2631347 0.046344 2.01857 
FAM54A 0.00260018 2.12741 SQLE 0.0114418 2.01714 
LMOD1 0.000458295 2.12602 PSME3 0.00232806 2.017 
CELF5 0.0318365 2.12593 KLF5 0.0425953 2.01452 
FZD6 0.000822425 2.12475 GPD1L 0.000976915 2.01167 
C7orf69 0.00373963 2.12408 LOC391334 0.00369431 2.01149 
GFPT2 4.69E-05 2.12213 ELANE 0.0498767 2.00882 
HIF1A 0.00416025 2.11409 LIPN 0.00140853 2.00722 
KIR3DP1 0.0497948 2.10917 STK17B 0.00347825 2.00367 
LMCD1 0.00163141 2.10535 PPME1 0.0295785 2.00351 
MMP24 0.0178651 2.10029 ING2 0.0094718 2.00301 
B3GNT5 0.00443162 2.09994 LOC646048 0.00869057 2.00188 
LBH 0.00905975 2.09928 C21orf122 0.00156753 1.99988 
UQCRC1 0.000891989 2.09869 ODZ2 0.0350808 1.99767 
C5orf58 0.00164073 2.09774 CD302 0.00165848 1.99728 
RXFP3 0.0482927 2.09724 HPS5 0.00254274 1.98919 
ZNF828 0.00708639 1.98828 TUBB6 0.00762767 1.88766 
LOC100129536 0.00144269 1.98684 SYDE1 0.0052336 1.88589 
TMEM64 0.00237239 1.9828 C1orf133 0.0334995 1.88411 
C14orf56 0.045008 1.97702 NOP16 0.00842041 1.88205 
MMP15 0.00054594 1.97466 SEPN1 0.0248979 1.88112 
DKK1 0.010454 1.97412 LRRC16A 0.0249664 1.88084 
PXDN 0.00486628 1.97317 LOC100129324 0.0443199 1.87754 
NFXL1 0.0153216 1.97273 COTL1 0.0173498 1.87628 
S100A11 0.00305132 1.96806 HSPB1 0.000119283 1.87343 
CTPS 0.00736087 1.96543 BRMS1L 0.0346498 1.87094 
ACSS1 0.0184484 1.96488 NFYB 0.00202677 1.8689 
HNMT 0.00761871 1.96127 AP1M1 0.00307059 1.86845 
TG 0.0107898 1.96093 WEE1 0.00145312 1.8668 
AX747582 0.00845319 1.95636 MTMR10 0.00716182 1.86373 
GRAMD1C 0.00226138 1.95518 C3orf43 0.0321532 1.86292 
OR2AG2 0.0162415 1.95096 SSH2 0.00311066 1.86272 
SKP2 0.000752515 1.95061 TMEM110 0.00841112 1.86215 
CNN1 0.0172085 1.94926 ACTB 0.0198031 1.85667 
CDH15 0.00260405 1.94704 TST 0.00656643 1.85402 
NOSTRIN 0.0277534 1.9418 TTC32 0.00535253 1.85333 
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LIMS2 0.0211709 1.93969 TRIM7 0.00482179 1.85086 
HMMR 0.0141799 1.93876 ITGBL1 0.00273311 1.84438 
RHOBTB3 0.00270591 1.93864 CCNE2 0.032104 1.83894 
CDCA4 0.0148564 1.93506 C9orf3 0.000526926 1.83891 
TMTC1 0.00778027 1.93196 GPRC5B 0.0202692 1.83612 
THC2539563 0.0165637 1.92263 TRAM1 0.0074447 1.83573 
TIMM22 0.00145301 1.92005 RGNEF 0.0416197 1.83562 
MRM1 0.00286021 1.91949 MMP19 0.0111424 1.83523 
YRDC 0.0375096 1.91836 LOC400743 0.0135742 1.83486 
POTEF 0.00355557 1.91792 UBL7 0.0245274 1.83452 
WDR1 0.00570827 1.91536 PIK3C2A 0.0187197 1.83449 
BANF1 0.00283209 1.91218 CORO1B 0.0452685 1.83428 
TMCO6 0.000575061 1.91053 TCF19 0.0310745 1.83413 
LOC283663 0.0140178 1.90931 TP53I11 0.00659414 1.83377 
NCAPH 0.0212179 1.90562 LRRC42 0.00157328 1.83296 
WDR37 0.0198291 1.90296 HEG1 0.0123619 1.83219 
LOC100129269 0.0413582 1.90202 STOM 0.000282 1.83158 
RRAS2 0.00256184 1.90171 EPHB6 0.00255392 1.83116 
SDHB 0.00824247 1.90123 SERPINA3 0.013681 1.82793 
NLN 0.0209493 1.89853 TGFBR2 0.000128245 1.82327 
BRIX1 0.0136274 1.89733 OPN3 0.00906124 1.82318 
DCXR 0.00131425 1.89688 RRP9 0.00220878 1.82082 
TRAPPC1 0.00530354 1.89552 FJX1 0.0189592 1.82023 
ASF1B 0.0469889 1.89282 PRICKLE3 0.0409922 1.81724 
SNAR-A3 0.0243274 1.89057 GHR 0.0279752 1.81717 
ATOH8 0.00349795 1.88994 RASGRP2 0.0109952 1.81531 
LAMA2 0.0118164 1.88945 PLA2G4E 0.030434 1.81343 
MT1F 0.00309801 1.88839 SYPL2 0.0302298 1.81236 
TACC3 0.0102217 1.88794 SEH1L 0.010897 1.81144 
LOC100287322 0.00902287 1.8044 MAP1D 0.000839781 1.74591 
ZNF236 0.0353299 1.8036 BC031250 0.0412106 1.744 
ATP1B1 0.017102 1.80204 VCL 0.0317248 1.74152 
SWAP70 0.00601783 1.80193 UBASH3B 0.012351 1.74036 
B3GNT2 0.0334527 1.79871 ADAP1 0.0225462 1.73795 
ST6GALNAC2 0.023229 1.79789 FBLN5 0.00390276 1.73776 
TUBB2A 0.015036 1.79654 TCEAL6 0.0034694 1.73589 
ANXA2 0.00206354 1.7958 ENST00000390268 0.038455 1.73299 
UXT 0.0114532 1.79375 INMT 0.0243677 1.73051 
ANGPT1 0.0403703 1.79187 PRDX6 0.0449437 1.73049 
FERMT2 0.00244785 1.79174 ZFP36 0.00078675 1.72922 
MYO1E 0.0262112 1.79133 C20orf134 0.00915441 1.72737 
FAM83H 0.0116877 1.7882 P704P 0.0207662 1.72579 
KLF6 0.00638809 1.78657 LOC100128934 0.0208209 1.72542 
DLK2 0.00350101 1.7864 SMARCD2 0.00092234 1.72355 
NCL 0.0117862 1.78619 LOC644538 0.00754975 1.72277 
MTRR 0.0117564 1.78587 DONSON 0.0126751 1.7221 
AFAP1L1 0.0177821 1.78496 ENST00000434415 0.00520962 1.72199 
LOC92249 0.000703134 1.78488 SNRPB 0.0285952 1.72109 
KIAA1467 0.0121673 1.7841 GSTT2B 0.00788193 1.71968 
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MRVI1 0.0123391 1.78339 COL5A3 0.0130896 1.71903 
ZYX 0.0468308 1.78334 SCAF1 0.0196109 1.71662 
ITGA4 0.00513756 1.78021 EARS2 0.0313925 1.71609 
LOC100290344 0.00155041 1.77948 MFSD6 0.0161656 1.71476 
THC2715632 0.0124454 1.77828 ROR1 0.00506866 1.71476 
MGLL 0.0364153 1.77693 ARSK 2.29E-05 1.71455 
PUS7 0.0040995 1.77537 APOOL 0.000623268 1.71439 
STBD1 0.021483 1.77418 C10orf114 0.0234086 1.71071 
SEC14L2 0.0127481 1.77342 CDC42SE2 0.00277149 1.71053 
BF515046 0.0214467 1.76782 F12 0.0433054 1.70921 
CCDC107 0.00458112 1.76646 PKDCC 0.00412631 1.70851 
CTHRC1 0.00325109 1.76522 CCDC69 0.00833739 1.70729 
IRS2 4.84E-05 1.76474 ANXA2P3 0.00434377 1.70558 
TMEM2 0.016153 1.76296 TAS2R9 0.0452797 1.70384 
MFAP5 0.0356614 1.76125 NID1 0.0219034 1.70331 
DA567289 0.0184802 1.7595 ARSJ 0.0327042 1.7027 
PDLIM1 0.0171536 1.75844 AKAP7 0.00878199 1.70249 
SHBG 0.0016997 1.7583 CDK2AP2 0.0234804 1.70193 
TACC1 0.00582566 1.75689 C1orf152 0.00119424 1.70175 
TPM2 0.00212428 1.75592 SCAMP2 0.0146757 1.7017 
COQ2 0.0452233 1.75548 ELN 0.0214547 1.70075 
CHST2 0.0152059 1.755 RSPO1 0.0343332 1.70073 
PPARG 0.0262484 1.75222 IL1F10 0.0181831 1.70026 
HIP1 0.0231741 1.74858 MCM6 0.0049255 1.69953 
SYT2 0.0267923 1.74762 LDLR 0.0377244 1.69872 
IL18RAP 0.00556959 1.74752 ACER1 0.0150161 1.69818 
ARHGAP29 0.00878362 1.7473 C7orf40 0.0137765 1.69793 
HIPK2 0.00966278 1.7471 PRRG1 0.00591503 1.69748 
CNN2 0.00647049 1.747 MYL12A 0.0156914 1.69725 
ECE2 0.0209534 1.69643 TPM1 0.00213395 1.6531 
MYL6 0.0117597 1.6956 TLE1 0.00573661 1.65247 
PEBP4 0.0364478 1.69473 OR6K2 0.0421191 1.64882 
TCEAL2 0.00862442 1.69264 STON1 0.0195369 1.64803 
PARVB 0.0271266 1.6916 NAA10 0.00421202 1.64523 
UAP1 0.00442433 1.69151 SPOCD1 0.00964886 1.64475 
PRPF3 0.0238776 1.69001 SNAPC2 0.028432 1.6437 
PLSCR4 0.000556663 1.68971 ENPP4 0.000663693 1.6429 
LOC643371 0.0132777 1.68945 DUSP23 0.045555 1.6415 
LOC389333 0.0162535 1.68786 FARSB 0.00319796 1.64021 
TCIRG1 0.0136844 1.68759 MUC1 0.00419683 1.6393 
FABP5 0.00419207 1.68682 LOC100128714 0.000836864 1.639 
IGF2 0.00430152 1.68655 FGF1 0.0434016 1.6388 
KLHDC3 0.0243576 1.68567 HR 0.0105812 1.63844 
ANO9 0.021372 1.68523 CLTB 0.00141911 1.63841 
FKBP1B 0.00211799 1.68503 MTSS1L 0.00292838 1.63676 
AX746533 0.0395465 1.68485 ADAM19 0.00985981 1.63592 
UBE2N 0.00999596 1.68317 AK131288 0.00651412 1.63472 
POTEE 0.031172 1.68208 OR2M7 0.029241 1.63449 
CENPVL1 0.0146573 1.67962 SLC25A32 0.00479982 1.63413 
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SRPX 0.00036694 1.67958 LRRC59 0.00615603 1.63396 
SHMT1 0.0280122 1.6767 SLC16A3 0.0236032 1.63375 
POTEKP 0.0352168 1.6765 PALLD 0.0120431 1.63368 
FAM114A2 0.0295041 1.67537 HMHB1 0.0419993 1.63363 
DNAJC17 0.00170186 1.67395 PHOSPHO2 0.0247257 1.63363 
CD3EAP 0.00513222 1.67367 NANOS1 0.0428206 1.63205 
OR10P1 0.0134752 1.67212 MSRB3 0.00357306 1.63186 
BC018676 0.00151845 1.6721 DCT 0.00721748 1.63157 
C9orf29 0.0294436 1.67129 DSTN 0.00352243 1.6293 
KIF17 0.00089881 1.67089 GRAMD3 0.0327261 1.62699 
DHCR24 0.0161305 1.66965 FAM198B 0.00097895 1.62566 
GPR173 0.0371352 1.66959 CLDN7 0.0322532 1.62537 
SHOX 0.00212326 1.66851 RUNX2 0.0268564 1.62489 
PCGF5 0.00245105 1.66764 LPIN3 0.0131145 1.62462 
ACTN1 0.031856 1.66748 GCHFR 0.0276693 1.6245 
CD14 0.00424562 1.66682 CHST15 0.0367848 1.62196 
LSM12 0.00186415 1.66515 KRTAP19-8 0.0208002 1.62194 
KBTBD11 0.00753394 1.664 DKFZp667E0512 0.0341119 1.62155 
ENST00000374441 0.00490774 1.66385 PIP4K2C 0.0176893 1.62 
TSEN2 0.00079817 1.66345 CSRP1 0.029417 1.61974 
RAI14 0.00725905 1.662 LOC400950 0.0216949 1.61924 
KIAA0114 0.00321781 1.66087 OIP5 0.0490564 1.61912 
CRHR1 0.0348277 1.66061 TUBA1B 0.0303507 1.61872 
SRPX2 0.00241227 1.6606 TIMM16 0.0086793 1.61744 
ZRANB1 0.0239837 1.65782 FLNA 0.02978 1.61702 
C10orf96 0.0121685 1.65765 PAPSS2 0.0375943 1.61627 
NPAS1 0.00104748 1.65599 CGREF1 0.016036 1.61571 
COMTD1 0.029183 1.65516 ANXA2P1 0.0195384 1.61496 
NRAS 0.00106167 1.655 SERTAD3 0.0146449 1.61403 
PNO1 0.0465145 1.61377 SEMA7A 0.00883937 1.57502 
SLC30A6 0.000340055 1.61364 BARHL1 0.0389394 1.57497 
CYTH3 0.0353411 1.61233 TMEM150A 0.0183261 1.57445 
AK123701 0.0279208 1.61074 C6orf150 0.00443606 1.57318 
PPP1R13L 0.00364898 1.61034 ATF6 0.0114363 1.57296 
AHCTF1 0.018066 1.61025 CYP7B1 0.0120147 1.5722 
SCHIP1 0.00872129 1.60964 CPNE7 0.0276006 1.57007 
REEP4 0.000543764 1.606 TGIF1 0.0178419 1.57001 
ANXA6 0.0339389 1.60521 ZHX3 4.46E-05 1.56993 
PRR21 0.0248492 1.6049 AMOTL2 0.0244798 1.56989 
TLR4 0.0493724 1.60452 EID3 0.0193207 1.56988 
COL4A2 0.00176503 1.60439 GSTT2 0.00137581 1.5697 
SSB 0.00617313 1.60385 C5orf25 0.000714449 1.569 
COQ3 0.00687164 1.60221 ACSL1 0.00946129 1.56861 
PPIAL4A 0.0081133 1.6016 TIPARP 0.000641681 1.56846 
FKBP11 0.0163706 1.60132 CBX8 0.0430133 1.56843 
ARL4A 0.0302989 1.60103 ARNT2 0.015852 1.56725 
ATP13A2 0.0139831 1.59907 TNFRSF12A 0.0182899 1.56607 
PVT1 0.00470682 1.5987 LOC646821 0.0265603 1.56384 
KLK4 0.0402675 1.59748 STAG3L1 0.00289827 1.56379 
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USP4 0.0184042 1.59571 AQP8 0.0249671 1.56347 
PI3 0.00274427 1.59518 CD200 0.0323791 1.56275 
SH3PXD2B 0.0141415 1.59259 H2AFJ 0.0333066 1.56207 
UCHL3 0.0110704 1.59221 RBM14 0.000551019 1.55969 
MYBBP1A 0.0301502 1.59204 NOL6 0.0114674 1.55958 
RAD1 0.0110491 1.59007 RASL10B 0.0107211 1.55778 
LHX1 0.0471444 1.58945 C1QTNF5 0.0315733 1.55643 
IMPAD1 0.00244333 1.58851 UGP2 0.00902641 1.55609 
COL9A3 0.00837941 1.58652 PDSS1 0.0316673 1.55577 
NOC3L 0.00583487 1.58609 EEF1E1 0.00844804 1.55479 
LOC401557 0.0314518 1.58577 HLA-DPB2 0.0326049 1.55424 
KRTAP9L1 0.0296681 1.58468 EYA2 0.0272598 1.55416 
REEP1 0.00535273 1.58398 CYP1B1 0.00408749 1.55401 
CAV1 0.00317772 1.58333 C8orf85 0.0140055 1.55387 
EMP1 0.0344204 1.5828 PTPDC1 0.00293183 1.55347 
CLOCK 0.000948691 1.5826 SGK269 0.0157111 1.55303 
KANK1 0.0308752 1.58206 RRAS 0.00576408 1.55272 
TMOD2 0.0217739 1.58025 UBR3 0.0175791 1.55249 
INHBA 0.0185378 1.57967 HHEX 0.0117605 1.5524 
SLC35D1 0.00461209 1.57963 VKORC1L1 0.00456739 1.55211 
BCL7A 0.0212591 1.57923 PTPLA 0.00786451 1.54888 
EIF5A 0.0238916 1.57799 MPP3 0.0390802 1.54885 
DHX35 0.00544215 1.5779 RAB5B 0.0120912 1.54728 
MSI1 0.00250336 1.57778 CR615613 0.0251841 1.54671 
ILK 0.0227481 1.5769 SGTB 0.0169976 1.54639 
SLC19A2 0.0336608 1.57651 NCRNA00181 0.011972 1.54357 
AGPAT9 0.0457566 1.57627 DIO2 0.0036974 1.54344 
GCM1 0.0245097 1.57604 NOP2 0.0178898 1.54297 
TEAD3 0.00843151 1.57519 ENST00000395453 0.027586 1.54276 
STC2 0.00428328 1.54241 ZNF485 0.0316016 1.52082 
DPM2 0.00915178 1.54166 RUNX1 0.0461004 1.52043 
OR8B8 0.0196988 1.54159 FAM127B 0.0339392 1.51995 
ENST00000342688 0.00519207 1.54061 TWIST2 0.00200376 1.51932 
ZBTB7A 0.00788696 1.53949 NAP1L1 0.0121582 1.51875 
ZDHHC12 0.00684217 1.53934 TCTE1 0.00719065 1.51819 
MPI 0.0238554 1.53787 SH3GL1P3 0.0234892 1.5177 
ZWINT 0.0326763 1.53679 RAD51 0.038863 1.51761 
SP140L 0.00290213 1.53648 SFPQ 0.000477149 1.51678 
D13069 0.00136304 1.53621 ANG 0.00971459 1.51637 
LOC401561 0.00702947 1.53594 IGF2BP2 1.69E-05 1.51616 
CABIN1 0.00113746 1.53584 C7orf51 0.0468031 1.51615 
ACTR3 0.018905 1.53539 IRS1 0.0147083 1.51522 
ADAMTS9 0.0182146 1.53538 LOC340515 0.0175562 1.51522 
MED8 0.00138042 1.535 REG3A 0.0306929 1.51503 
NAA11 0.00473761 1.53474 BLM 0.0474108 1.5138 
URB2 0.001694 1.53426 CHCHD7 0.00481288 1.51368 
LOC344382 0.0182254 1.53405 FAM166A 0.0205222 1.51338 
INHBC 0.00960291 1.53377 REEP3 0.0446637 1.5132 
LCE1A 0.00423117 1.53363 TNFSF13 0.0360986 1.51284 
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TGFB1I1 0.00153039 1.53354 FN3K 0.00428976 1.51276 
GCAT 0.0438546 1.53285 DDX21 0.0144562 1.51194 
ENST00000377039 0.0358711 1.53251 SFRS7 0.0389748 1.51147 
LOC100009676 0.021047 1.53169 PTS 0.0261883 1.51129 
UFSP1 0.00677257 1.53131 ENST00000399730 0.00474636 1.50957 
CCND3 0.00263342 1.53086 GRRP1 0.0384513 1.50939 
C7orf11 0.00371683 1.53067 SAR1B 0.0164026 1.50891 
HPDL 0.0359797 1.53031 ENST00000366413 0.0260504 1.50808 
CFLAR 0.0157431 1.53002 NDUFS3 0.0251057 1.50776 
OR5L2 0.00382358 1.52988 LOC646576 0.0473773 1.50687 
PEA15 0.0158775 1.52966 SAMD4A 0.00270771 1.50563 
SGMS2 0.0273588 1.52934 SBDS 0.000455425 1.50489 
ENST00000376775 0.0351426 1.52884 LOC128322 0.00954339 1.50443 
CDA 2.40E-06 1.52856 TJP2 0.00470322 1.50322 
SELS 0.00793408 1.52767 AMD1 0.0163402 1.5032 
SPTBN2 0.00634065 1.52673 ERGIC1 0.0131549 1.50037 
RABL3 0.0292641 1.52611 DUS2L 0.0306426 1.50003 
PTPN18 0.00392213 1.52604 SVIL 3.91E-05 -1.50118 
TAF7 0.0244297 1.52481 ENST00000371488 0.018129 -1.50177 
PEMT 0.0286748 1.52465 LOC401286 0.0406118 -1.50186 
RNGTT 0.00267116 1.52432 PGPEP1 0.00642076 -1.50262 
MRPL15 0.00598968 1.52378 LOC84989 0.0255584 -1.50326 
PRDM13 0.00945784 1.52289 DSTYK 9.62E-06 -1.50372 
TXNIP 0.0110062 1.52264 CDYL 0.0144349 -1.50388 
LOC400236 0.0432812 1.52218 CLU 0.0117427 -1.50485 
TTC13 0.021895 1.52208 DZIP1 0.0104316 -1.50724 
FAM199X 0.0212841 1.52172 KLRG1 0.00584876 -1.50774 
RHOB 0.0354701 1.52138 ARHGEF2 0.00433198 -1.50825 
TCEAL5 0.0154601 1.52098 JMJD7-PLA2G4B 0.0081886 -1.51007 
TRIM22 0.00519648 -1.51009 PAN3 0.0467904 -1.53088 
SPATA4 0.0411625 -1.51087 PARP14 0.00361116 -1.53115 
FRAT1 0.0170407 -1.51164 CBR3 0.0313695 -1.53126 
PSIP1 0.0214491 -1.51176 SLC35E2 0.00766206 -1.53148 
UNK 0.00355972 -1.51186 EGFL8 0.0162427 -1.53151 
PBX2 0.0399724 -1.51247 C9orf140 0.00410175 -1.53226 
NFKBIE 0.0149794 -1.51322 PNPLA7 0.0215441 -1.53357 
CCDC102A 0.0326922 -1.51323 PAFAH1B3 0.0206772 -1.53383 
ENST00000432854 0.00592678 -1.51355 FAM107B 0.0301075 -1.53401 
C20orf177 0.0110692 -1.51368 TMEM121 0.00322258 -1.53422 
SNX30 0.0259454 -1.51489 LNP1 0.0368891 -1.53479 
NNAT 0.04094 -1.51674 OR4A15 0.0372018 -1.53544 
ZMAT3 0.0295509 -1.51674 TP53BP1 0.00357083 -1.53581 
ARID5A 0.0188059 -1.51712 DST 0.0182532 -1.53628 
LOC100132774 0.0129553 -1.51754 DPP4 0.00596302 -1.53686 
LOC100133131 0.00438744 -1.51788 ZNF780B 0.0053232 -1.53694 
SLC16A4 0.0245246 -1.518 GPT2 0.0324714 -1.5375 
TCF4 0.00422215 -1.51811 RPS6KA3 0.00285817 -1.53772 
PSD3 0.0212434 -1.51812 CTSLL2 0.0220518 -1.53788 
PRKACB 0.00126809 -1.5183 C1orf96 0.00799625 -1.53825 
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LOC100130009 0.00414006 -1.51882 DHFRL1 0.00437084 -1.53929 
SCARA3 0.00126832 -1.51937 C6orf225 0.043217 -1.53997 
ZNF74 0.0418136 -1.5196 LIMA1 0.00164674 -1.54037 
SLC45A3 0.0259792 -1.51975 GRAMD4 0.00123944 -1.54154 
CTNNBIP1 0.000725854 -1.52066 FANCE 0.00215588 -1.5421 
UTS2R 0.0194121 -1.52094 LRRC2 0.00240516 -1.5426 
ENST00000439203 0.000861267 -1.52145 PELI1 0.0270355 -1.54307 
INSIG1 0.0327888 -1.52223 HCFC1R1 0.00402001 -1.54366 
TTLL8 0.0119498 -1.52252 LOC100128416 0.0384879 -1.54451 
BAGE4 0.00793398 -1.52366 TIA1 0.0232977 -1.54501 
GAMT 0.0020288 -1.52378 USP27X 0.038469 -1.54513 
C9orf7 0.00158852 -1.52455 PIK3IP1 0.00770499 -1.54543 
MXI1 0.00832321 -1.525 AUTS2 0.010285 -1.54547 
ARHGEF6 0.0310599 -1.52589 SLC9A9 0.0108561 -1.54589 
KLF11 0.00235205 -1.52623 ZMIZ1 0.00322675 -1.54876 
TGFBR3 0.0243335 -1.5267 PLK2 0.0195957 -1.5492 
CRBN 0.0141834 -1.52675 ZNRF1 0.00954571 -1.55056 
WWC2 0.0451787 -1.52695 STAP2 0.00308432 -1.55117 
ACAD11 0.0476931 -1.52701 FES 0.0247493 -1.55169 
EPHB2 0.0168057 -1.52702 CARD17 0.0322264 -1.5533 
SESN2 0.00128195 -1.52719 RFX7 0.0334087 -1.55383 
NISCH 0.0268881 -1.52724 HMGB3L1 0.0115716 -1.55489 
KIAA0495 0.0382779 -1.52807 DDAH2 7.24E-05 -1.55491 
OCIAD2 0.0145437 -1.52815 PGM5 0.0217452 -1.55499 
ADNP 0.00143483 -1.52851 FAM125B 0.00439971 -1.55544 
BICC1 0.00733564 -1.52852 LOC283861 0.0216603 -1.55704 
OSBPL7 0.00569432 -1.52998 MOXD1 0.026759 -1.55709 
FHOD3 0.026902 -1.53069 LIPT1 0.00546301 -1.55854 
FYCO1 0.0129197 -1.53088 C6orf134 0.00811826 -1.55858 
FAM171A1 0.000119603 -1.55906 CIC 0.00282024 -1.58387 
LOC441795 0.0121469 -1.55918 SACS 0.00191987 -1.58394 
IGF2R 0.00105074 -1.55968 PRNP 0.00141919 -1.58435 
SSX2IP 0.0464588 -1.55989 HSPA12A 0.0109366 -1.58531 
TSHZ3 0.00713993 -1.5604 FZD1 0.0252886 -1.5856 
CAND2 0.0274221 -1.56079 AX747640 0.00455084 -1.58625 
LOC285629 0.0107335 -1.56239 TBC1D2B 0.00222875 -1.58926 
HGF 0.00067535 -1.56261 RN5-8S1 0.000105192 -1.59011 
NEK10 0.0101658 -1.56262 ARHGAP22 0.0183132 -1.59129 
C6orf154 0.0446415 -1.56294 CDKN1A 0.0118619 -1.59219 
PTPN13 0.00818166 -1.5656 SPEG 0.0322934 -1.59256 
Sep-05 0.00748971 -1.56627 EXT1 0.0124141 -1.59257 
OAF 0.0179696 -1.56655 NCRNA00219 0.00648519 -1.5932 
EPAS1 0.00121363 -1.56688 KIAA0895L 0.0279553 -1.59322 
PGAP1 0.00732748 -1.56794 EYA4 0.0172744 -1.59475 
VPS8 0.0466266 -1.56849 PTPRU 0.000925544 -1.59492 
PABPC4L 0.0200126 -1.56891 ZNF561 0.0120664 -1.59584 
JMY 0.00957186 -1.56926 CFB 0.0492871 -1.59601 
MARCKS 0.0220441 -1.5695 HIST1H3J 0.0285744 -1.59676 
PCSK4 0.031863 -1.56987 C2orf60 0.0015856 -1.59832 
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CPZ 0.0060581 -1.57003 TMEFF2 0.0168481 -1.59894 
BACH2 0.0386525 -1.57006 LRRC49 0.00267242 -1.60017 
NR2F1 0.0252862 -1.57035 PTEN 0.013739 -1.60028 
C16orf74 0.0033656 -1.57048 FGF7 0.000138676 -1.60135 
LOC554202 0.00469693 -1.57097 CCDC142 0.0156004 -1.60154 
EYA1 0.030475 -1.57168 SLC4A4 0.0385978 -1.60178 
RFX2 0.00724667 -1.57231 SLC25A29 0.000582752 -1.60207 
ZBTB2 0.0272753 -1.57372 IRF2BP2 0.0281924 -1.60393 
SLC27A1 0.000601986 -1.57382 C20orf108 0.000778739 -1.604 
NTNG2 0.0457537 -1.57412 ANKDD1A 0.00119112 -1.6064 
PLEKHN1 0.0381408 -1.57421 BCL9 0.0212728 -1.60678 
TIGD1 0.00327985 -1.57507 XPC 0.0384741 -1.60856 
C5orf41 0.00619559 -1.57538 MASTL 0.0423368 -1.60881 
HIST1H3A 0.00412538 -1.57599 LRRN4CL 0.00487135 -1.60944 
LOC375010 0.0383873 -1.57721 BCL2 0.0159714 -1.61054 
THAP11 0.010318 -1.57746 KCNE4 0.0201001 -1.61136 
HIST1H4B 0.0118353 -1.57778 GLIS2 0.0114409 -1.61181 
LOC286161 0.0284388 -1.57806 LONP1 0.0433688 -1.61228 
GATAD2B 0.0226438 -1.57909 ABCA7 0.00567939 -1.61241 
CCR10 0.00229571 -1.57911 TCF3 0.036804 -1.61336 
ERV3 0.0368821 -1.57935 HIST1H3E 0.0233539 -1.61351 
IQCD 0.039425 -1.57941 LOC100287428 0.0151964 -1.61445 
C14orf37 0.0492402 -1.57951 AK058117 0.0352799 -1.61696 
TMEM66 0.01153 -1.57965 HECTD1 0.00289452 -1.61715 
LOC100170939 0.0219398 -1.57981 ENST00000367596 0.01976 -1.61751 
PCSK5 0.0103333 -1.58082 TUBA4A 0.00111482 -1.61849 
SASH1 0.000198955 -1.58196 TOB1 0.000268462 -1.62097 
LOC388242 0.0115597 -1.58197 AKD1 0.00166826 -1.62342 
SLC37A2 0.0338481 -1.582 PMEPA1 0.0225467 -1.62404 
BC043411 0.00463014 -1.62515 MAST4 0.000717315 -1.65826 
SOD2 0.0109965 -1.6255 KRTAP4-11 0.0335412 -1.65855 
C7orf61 0.00337805 -1.62561 HSPB8 0.00368304 -1.65872 
SH3BGR 0.0245866 -1.62585 C8orf47 0.0133066 -1.66033 
CD44 0.00616166 -1.62596 DAB2IP 0.0318262 -1.66035 
HIST1H4K 0.0158534 -1.62666 HIST2H4B 0.0129093 -1.66159 
PPL 0.0396414 -1.62749 PER3 0.0290996 -1.66177 
RAPGEF6 0.0499704 -1.62765 C8orf31 0.0211327 -1.662 
IFI16 0.00541607 -1.62783 RHOJ 0.0338931 -1.66223 
SNHG7 0.0188353 -1.62897 C4orf46 0.0307614 -1.66389 
CCNG1 0.013129 -1.63104 TSHZ1 0.0283001 -1.66502 
PTPRK 0.00463236 -1.63175 NBEA 0.0017485 -1.66531 
CR620599 0.000494353 -1.63331 FRMD4A 0.0354197 -1.66574 
SOCS1 0.00656085 -1.63468 PGF 0.0148908 -1.66606 
CA11 0.0232012 -1.63497 CASK 0.0059835 -1.66618 
BTG2 0.00872136 -1.63624 COLEC12 0.00566187 -1.66626 
NAALADL2 0.00430369 -1.6368 GALNT12 0.0414699 -1.66682 
RPA4 0.0185263 -1.63774 PBXIP1 0.0114431 -1.66771 
AGAP1 0.0029188 -1.64008 CFP 0.000356378 -1.66785 
AX747706 0.0042293 -1.64027 PCDHB9 0.0282593 -1.66842 
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C21orf49 0.00910901 -1.64131 CARD10 0.0262575 -1.66969 
SPATA13 0.00279529 -1.64136 PTPRS 0.00361604 -1.66977 
LOXL1 0.0224028 -1.64156 XAF1 0.0117507 -1.67157 
ACCN2 0.0059297 -1.64164 KIAA1549 0.0163473 -1.67198 
KRBA2 0.026965 -1.64187 KCNAB3 0.0381156 -1.67238 
C21orf66 0.00185886 -1.64204 METRNL 0.000238882 -1.67329 
ZNF667 0.00527452 -1.64351 CEP57 0.00714972 -1.67499 
PGBD2 0.0168251 -1.64447 ANGPTL6 0.043869 -1.67641 
LOC729175 0.00211095 -1.64581 DTWD1 0.00758613 -1.67643 
AGT 0.027293 -1.64589 GRASP 0.00193064 -1.67698 
TBX3 0.0172112 -1.64615 DYNLRB2 0.0249205 -1.67826 
SCARNA9 0.00113747 -1.64706 MAP1A 0.0123902 -1.67888 
IFT88 0.00195007 -1.64851 FAM46A 0.0405706 -1.67908 
IFIT3 0.00695599 -1.64925 CENPL 0.0161494 -1.67969 
IFI30 0.00140305 -1.64944 AHCYL2 0.0175128 -1.68008 
P4HA2 8.84E-05 -1.65031 ADAL 0.0172775 -1.68042 
LOC100132891 0.0117061 -1.6522 NDRG3 0.0213009 -1.68045 
UCN 0.0135158 -1.65232 TNIK 0.0298829 -1.68131 
LOC644925 0.0017931 -1.65258 NFE2L3 0.0145034 -1.68365 
ADSSL1 0.042551 -1.65277 NEK11 0.0299512 -1.68536 
SYNJ2 0.00265125 -1.65338 SLC43A3 0.0208433 -1.68536 
MFAP4 0.00772648 -1.65375 KLF3 0.0179288 -1.68711 
PHACTR1 0.0114834 -1.65397 VAMP4 0.0047297 -1.68747 
NAF1 0.0186522 -1.65402 GPRASP2 0.00117835 -1.6894 
PLCB1 0.00486583 -1.65479 ZCCHC14 0.00195396 -1.69103 
BTN3A1 0.0133041 -1.65555 SP4 0.0210173 -1.69166 
TBX4 0.0105486 -1.65566 CIDEA 0.00620517 -1.69308 
CLSTN3 0.00490672 -1.65616 TNFRSF10B 0.00269714 -1.69333 
FAM20A 0.0120662 -1.65618 CYS1 0.00652154 -1.69385 
ZMYM3 0.006019 -1.69545 LOC100291791 0.0212388 -1.75355 
ANKRD36 0.0172586 -1.69602 PRR3 0.0274573 -1.75369 
LHFPL2 0.00110919 -1.69722 ZNF497 0.00480268 -1.75486 
FAM155A 0.00346109 -1.69912 MKL2 0.0175421 -1.75511 
ARHGEF9 0.0041324 -1.69967 SCN2A 0.0101107 -1.75649 
RNF146 0.00551771 -1.69985 NAB1 0.00264615 -1.7566 
LOC729595 0.0330492 -1.70081 PRR19 0.0113106 -1.75719 
BATF2 0.0353445 -1.70138 VPS37D 0.00121596 -1.75867 
MYST2 0.0356337 -1.70279 SORL1 0.0224045 -1.7594 
SOX9 0.0398713 -1.70363 MTHFR 0.00074491 -1.76002 
THC2620530 0.0178753 -1.70371 SOCS2 0.0293658 -1.76019 
LOC100049716 0.0151159 -1.70412 TMEFF1 0.00745907 -1.76084 
SLC5A12 0.0490626 -1.70456 RGS10 0.0165217 -1.76131 
TEF 0.024159 -1.70601 ZNF653 0.0242651 -1.76346 
PFN4 0.00382213 -1.70605 FAM161A 0.00469633 -1.76665 
SEC31B 0.000431119 -1.70807 PRTFDC1 0.00643595 -1.7693 
NINL 0.00421214 -1.70862 PURG 0.0397532 -1.77074 
ING4 0.00133649 -1.71 SELENBP1 0.016457 -1.7712 
EDA2R 0.00952513 -1.71049 STARD10 0.00278286 -1.77196 
C3orf65 0.0024727 -1.71099 TIMP3 0.00502799 -1.77224 
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MSX2P1 0.00712371 -1.71314 LOC286367 0.0132135 -1.77311 
CARD16 0.0202562 -1.7135 KRTAP10-5 0.017222 -1.7738 
THC2655610 0.0036342 -1.71357 RASGEF1A 0.0370069 -1.77429 
C20orf132 0.0321411 -1.71594 ANKIB1 0.0140934 -1.77583 
BAI2 0.00268282 -1.7167 TMEM88 0.0434898 -1.77783 
RASSF5 0.0283061 -1.71883 FCGR2A 0.0441334 -1.77799 
KRTAP12-1 0.0136459 -1.71975 SHC2 0.00740202 -1.77841 
PPAP2C 0.0107034 -1.72071 SOCS3 0.0226194 -1.77916 
LOC100130819 0.00473786 -1.72083 PDE4D 0.0275595 -1.77955 
RALGDS 3.43E-05 -1.72118 IFIT2 0.00668926 -1.78029 
CASP1 0.0249651 -1.72716 LIF 0.0221744 -1.78151 
CAMK4 0.0449033 -1.72745 SERPINE2 0.0027427 -1.78308 
LUZP1 0.0281258 -1.72824 MCM7 0.00708165 -1.78447 
SSC5D 0.00873221 -1.72928 MYLIP 0.0372086 -1.78476 
POU6F1 0.0331716 -1.72947 DLG3 0.00784381 -1.78483 
L3MBTL 0.0425477 -1.73008 FAM129A 0.0186803 -1.78573 
ENST00000380683 0.0305764 -1.73058 PTPN4 0.013027 -1.78616 
IFI44 0.00135842 -1.734 C20orf96 0.0283764 -1.78686 
PRKCE 0.0149573 -1.7389 RIBC1 0.0379209 -1.78741 
POU2F1 0.0011445 -1.73912 JMJD7 0.0107785 -1.78951 
TRIM5 0.000905955 -1.7399 PHKG2 0.000605278 -1.79094 
IFFO1 0.000895382 -1.74309 HEXIM2 0.00687816 -1.7913 
LOC153684 0.00318901 -1.74384 SNX21 0.000333609 -1.79147 
MANBA 0.00149642 -1.74444 STRN3 0.00806945 -1.79592 
GYPC 0.00371899 -1.74593 HIST1H2AE 0.0189585 -1.79718 
TNFRSF14 0.00281423 -1.74941 FOXP2 0.00878485 -1.79894 
TCAP 0.0444795 -1.74962 RBP1 0.0220172 -1.79933 
COL6A6 0.0130339 -1.74985 SLC8A1 0.00987762 -1.80136 
PIP5KL1 0.0193506 -1.75202 GPR162 0.000634474 -1.80235 
ATF5 0.00187252 -1.80327 C4orf38 0.0491376 -1.85925 
FLJ10357 0.00515077 -1.80358 TMEM200A 0.000813525 -1.86001 
EFCAB7 0.00849823 -1.80586 PPAP2A 0.0157463 -1.86252 
LOC100129365 0.0253237 -1.80771 NUMA1 0.0480917 -1.86358 
HBP1 6.84E-05 -1.80827 ASPRV1 0.0114617 -1.86435 
PARP11 0.0258225 -1.81082 SULF2 0.00131374 -1.86519 
GALM 0.003476 -1.81111 MAMSTR 0.0316064 -1.86552 
JMJD1C 0.00409768 -1.81133 C14orf79 0.0204964 -1.86717 
TCEAL7 0.000978636 -1.81202 POPDC2 0.0164453 -1.86739 
VLDLR 0.0107936 -1.81259 CSDC2 0.0323883 -1.86758 
LRIG1 0.00421353 -1.81332 TRIM2 0.00120328 -1.87009 
SERTAD2 8.93E-06 -1.81362 TMEM132A 0.00860836 -1.87226 
LYZL1 0.0140937 -1.81371 LOC282997 0.000162601 -1.87541 
FNDC1 0.0124359 -1.81688 ARL4C 0.00639056 -1.87693 
OSBPL3 0.00277281 -1.81795 CPEB1 0.00159968 -1.8786 
ULK1 0.00718744 -1.81916 ZBED3 0.00796132 -1.88414 
PYROXD2 0.00762256 -1.82146 ZNF710 0.0360452 -1.88414 
GPC2 0.0261739 -1.8215 PITX1 0.0195004 -1.88446 
CD248 0.00174394 -1.82167 CD86 0.00242742 -1.88519 
DDIT3 0.000237384 -1.82169 GALNTL1 0.0096522 -1.88647 
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ENST00000395936 0.0260157 -1.82247 CCDC74B 0.00119343 -1.88889 
FLJ90757 0.000294096 -1.8225 ABI3BP 0.0220532 -1.88936 
ANK2 0.0111876 -1.82602 PDCD4 0.0170675 -1.89019 
FLYWCH1 0.00494036 -1.82749 GPR125 0.0360252 -1.89059 
ROBO1 0.00760105 -1.83005 RP1-21O18.1 0.00975741 -1.89328 
HIVEP2 6.07E-05 -1.83162 COL15A1 0.0295365 -1.89335 
ZNF154 0.0363896 -1.83166 AK074144 0.0223447 -1.89441 
SPATA18 0.00511123 -1.83168 C13orf33 0.0305718 -1.89452 
AX747437 0.0289977 -1.8326 AHNAK2 0.0049417 -1.89616 
CPAMD8 0.0227381 -1.83279 PFKFB3 0.00230741 -1.89647 
GXYLT2 0.0120212 -1.83413 PELI2 0.000242001 -1.89671 
LIG1 0.00731637 -1.8349 RAVER2 0.0260669 -1.89701 
TMEM37 0.0189832 -1.83492 LOC100128163 0.040367 -1.89801 
RN18S1 0.00160088 -1.83672 SLURP1 0.0199161 -1.89843 
BEND6 0.00650894 -1.83724 FAM161B 0.0294612 -1.89988 
ASGR1 0.0128841 -1.83878 CAPS2 0.0472048 -1.90106 
NR3C1 0.000498005 -1.84159 TCF7 0.00366817 -1.90161 
EFR3B 0.0157715 -1.84229 ST6GAL1 0.0137812 -1.90173 
MIR155HG 0.0056669 -1.84519 SPI1 0.0370844 -1.90427 
C11orf20 0.020531 -1.84819 CHADL 0.00374819 -1.90464 
CCL15 0.0332264 -1.84911 PLCL2 0.00842468 -1.90509 
MGC2848 0.0303144 -1.84982 CCDC85C 0.000536567 -1.90607 
HIST1H4I 0.0108644 -1.85003 CLIC2 0.00280036 -1.90808 
SEMA5A 0.000115808 -1.85342 VEGFA 7.80E-05 -1.90829 
PKIA 0.00511557 -1.85379 MALL 0.0265984 -1.90837 
PRKG1 0.00150954 -1.85582 RASA4 0.0154752 -1.91052 
MCPH1 0.0178924 -1.85766 BCL2L11 0.0182161 -1.91192 
ALDH3A2 0.0325662 -1.85835 LARP6 0.00148867 -1.91759 
MX2 0.043301 -1.85847 ANKRD10 0.0108932 -1.9192 
FAM65B 0.0455055 -1.91935 CLN8 0.00177106 -2.00272 
COL21A1 0.0404951 -1.91941 SOBP 0.00246175 -2.00551 
C3orf58 0.0405864 -1.92104 KIAA1683 0.0015688 -2.00702 
SDCBP2 0.0279108 -1.92118 TCP11L2 0.0100366 -2.00873 
PPP1R1B 0.0368319 -1.922 NT5E 0.00138952 -2.01248 
PHLDB3 0.00452662 -1.92721 C2orf84 0.017976 -2.01651 
C10orf41 0.00603495 -1.93223 PLXNC1 0.00731964 -2.01663 
C15orf51 0.000213284 -1.93515 LOC730058 0.0331972 -2.02103 
JUN 0.00118891 -1.93669 ADAMTS19 0.0155415 -2.02252 
HIST1H4A 0.0129631 -1.93723 DDB2 0.0142488 -2.02277 
TRERF1 0.00299111 -1.93972 SLC7A4 0.0360427 -2.02478 
ELTD1 0.00306059 -1.94304 C15orf48 0.00237774 -2.02618 
TNFRSF11B 0.047084 -1.94468 FAM117B 0.02049 -2.02684 
ST3GAL5 0.00717268 -1.94564 GPR179 0.0471732 -2.03225 
TNFRSF10C 0.000208728 -1.94574 CDCP1 0.0207959 -2.03703 
C12orf70 0.0318504 -1.94742 TP53INP1 0.000192707 -2.03705 
GJC2 0.0089249 -1.94782 MAPK10 0.00878403 -2.03901 
NDRG4 0.00359485 -1.94904 OR52K2 0.0151664 -2.04112 
HIST1H4H 0.00813219 -1.95217 FKBPL 0.00414387 -2.0438 
MTMR9L 0.000226335 -1.95239 NINJ1 0.000152413 -2.04386 
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PTGFR 0.0404748 -1.95551 GPRC5C 0.00673569 -2.04442 
CLDN11 0.0101785 -1.95669 RTTN 0.0411547 -2.04525 
SC5DL 0.00981905 -1.9592 DQ895628 0.0284148 -2.04585 
PDZRN3 0.000667329 -1.96065 DCUN1D2 0.00446433 -2.04922 
GNAZ 0.00344932 -1.96067 C3orf71 0.0375797 -2.05171 
SGIP1 0.00290057 -1.96324 HTRA3 0.0381453 -2.0537 
GPR153 0.0493253 -1.96692 LOC440082 0.0219406 -2.05736 
TNXB 0.00405074 -1.96984 CRTC1 0.00123513 -2.06474 
HMOX1 0.000217658 -1.9699 TXLNB 0.0137409 -2.06565 
CACNA1G 0.0163947 -1.9703 VWF 0.00134621 -2.06973 
PHEX 0.0135048 -1.97352 ZNF821 0.0257483 -2.07192 
TMEM140 0.00370241 -1.97784 RASL12 0.0151539 -2.07496 
AKR1C4 0.0431062 -1.98033 DBNDD1 0.0280648 -2.07513 
LOC401357 0.0190159 -1.98697 PLD1 0.0392563 -2.0833 
POSTN 0.0243548 -1.98888 CHRDL1 0.0128169 -2.08377 
DYTN 0.0050043 -1.98893 HIST1H4E 0.00600529 -2.08387 
MRPS6 0.00154995 -1.98902 TNFAIP2 0.00863218 -2.09067 
ENC1 0.0245506 -1.98922 ZBTB46 0.00472291 -2.09757 
PIK3C2B 0.0242041 -1.98927 CCDC30 0.0259982 -2.09826 
C5orf4 0.019397 -1.98959 LAMB3 0.000276104 -2.10045 
FLJ41603 0.0211472 -1.99124 IER3 0.00122035 -2.10279 
AK123797 0.0200231 -1.99217 FLJ44253 0.0364392 -2.1055 
LOC100128055 0.0245863 -1.99254 PER2 0.00463593 -2.1093 
MBP 0.00896874 -1.99458 TAC3 0.0150556 -2.11262 
AF072164 0.040833 -1.99467 AIF1L 0.0367536 -2.11437 
LOC100130996 0.00565763 -1.99496 GGTLC1 0.00294074 -2.11674 
UACA 0.00209645 -1.99606 ITGA7 0.000358097 -2.11706 
MSR1 0.0123097 -1.99945 USP6NL 0.0209651 -2.1199 
TRO 0.000815526 -2.00129 VASH2 0.0274618 -2.12432 
SH2B2 0.00188046 -2.12618 SLC5A3 0.00609932 -2.26351 
PAQR5 0.00279041 -2.12679 DCHS1 0.00523407 -2.26518 
IRAK2 0.00288731 -2.13016 CSGALNACT1 0.0215879 -2.26544 
DRAM1 6.05E-05 -2.13031 SMAD1 0.00177219 -2.26762 
MGC42105 0.0481199 -2.13361 UNC5B 0.00149188 -2.26793 
KRT19 0.0252756 -2.13385 NFATC4 0.00588824 -2.27027 
ZNF606 0.0201636 -2.13848 LOC285141 0.0307332 -2.27033 
SPTLC3 0.00133782 -2.13921 TNC 0.000485016 -2.27137 
DENND5B 0.00502217 -2.14032 CRABP2 0.000284095 -2.27441 
ENST00000390301 0.00922738 -2.1436 ITGA11 0.0127115 -2.27469 
PRRX1 0.00407039 -2.14525 TNFRSF25 0.00860519 -2.2751 
MATN2 0.0160175 -2.14538 AMIGO2 0.0188621 -2.27692 
GADD45G 0.00577251 -2.14843 PLA2G4A 0.0178399 -2.28179 
HOXA3 0.0293659 -2.14896 RELB 0.000732311 -2.28955 
HTR2B 0.0059829 -2.15029 PCNXL2 0.011275 -2.29363 
QPRT 0.000322493 -2.15416 ITPKB 0.00376458 -2.29408 
LOC728903 0.0325493 -2.15499 LOC728392 0.0123275 -2.29463 
CCRL1 0.0458366 -2.15526 FAIM2 0.00390309 -2.29614 
ABCB4 0.025316 -2.16359 OLFML1 0.0146794 -2.2974 
SECTM1 0.0056696 -2.164 C14orf132 0.00485107 -2.29851 
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BC030764 0.00261796 -2.16711 PLEKHG1 0.0105358 -2.30307 
TNNC2 0.00433159 -2.17335 PLEKHG4 0.00113659 -2.30361 
KILLIN 0.0206867 -2.18127 THC2564554 0.043092 -2.30396 
ADAM8 0.00359133 -2.19147 TYMS 0.018108 -2.30487 
ENPP2 0.0484056 -2.19226 MAF 0.00262797 -2.30716 
CCDC48 0.00484607 -2.19337 FOLR3 0.00112763 -2.30988 
RNF122 0.00145982 -2.20561 TCEA3 0.00213543 -2.31001 
LOC390251 0.024576 -2.20659 COL4A5 0.0229976 -2.31249 
MBD5 0.00217481 -2.20768 ARHGAP28 0.0363884 -2.31275 
MAFB 0.0283171 -2.20814 ZNF323 0.0437756 -2.31434 
RGS5 0.0197477 -2.21163 HOXA10 0.0222964 -2.32598 
LOC157562 0.0223075 -2.22041 PPARGC1A 0.0211435 -2.327 
SEMA3B 0.000894984 -2.22444 ETV1 0.00189265 -2.32789 
C17orf44 0.0333928 -2.22605 TMEM130 0.00144731 -2.33212 
ZFP14 0.0192304 -2.22655 ZNF483 0.017416 -2.335 
LOC645431 0.0303829 -2.22744 CIT 0.00783073 -2.33737 
ZNF521 0.0048713 -2.22913 ABCA11P 0.0152178 -2.33772 
MALAT1 0.0489195 -2.23252 COL14A1 0.00182548 -2.33831 
THC2539584 0.049034 -2.23648 LPPR3 0.036024 -2.33837 
CD36 0.0109877 -2.23897 HBD 0.0243098 -2.3389 
ABCA1 0.0207415 -2.24225 VAT1L 0.0354067 -2.34081 
SYTL2 0.00331061 -2.24309 PHGDH 0.0107903 -2.34366 
FLJ13197 0.0435998 -2.24525 SPTBN4 0.00138058 -2.34695 
GBP2 0.00375895 -2.24538 FAM134B 0.0222865 -2.34911 
PLXDC1 0.00825863 -2.25051 C18orf56 0.00985652 -2.35272 
ZNF165 0.0347887 -2.25079 CRYM 0.00051315 -2.35813 
ZNF221 0.0353176 -2.2514 THC2728054 0.0168281 -2.36191 
LRDD 0.00229135 -2.25431 LOC283454 0.00151061 -2.36518 
GPR62 0.00734075 -2.26238 IL13RA2 0.0386779 -2.3665 
C1orf228 0.00199302 -2.37091 Sep-12 0.017346 -2.61068 
LOC203510 0.0105021 -2.37188 GDF10 0.0106163 -2.61162 
RGS2 0.0216326 -2.3742 PHLDA1 0.00163238 -2.62249 
CA14 0.0109646 -2.37797 FLJ41484 0.0225578 -2.6502 
RAP2B 0.0012435 -2.37995 KRTAP13-2 0.0343849 -2.66001 
NHS 0.00816653 -2.38049 LRRC25 0.0404329 -2.68019 
HSPA4L 0.00502894 -2.38086 FLJ22536 0.0335532 -2.68094 
LUM 0.00459266 -2.38331 FAM171B 0.00253607 -2.68106 
DACT3 0.00361146 -2.38466 KLF4 0.0263349 -2.686 
NEDD4L 0.00340027 -2.39217 OR10G9 0.0347738 -2.70534 
RCOR2 0.00273849 -2.39429 CDKN2B 0.00010202 -2.70931 
TMEM158 0.0182022 -2.40322 SLC7A14 0.000666958 -2.72656 
ADAMTS14 0.0347588 -2.40669 SALL2 0.00557715 -2.72715 
RSPO3 0.0135325 -2.4155 TARSL2 0.000528049 -2.72922 
FDXR 0.000493899 -2.41657 ENST00000402420 0.0388179 -2.73066 
SNCAIP 0.0003216 -2.41885 TMCC2 0.0362454 -2.73384 
GRAMD1A 0.00304616 -2.42083 TNFSF13B 0.0457193 -2.75552 
FAM102A 6.19E-05 -2.42137 BAALC 0.00914276 -2.76266 
FLRT2 0.000293604 -2.42699 GDF15 0.000129115 -2.77627 
PRRT2 0.0171098 -2.42928 VWCE 0.0156536 -2.79722 
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BBC3 0.00116986 -2.43318 C6orf138 0.00222058 -2.79844 
PLA2G4C 0.000799513 -2.43367 RAB7B 0.000687243 -2.80818 
OXER1 0.00136629 -2.44069 RDH5 0.00231506 -2.81584 
KCNMA1 0.0031953 -2.44479 IGDCC4 0.00148491 -2.81815 
SH3BP5 0.0181129 -2.45401 EPHB3 0.000703597 -2.82279 
CHRDL2 0.0260872 -2.4558 RCAN2 0.0011036 -2.82403 
CGNL1 0.0134285 -2.46573 CLGN 0.000254954 -2.8298 
FST 0.00322235 -2.46728 CNTN3 0.026407 -2.83565 
PLAU 0.00127162 -2.47345 OR2Y1 0.022669 -2.83964 
C20orf195 0.00312693 -2.47866 DIP2A 0.0212757 -2.85123 
GFRA1 0.00105592 -2.48121 LOC100130111 0.00387314 -2.88354 
CA12 0.00571127 -2.48146 IGSF10 0.00879671 -2.88593 
ZNF846 0.023978 -2.48209 FIGF 0.0321458 -2.89233 
SAMD12 0.00558809 -2.48494 P2RX7 0.000988212 -2.90941 
SMO 0.00162981 -2.48883 HSD17B2 0.0113764 -2.90988 
ACP5 0.000682876 -2.48975 PKP3 0.00291831 -2.94756 
DDIT4L 0.0392359 -2.50747 KCTD12 0.0190956 -2.96429 
RASSF2 0.0125668 -2.51323 LOC646936 0.00213994 -2.9659 
ARVCF 0.000616711 -2.52069 LDB2 0.000510225 -3.00525 
GDF1 0.013016 -2.5208 AQP3 0.0357826 -3.00815 
ADCY1 0.0106139 -2.54299 RFTN2 0.00133565 -3.02176 
IL17RD 0.01906 -2.54413 MIAT 0.00476707 -3.02631 
AF359419 0.0315234 -2.55552 LRRC15 0.0244118 -3.04724 
LOC100132815 8.29E-05 -2.55603 MX1 0.00333702 -3.05139 
LOC729603 0.0119687 -2.55654 KIAA2026 0.0307381 -3.05586 
RASGRF2 0.0228091 -2.56552 LASS1 0.00484164 -3.05796 
FLJ37644 0.0139146 -2.5689 CTTNBP2 0.0321254 -3.06626 
ADAMTSL1 0.0397345 -2.57095 ARSI 0.0070051 -3.07722 
GYG2 0.0377113 -2.5869 RAB33A 0.000675221 -3.0787 
PCDHB5 0.00579755 -3.08415 FGF13 0.00643471 -3.76609 
ENST00000423322 0.0136764 -3.08419 E2F7 0.000767994 -3.78745 
PRKCG 0.00417623 -3.09221 SOX4 0.0153381 -3.82857 
C17orf76 0.000836986 -3.11032 MEX3A 0.00161493 -3.8398 
TMEM35 0.00311096 -3.13942 TNFAIP6 0.00422564 -3.87415 
ANGPTL2 5.47E-05 -3.13951 TRIM45 0.000116789 -3.92432 
DCLK1 0.0241395 -3.18545 SYT7 0.000705314 -3.94339 
MEX3B 0.0441479 -3.19048 GLI1 0.00714094 -3.95142 
TMEM217 0.000680899 -3.20839 CXCL12 0.00359088 -3.96001 
FSTL5 0.0432873 -3.2283 MXRA5 5.14E-05 -3.96914 
GPER 0.00214358 -3.23689 GPR68 0.00266368 -4.32065 
MYBPH 0.0398398 -3.23747 PDE4B 0.0199266 -4.39107 
EVI2A 0.00133385 -3.25217 CCL11 0.00543929 -4.42498 
DACH1 0.0308535 -3.25745 RRAD 0.00650411 -4.68968 
AMOT 0.00728667 -3.26956 LRRN3 0.0207673 -4.70784 
IFIT1 0.000709866 -3.31245 RAB26 0.00377299 -4.96857 
LRRC17 0.0307473 -3.32752 FAM46C 0.00140449 -5.03319 
LOC375196 0.0328343 -3.35661 CD274 0.0269718 -5.10222 
OR1K1 0.00541602 -3.35979 BDKRB1 0.000679002 -5.22339 
ENST00000331733 0.0103568 -3.36124 GPR56 0.00348262 -5.43723 
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LOC283070 0.0138072 -3.36408 LOC649941 0.0373539 -5.4505 
SLC6A9 0.0001186 -3.4027 CNIH3 0.000112112 -5.56423 
BDKRB2 0.000469808 -3.43774 NR0B1 0.0043313 -5.78435 
LOC100132167 0.0226973 -3.44223 MMP10 0.0199715 -5.85228 
ISG20 0.00891136 -3.47533 NOV 2.59E-05 -6.38307 
SEMA3A 0.00853538 -3.48542 SIPA1L2 0.00144401 -6.38375 
NFE2 0.000617891 -3.5063 IL4I1 0.00200558 -6.40553 
CCL7 0.0349931 -3.53607 CHST8 0.0353442 -6.63884 
HSPA12B 0.0131438 -3.59906 OR6N1 0.0141912 -7.02028 
CH25H 0.00893032 -3.64039 G0S2 0.00103256 -7.60972 
COL13A1 0.00136208 -3.72113 MMP1 0.00057377 -9.69951 
ALDH1A3 0.0145858 -3.76022 HLA-DRB3 0.0408609 -12.2717 
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ASNSD1 Asparagine synthetase domain containing 1 -2.1 (< .01) 11.0 (< .01) 
BEND6 BEN domain containing 6 -1.7 (< .01) -1.8 (< .01) 
C16orf74 Chromosome 16 open reading frame 74 -1.8 (< .01) -1.6 (< .01) 
C6orf108 2'-Deoxynucleoside 5'-Phosphate N-Hydrolase 1 -1.8 (< .01) 17.9 (< .01) 
C9orf140 Suppressor APC Domain Containing 2 -1.8 (< .01) -1.5 (< .01) 
CAPNS2 Calpain, small subunit 2 -1.7 (< .01) 6.7 (< .01) 
CD36 CD36 Molecule (Thrombospondin Receptor) -2.3 (< .01) -2.2 (< .01) 
DCTN3 Dynactin 3 (p22) -2.0 (< .01) 18.0 (< .01) 
EFR3B EFR3 homolog B 1.8 (< .01) -1.8 (< .01) 
GYG2 Glycogenin 2 -2.1 (< .01) -2.6 (< .01) 
OLFML1 Olfactomedin-like 1 2.0 (< .01) -2.3 (< .01) 
SDSL Serine dehydratase-like -1.5 (< .01) 8.7 (< .01) 
SHC2 Src homology-2 domain containing  transf  protein 2 5.1 (< .01) -1.8 (< .01) 
SNRNP27 Small nuclear ribonucleoprotein 27kDa  -3.5 (< .01) 11.3 (< .01) 
TRIP12 Thyroid hormone receptor interactor 12 -1.7 (< .01) 22.9 (< .01) 
VLDLR Very low density lipoprotein receptor -1.9 (< .01) -1.8 (< .01) 
ZBTB16 Zinc finger and BTB domain containing 16 -1.7 (< .01) 16.2 (< .01) 
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 Flanking Loci 
Class of 
lncRNA 
Ensemble gene ID Transcript FC 5 Prime 3 Prime 
lincRNA ENST00000514823 RP11-93L9.1 2.1 (< .05) SPATA5 SPRY1 
lincRNA ENST00000434601 LINC00422 1.9 (< .05) FGF9 BASP1P1 
lincRNA ENST00000450063 AC006159.3 1.9 (< .05) MET CAPZA2 
lincRNA ENST00000438897 AC068491.2 1.8 (< .05) BCC2L11 LOC541471 
lincRNA ENST00000454968 LINC00963 1.8 (< .05) NCS1 ASS1 
lincRNA ENST00000415714 RP1-60O19.1 1.8 (< .05) ORSL1 NR_033557 
lincRNA ENST00000437696 RP11-359G22.2 1.8 (< .05) LINC00261 SSTR4 
lincRNA ENST00000560760 RP11-38G5.2 1.7 (< .05) MEX3B EFTUD1 
lincRNA ENST00000413945 LINC00472 1.6 (< .05) B3GAT2 RIM51 
lincRNA ENST00000443965 GS1-600G8.5 1.6 (< .05) NR_045260 EGFL6 
lincRNA ENST00000456532 RP5-1158E12.3 1.6 (< .05) CXORF36 ZNF673 






1.5 (< .05) 
MSN MSN 
lincRNA ENST00000503532 RP11-341G5.1 1.5 (< .05) LOC152742 LOC441009 
lincRNA ENST00000418358 AC011747.3 1.5 (< .05) LINC00299 IDZ 
lincRNA ENST00000524165 PVT1 -1.5 (< .05) MYC LOC728724 
lincRNA ENST00000446423 FKBP1A-SDCBP2 -1.6 (< .05) SDCBP2 NSFLIC 
Antisence ENST00000501164 SDCBP2-AS1 -1.6 (< .05) TP531NP1 C8ORF38 
lincRNA ENST00000443576 RP11-141M1 -1.8 (< .05) RFC3 NBEA 
lincRNA ENST00000513480 CTD-2127H9.1 -1.8 (< .05) LIFR OSMR 
lincRNA ENST00000414790 H19 -3.0 (< .05) DBX1 HTATIP2 
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 Flanking Loci 
Class of 
lncRNA 
Ensemble gene ID 
Name FC 5 Prime 3 Prime 
lincRNA ENSG00000230590 FTX 1.8 (< .05) ZCCHC13 SLC16A2 
Antisence ENST00000507244 STX18-AS1 1.8 (< .05) D4S234E NR_037888 
lincRNA ENST00000418006 LINC00940 1.7 (< .05) CACNA1C LOC28344O 
lincRNA ENSG00000233237 LINC00472 1.7 (< .05) B3GAT2 RIM51 
Antisence ENST00000433079 MKLN1-AS1 1.6 (< .05) MKLN1 PODXL 
lincRNA ENSG00000237879 LINC00398 1.6 (< .05) EEFIDP3 FRY 
lincRNA ENST00000521586 RP11-382A18.2 1.6 (< .05) PCAT1 POU5F1B 
lincRNA ENST00000440496 LINC00630 1.5 (< .05) NR_038988 BEX1 
lincRNA ENST00000456532 RP5-1158E12.3 1.5 (< .05) CXORF36 ZNF673 
lincRNA ENST00000520431 RP11-527N22.2 1.5 (< .05) KCNU1 ZNF703 
lincRNA ENSG00000249859 PVT1 1.5 (< .05) MYC LOC728724 
lincRNA ENST00000448786 AC007879.2 1.5 (< .05) KLF7 CRABI 
lincRNA ENST00000433747 RP11-120D5.1 1.5 (< .05) MID1 ARHGAP6 
lincRNA ENSG00000088832 FKBP1A-SDCBP2 -1.5 (< .05) SDCBP2 NSFLIC 
lincRNA ENST00000420774 AC004540.5 -1.5 (< .05) SNX10 LOC441204 
lincRNA ENST00000424283 RP1-261G23.5 -1.6 (< .05) GTPBP2 MAD2L1BP 
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 Flanking Loci 
Class of 
lncRNA 
Ensemble gene ID 
Name FC 5 Prime 3 Prime 
lincRNA ENST00000552334 RP11-701H24.2 5.6 (< .05) GABRA5 OCA2 
Antisence ENST00000439601 AC131097.3 4.1 (< .05) CXXC11 AC093642 
lincRNA ENST00000415611 AC005682.5 3.5 (< .05) IL6 KLHL7 
lincRNA ENST00000529893 RP1-80B9 3.2 (< .05) FOXC1 C6orf195 
Sense 
overlapping 
ENST00000304425 MIR31 host gene 
3.1 (< .05) 
IFNA8 C9orf53 
lincRNA ENST00000443576 RP11-141M1 2.7 (< .05) STARD13 RFC3 




2.2 (< .05) 
KLF14 MKLN1 
lincRNA ENST00000553465 MEG8-001  2.0 (< .05) MIR136 MIR1197 
lincRNA ENST00000435643 AC007879.1 1.8 (< .05) MIR2355 MIR1302 
lincRNA ENST00000433843 SNHG5 1.8 (< .05) SYNCRIP RN7SL643P 
lincRNA ENST00000561123 RP11-307C19.2 1.6 (< .05) HMG20A LINGO1 
lincRNA ENST00000435702 AP001046 1.6 (< .05) CRYAA SIK1 






1.5 (< .05) 
CCDC152 NIM1 
lincRNA ENST00000417947 AC096574.5 -1.5 (< .05) MLPH RBM44 
lincRNA ENSG00000249859 PVT1 -1.6 (< .05) MYC LOC728724 
lincRNA ENST00000414120 LINC00887 -1.7 (< .05) ATP13A4 CPN2 
Antisence ENST00000511571 RP11-453E17 -1.7 (< .05) STAP1 TMPRSS11BNL 
lincRNA ENST00000423943 RP11-48O20.4 -1.8 (< .05) DUSP23 PIGM 
lincRNA ENST00000418539 BCYRN1 -1.8 (< .05) CALM2 AC138655 
Antisence ENST00000422059 RP5-1120P11.1 -1.8 (< .05) VEGFA MRPL14 
lincRNA ENST00000464767 LINC00341 -1.9 (< .05) DICER1 TCL1A 
lincRNA ENST00000373171 LINC00951 -1.9 (< .05) MOCS1 UNC5CL 
lincRNA ENST00000518765 RP11-527N22.1 -2.0 (< .05) KCNU1 ERLIN2 
lincRNA ENST00000473636 LINC00882 -2.0 (< .05) CBLB BBX 
lincRNA ENST00000457340 RP11-503C24.1 -2.2 (< .05) AL009178.1 DACT2 
lincRNA ENST00000514844 RP11-46C20.1 -2.3 (< .05) CDH9 CDH6 
lincRNA ENST00000451230 AC108463.1 -2.5 (< .05) BCL2L11 MIR4435 
lincRNA ENST00000455957 HCG17 -2.8 (< .05) TRIM15 TRIM39 
lincRNA ENST00000506086 RP11-229C3.2 -3.2 (< .05) GCNT4 ANKRD31 
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 Flanking Loci 
Class of 
lncRNA 
Ensemble gene ID 
Name FC 5 Prime 3 Prime 
lincRNA ENSG00000236605 ACO23115.4 3.9 (< .05) MEIS1 ETAA1 
Antisence ENSG00000238273 ACO12360.6 3.6 (< .05) MRPS9 NCK2 
lincRNA ENSG00000258123 RP11-314D7.2 3.5 (< .05) TRHDE ATXN7L3B 
Antisence ENSG00000270953 RP11-2E11.9 3.4 (< .05) MEST MIR29 
lincRNA ENSG00000259331 RP11-57P19.1 3.2 (< .05) MCTP2 NR2F2 
lincRNA ENSG00000273615 RP11-1136G4.2 3.1 (< .05) IRX3 IRX5 
lincRNA ENSG00000279440 CTA-992D9.11 3.0 (< .05) CRYBA4 MN1 
lincRNA ENSG00000272798 CTA-390C10.9 3.0 (< .05) LRP5L ADREK2 
lincRNA ENSG00000254275 lincRNA00824 3.0 (< .05) TMEM75 GSDMC 
lincRNA ENSG00000231082 RP11-514F8.2 3.0 (< .05) SH2D4B NRG3 
lincRNA ENSG00000256748 RP11-234B24.2 2.9 (< .05) RAD51AP1 GALNT8 
lincRNA ENSG00000204603 lincRNA01257 2.8 (< .05) GPR133 SFSWAP 
lincRNA ENSG00000229323 DLEU1-AS1 2.7 (< .05) DLEU1 DLEU7 
lincRNA ENSG00000237756 RP11-77M5.1 2.7 (< .05) NUF2 PBX1 
lincRNA ENSG00000260604 RP1-140K8.5 2.6 (< .05) FAM50B PRPF4B 
lincRNA ENSG00000266869 RP6-114E22.1 2.6 (< .05) SIPA1L1 RGS6 
lincRNA ENSG00000271860 RP11-436D23.1  2.5 (< .05) MMS22L POU3F2 
lincRNA ENSG00000245149 RNF139-AS1 2.5 (< .05) TRMT12 RNF139 
lincRNA ENSG00000244342 lincRNA00698 2.4 (< .05) CADPS SYNPR 
lincRNA ENSG00000267055 RP11-486P11.1 2.4 (< .05) TMEM196 MACC1 
lincRNA ENSG00000230156 lincRNA00443 2.4 (< .05) ARGLU1 FAM155A 
lincRNA ENSG00000231671 lincRNA01307 2.4 (< .05) SIPR1 OLFM3 
lincRNA ENSG00000236983 lincRNA00614 2.4 (< .05) ABI1 YME1L1 
lincRNA ENSG00000233365 RP4-655C5.4 2.3 (< .05) T PRR18 
lincRNA ENSG00000226673 lincRNA01108 2.2 (< .05) CD83 JARID2 
lincRNA ENSG00000278630 RP11-78L16.1 2.2 (< .05) OLFM4 PRR20A 
Antisence ENSG00000247381 PDX1-AS1 2.2 (< .05) GSX1 PDX1 
lincRNA ENSG00000235152 RP5-865N13.2 2.2 (< .05) DISC1 SIPA1L2 
lincRNA ENSG00000241475 RP4-781K5.5 2.1 (< .05) IRF2BP2 TOMM20 
Perry 43 
 
lincRNA ENSG00000270604 HCG17 2.1 (< .05) TRIM26 HLA-L 
Sense intronic ENSG00000276672 RP11-142E9.1 2.0 (< .05) RFC3 NBEA 
lincRNA ENSG00000272168 CASC15 2.0 (< .05) SOX4 PRL 
lincRNA ENSG00000230587 AC093609.1 2.0 (< .05) HAAO ZFP36L2 
lincRNA ENSG00000233723 lincRNA01122 1.9 (< .05) FANCL BCL11A 
lincRNA ENSG00000228739 RP11-21817.2 1.9 (< .05) MLANA IL33 
lincRNA ENSG00000228798 AP000473.5 1.9 (< .05) MIR125B2 CXADR 
lincRNA ENSG00000219445 RP11-3B12.3 1.9 (< .05) POT1 GRM8 
lincRNA ENSG00000260986 RP11-854K16.3 1.9 (< .05) POTEB2 POTEB3 
lincRNA ENSG00000246084 CTD-2506J14.1 1.9 (< .05) VRK1 C14ORF177 
lincRNA ENSG00000223863 AC008074.4 1.8 (< .05) LGALSL AFTPH 
lincRNA ENSG00000226375 RP3-395P12.2 1.8 (< .05) TNFSF18 TNFSF4 
lincRNA ENSG00000224717 RP11-576D8.4 1.8 (< .05) LEMD1 CDK18 
lincRNA ENSG00000214870 AC004540.5 1.7 (< .05) SNX10 KIAA0087 
lincRNA ENSG00000232413 RP11-343J18.2 1.7 (< .05) PBX3 MVB12B 
lincRNA ENSG00000267586 lincRNA00970 1.7 (< .05) PIK3C3 RIT2 
lincRNA ENSG00000272144 CTD-2035E11.5 1.7 (< .05) ANXA2R ZNF131 
lincRNA ENSG00000248300 RP11-74M11.2 1.7 (< .05) HS3ST1 RAB28 
lincRNA ENSG00000257086 RP11-783K16.13 1.7 (< .05) FERMT3 BAD 
lincRNA ENSG00000239482 RP11-90K6.1 1.6 (< .05) SLC9C1 BTLA 
lincRNA ENSG00000259198 RP11-133K1.6 1.6 (< .05) C15ORF52 DISP2 
lincRNA ENSG00000230812 lincRNA01358 1.5 (< .05) JUN FGGY 
Antisence ENSG00000258982 RP11-63812.4 1.5 (< .05) DEGS2 YY1 
lincRNA ENSG00000248371 CTC-347C20.2 1.5 (< .05) ZNF366 TNPO1 
lincRNA ENSG00000224228 RP1-15D23.2 1.5 (< .05) FASLG TNFSF18 
lincRNA ENSG00000263622 RP11-389J22.3 1.5 (< .05) CDH7 CDH19 
lincRNA ENSG00000271788 CTD-2201E18.5 1.4 (< .05) CCDC152 ANXA2R 
Antisence ENSG00000224743 TEX26-AS1 1.4 (< .05) ALOX5AP MEDAG 
lincRNA ENSG00000255839 RP11-338K17.8 1.3 (< .05) TCTN2 ATP6VDA2 
lincRNA ENSG00000228636 RP5-1051H14.2 1.3 (< .05) GATA3 CELF2 
lincRNA ENSG00000259725 CTD-3032H12.1 1.2 (< .05) IRX3 IRX5 
lincRNA ENSG00000248605 CTD-2306M5.1 -1.1 (< .05) CDH10 CDH9 
lincRNA ENSG00000268184 RP11-420K14.8 -1.3 (< .05) ZNF100 ZNF43 
lincRNA ENSG00000273100 RP11-302L19.3 -1.6 (< .05) ERMARD DLL1 
lincRNA ENSG00000249631 RP11-281P23.2 -1.6 (< .05) HS3ST1 RAB28 
lincRNA ENSG00000259504 RP11-352D13.5 -1.7 (< .05) PAQR5 KIF23 
lincRNA ENSG00000225269 lincRNA00705 -1.8 (< .05) KLF6 AKR1E2 
lincRNA ENSG00000235154 CTA-280A3_B.2 -1.8 (< .05) FP325331.1 FAM19A5 
lincRNA ENSG00000249021 CTC-505O3.3 -1.9 (< .05) TICAM2 CDO1 
lincRNA ENSG00000248515 RP11-608O21.1 -1.9 (< .05) LCORL SLIT2 
lincRNA ENSG00000236204 lincRNAO1376 -1.9 (< .05) NT5C1B OSR1 
lincRNA ENSG00000248588 CTC-458G6.4 -1.9 (< .05) ARRDC3 NR2F1 
lincRNA ENSG00000254275 lincRNA00824 -2.1 (< .05) TMEM75 GSDMC 
lincRNA ENSG00000257859 CASC18 -2.4 (< .05) C12ORF75 NUAK1 
lincRNA ENSG00000251580 RP11-539L10.3 -2.4 (< .05) MAN2B2 MRFAP1 
lincRNA ENSG00000249740 OSMR-AS1 -2.4 (< .05) LIFR OSMR 
Antisence ENSG00000233340 RP11-25C19.3 -2.7 (< .05) VTI1A TCFL2 
lincRNA ENSG00000239628 RP11-543D10.2 -2.7 (< .05) SKIL CLDN11 
Antisence ENSG00000224691 GS1-174L6.4 -3.4 (< .05) HMCN1 PRG4 
lincRNA ENSG00000270020 RP11-463O9.9 -3.8 (< .05) IRF8 FOXF1 
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 Flanking Loci 
Class of 
lncRNA 
Ensemble gene ID Name FC 5 Prime 3 Prime 









2.9 (< .05) 
CRYBB1 MN1 
Antisence ENST00000439601 AC131097.3 2.5 (< .05) CXXC11 CICP10 
lincRNA ENST00000432823 RP1-80N2.2 2.4 (< .05) LY86 RREB1 
lincRNA ENST00000438897 AC068491.2 2.4 (< .05) BCL2L11 MIR4435 
lincRNA ENST00000478824 CTD-2377D24.6 2.1 (< .05) HOXB4 MIR3185 
lincRNA ENST00000507058 CTC-276P9.2 1.9 (< .05) PITX1 H2AFY 




1.8 (< .05) 
KLF14 MKLN1 
lincRNA ENST00000366424 AC144450.2 1.7 (< .05) TPO PXDN 
Antisence ENST00000435800 RP11-31F15.1 1.7 (< .05) SLC16A1 LRIG2 
Antisence ENST00000460833 ADAMTS9-AS2 1.7 (< .05) ADAMTS9 MAGI1 
lincRNA ENST00000446884 RP1-30G7.2 1.7 (< .05) MIR222 KRBOX4 
lincRNA ENST00000560760 RP11-38G5.2 1.5 (< .05) KIAA1024 MTHFS 
lincRNA ENST00000416401 RP11-77M5.1 1.5 (< .05) RGS5 NUF2 
lincRNA ENST00000433079 AC058791.2 -1.5 (< .05) MIR29 MKLN1 
lincRNA ENST00000552334 RP11-701H24.2 -1.5 (< .05) SNURF UBE3A 
Antisence ENST00000519104 RP3-399L15.3 -1.5 (< .05) HDAC2 FRK 
lincRNA ENST00000444265 LINC00340 -1.5 (< .05) SOX4 PRL 
lincRNA ENST00000421322 XIST -1.6 (< .05) CHIC1 ZCCHC13 
lincRNA ENST00000464767 LINC00341 -1.6 (< .05) CLMN SYNE3 
Antisence ENST00000416630 DCTN1-AS1 -1.6 (< .05) MTHFD2 MOGS 




-1.8 (< .05) 
SLC37A1 PDE9A 
lincRNA ENST00000437261 AC108066.1 -1.9 (< .05) MIR548 IKZF2 
Antisence ENST00000434399 AC005154.6 -1.9 (< .05) GGCT GARS 
lincRNA ENST00000514791 RP11-434D9.2 -2.0 (< .05) CD180 PIK3R1 
lincRNA ENST00000435643 AC007879.1 -2.2 (< .05) KLF7 CREB1 
lincRNA ENST00000433747 RP11-120D5.1 -2.2 (< .05) MID1 ARHGAP6 
lincRNA ENST00000418006 LINC00940 -2.3 (< .05) LRTM2 DCP1B 
lincRNA ENST00000434601 RP11-101P17.9 -2.7 (< .05) MRP63 ZDHHC20 
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Ensemble gene ID Name FC 5 Prime 3 Prime 
lincRNA ENST00000444958 DANCR 6.3 (< .05) USP46 ERVMER34-1 
lincRNA ENST00000473636 LINC00882 3.4 (< .05) CBLB CCDC54 
Processed 
transcript 
ENST00000443587 DLEU2 3.1 (< .05) TRIM13 DLEU7 
lincRNA ENST00000478824 CTD-2377D24.6 2.6 (< .05) TTLL6 CALCOCO2 
lincRNA ENST00000412526 LINC00161 2.5 (< .05) ADAMTS5 N6AMT1 
lincRNA ENST00000420594 AC073130.1 2.4 (< .05) TES CAV2 
Processed 
transcript 
ENST00000453698 SNHG11 2.4 (< .05) LBP RALGAPB 
Antisense ENST00000420563 AC053503.4 2.4 (< .05) DNPEP DES 
Perry 45 
 
lincRNA ENST00000511497 RP11-420A23.1 2.3 (< .05) PGRMC2 PHF17 
Processed 
transcript 
ENST00000413755 SNHG17 2.3 (< .05) LBP RALGAPB 
lincRNA ENST00000512322 RP11-792D21.2 2.2 (< .05) ANXA3 BMP2K 
Antisence ENST00000519104 RP3-399L15.3 2.1 (< .05) HDAC2 HS3ST5 
lincRNA ENST00000416534 AC007463.2 2.1 (< .05) RNF144A ID2 
lincRNA ENST00000427903 RP1-60O19.1 2.1 (< .05) QRSL1 C6orf203 
lincRNA ENST00000442796 LINC00312 2.0 (< .05) LMCD1 SSUH2 
lincRNA ENST00000437523 RP11-344P13.4 2.0 (< .05) FCGR1B PP1AL4G 
lincRNA ENST00000560760 RP11-38G5.2 2.0 (< .05) KIAA1024 MTHFS 
lincRNA ENST00000454596 RP11-69I8.2 1.9 (< .05) ENPP1 CTGF 
lincRNA ENST00000366424 AC144450.2 1.8 (< .05) TPO PXDN 
lincRNA ENST00000412606 AC096559.1 1.8 (< .05) LPIN1 TRIB2 
Antisence ENST00000439075 RP11-510H23.1 1.8 (< .05) NKAIN2 RNF217 
lincRNA ENST00000440888 RP11-315I14.2 1.8 (< .05) DMRTA1 ELAVL2 
lincRNA ENST00000523242 CTB-43E15.1 1.7 (< .05) BOD1 CPEB4 
lincRNA ENST00000366185 RP11-258C19.5 1.7 (< .05) FAM156A KDM5C 
Processed 
transcript 
ENST00000426282 CTA-217C2.1 1.7 (< .05) PHF21B KIAA0930 
lincRNA ENST00000436112 RP3-523C21.1 1.7 (< .05) CTGF MOXD1 
lincRNA ENST00000435967 RP4-594A5.1 1.6 (< .05) ICA1 NXPH1 
lincRNA ENST00000488287 CT64 1.6 (< .05) NMD3 SPTSSB 
lincRNA ENST00000446884 RP1-30G7.2 1.6 (< .05) CXorf36 KRBOX4 
lincRNA ENST00000417112 RP11-554I8.2 1.5 (< .05) PRKCQ SFMBT2 
lincRNA ENST00000416401 RP11-77M5.1 1.5 (< .05) RGS5 NUF2 
lincRNA ENST00000511840 CTD-2066L21.2 1.5 (< .05) NPR3 TARS 
Retained 
intron 
ENST00000436578 AC005532.5 1.5 (< .05) C1GALT1 COL28A1 
lincRNA ENST00000430244 RP11-166O4.5 1.5 (< .05) TYW1 AUTS2 
lincRNA ENST00000471357 LINC00880 1.5 (< .05) LEKR1 CCNL1 
lincRNA ENST00000508147 RP11-622A1.2 1.5 (< .05) AFM RASSF6 
Sense 
overlapping 
ENST00000530072 RP11-166D19.1 -1.5 (< .05) SORL1 BLID 
lincRNA ENST00000455957 HCG17 -1.5 (< .05) TRIM15 TRIM39 
Retained 
intron 
ENST00000521127 SNHG6 -1.5 (< .05) MCMDC2 PPP1R42 
lincRNA ENST00000451230 AC108463.1 -1.6 (< .05) BCL2L11 ZC3H8 
lincRNA ENST00000449259 AC007386.2 -1.6 (< .05) SERTAD2 SLC1A4 
lincRNA ENST00000453722 LINC00511 -1.6 (< .05) SOX9 SLC39A11 
Processed 
transcript 
ENST00000431616 LINC00630 -1.6 (< .05) BHLHB9 RAB40AL 
lincRNA ENST00000443576 RP11-141M1.1 -1.7 (< .05) STARD13 RFC3 
Processed 
transcript 
ENST00000430756 RP11-761E20.1 -1.7 (< .05) PLS3 AGTR2 
Processed 
transcript 
ENST00000416650 RSBN1L-AS1 -1.7 (< .05) PTPN12 RSBN1L 
Sense 
intronic 
ENST00000433544 RP11-488P3.1 -1.7 (< .05) BCAR3 DNTTIP2 
lincRNA ENST00000415611 AC005682.5 -1.7 (< .05) TOMM7 FAM126A 
lincRNA ENST00000505448 RP11-774O3.3 -1.7 (< .05) HTRA3 ACOX3 
Antisence ENST00000496733 TMEM161B-AS1 -1.8 (< .05) TMEM161B MEF2C 
lincRNA ENST00000529893 RP1-80B9.2 -1.8 (< .05) GMDS C6orf195 
lincRNA ENST00000552334 RP11-701H24.2 -1.8 (< .05) SNURF UBE3A 
lincRNA ENST00000515871 CTC-325J23.3 -1.8 (< .05) ANKRD34B DHFR 
lincRNA ENST00000433747 RP11-120D5.1 -1.8 (< .05) MID1 AMELX 
lincRNA ENST00000438762 AP000473.5 -1.8 (< .05) USP25 CXADR 
Perry 46 
 
Antisence ENST00000511571 RP11-453E17.1 -1.9 (< .05) TMPRSS11A TMPRSS11B 
Antisence ENST00000456602 RBM26-AS1 -1.9 (< .05) RBM26 NDFIP2 
lincRNA ENST00000437261 AC108066.1 -1.9 (< .05) ERBB4 IKZF2 
lincRNA ENST00000454635 LINC00963 -1.9 (< .05) IER5L NTMT1 
lincRNA ENST00000433079 AC058791.2 -1.9 (< .05) KLF14 MKLN1 
lincRNA ENST00000444488 TPRG1-AS1 -1.9 (< .05) LPP TPRG1 
lincRNA ENST00000505155 RP11-584P21.2 -1.9 (< .05) EPHA5 CENPC 
lincRNA ENST00000444265 LINC00340 -2.0 (< .05) SOX4 PRL 
lincRNA ENST00000537192 RP11-1038A11.3 -2.0 (< .05) KCNA5 NTF3 
lincRNA ENST00000514791 RP11-434D9.2 -2.0 (< .05) CD180 PIK3R1 
lincRNA ENST00000508619 RP3-513G18.2 -2.0 (< .05) LRPAP1 ADRA2C 
Antisence ENST00000437157 RP3-510D11.1 -2.0 (< .05) GPR157 H6PD 
lincRNA ENST00000412722 LINC00427 -2.1 (< .05) KATNAL1 HMGB1 
lincRNA ENST00000398518 MEG3 -2.1 (< .05) DLK1 RTL1 
lincRNA ENST00000418006 LINC00940 -2.1 (< .05) LRTM2 DCP1B 
lincRNA ENST00000534336 MALAT1 -2.2 (< .05) FRMD8 SCYL1 
Antisence ENST00000434399 AC005154.6 -2.5 (< .05) GGCT GARS 
lincRNA ENST00000455395 FTX -3.7 (< .05) NAP1L2 ZCCHC13 
Processed 
transcript 
ENST00000451141 MIAT -4.3 (< .05) CRYBB1 MN1 
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Supplementary Figure 1: Effect of dexamethasone and FCS upon asthmatic ASM cell 134 
proliferation and IL-6 release. ASM cells were incubated with dexamethasone (10
-7
 M) for 1 135 
h before being stimulated with FCS (2.5 %) for 24 h. DNA synthesis (A), cell viability (B), 136 
and IL-6 (C) release were measured by BrdU ELISA, MTT assay, or DuoSet ELISA 137 
respectively. Bars represent mean ± SEM from 9 ASM cell donors. ** p < 0.01; ***/### p < 138 
0.001. 139 
 140 
Supplementary Figure 2: Transfection efficiency in ASMCs from healthy subjects and 141 
severe asthmatics at 8 days.  142 
IL-6 release (A&B), or cellular viability (C-F) were measured by DuoSet ELISA Assay (R&D 143 
Systems), or MTT assay (Sigma) respectively at 8 days. Bars represent the means ± SEMs of 144 
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